var title_f33_45_34512="Gastric B cell lymphoma CPC Endosc";
var content_f33_45_34512=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F51705&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F51705&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 556px\">",
"   <div class=\"ttl\">",
"    Gastric B cell lymphoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 536px; height: 190px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Upper endoscopy showing a single 2 cm by 3 cm ulcerated lesion of malignant appearance in the gastric body.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Andres Gelrud, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_45_34512=[""].join("\n");
var outline_f33_45_34512=null;
var title_f33_45_34513="Female pelvic bones";
var content_f33_45_34513=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F60078&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F60078&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 563px\">",
"   <div class=\"ttl\">",
"    Superior view of female pelvis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 543px; height: 359px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_45_34513=[""].join("\n");
var outline_f33_45_34513=null;
var title_f33_45_34514="CMR septal LVH in HCM";
var content_f33_45_34514=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F87656&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F87656&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 596px\">",
"   <div class=\"ttl\">",
"    Four-chamber cardiac magnetic resonance (CMR) showing massive septal hypertrophy in a patient with hypertrophic cardiomyopathy (HCM)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 576px; height: 487px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Four-chamber cardiac magnetic resonance (CMR) image showing massive septal hypertrophy in a patient with hypertrophic cardiomyopathy (HCM).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Martin Maron, M.D.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_45_34514=[""].join("\n");
var outline_f33_45_34514=null;
var title_f33_45_34515="Amnion nodosum";
var content_f33_45_34515=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F78284&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F78284&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 560px\">",
"   <div class=\"ttl\">",
"    Amnion nodosum",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 540px; height: 384px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Arrow points to amnion nodosum on the membranes in a case of bilateral renal agenesis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Drucilla Roberts, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_45_34515=[""].join("\n");
var outline_f33_45_34515=null;
var title_f33_45_34516="Division of round ligament";
var content_f33_45_34516=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F51994&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F51994&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Opening the parametrium during a radical hysterectomy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 425px; height: 406px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The uterus is placed under tension and the round ligament divided as far laterally as possible. The pelvic peritoneum is then incised lateral to the external iliac artery and vein, and the incision carried cephalad to the corresponding paracolic gutter.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of William J Mann, Jr, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_45_34516=[""].join("\n");
var outline_f33_45_34516=null;
var title_f33_45_34517="Metoclopramide: Patient drug information";
var content_f33_45_34517=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Metoclopramide: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/13/216?source=see_link\">",
"     see \"Metoclopramide: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?0/47/759?source=see_link\">",
"     see \"Metoclopramide: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F195600\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Metozolv&trade; ODT;",
"     </li>",
"     <li>",
"      Reglan&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F195601\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Metoclop&reg;;",
"     </li>",
"     <li>",
"      Metoclopramide Hydrochloride Injection;",
"     </li>",
"     <li>",
"      Metoclopramide Omega;",
"     </li>",
"     <li>",
"      Nu-Metoclopramide;",
"     </li>",
"     <li>",
"      PMS-Metoclopramide",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10024148\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700738",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Some people who take this drug may have muscle movements that cannot be controlled. The risk may greater in older adults, especially women. The chance that this will happen or that it will never go away is greater in people who take this drug in higher doses or for a long time. Muscle problems may also occur after short-term use with low doses. Call your doctor right away if you have trouble controlling body movements or if you have muscle problems with your tongue, face, mouth, or jaw like tongue sticking out, puffing cheeks, mouth puckering, chewing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700454",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug comes with an extra patient fact sheet called a Medication Guide. Read it with care. Read it again each time this drug is refilled.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10024150\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691310",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used in patients getting tube feedings who have high residuals.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691876",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat heartburn.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691522",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to stop or treat upset stomach and throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691849",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat gastroesophageal reflux disease.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10024149\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702515",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to metoclopramide or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703562",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these health problems: GI (gastrointestinal) bleeding, hole in the GI tract, bowel block, pheochromocytoma, or seizures.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10024154\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697197",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high blood sugar (diabetes), talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697258",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have heart disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697307",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have mental illness, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697320",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have Parkinson's disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696628",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, or mixed drinks; quit smoking; raise head of the bed; avoid large meals before bed; lose weight; and avoid fatty foods, chocolate, caffeine, or citrus.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10024155\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698060",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling lightheaded, sleepy, having blurred eyesight, or a change in thinking clearly. Avoid driving and doing other tasks or actions that call for you to be alert or have clear eyesight until you see how this drug affects you.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697891",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698312",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to calm down.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698162",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to sleep.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10024157\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698706",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are planning to harm yourself or the want to harm yourself gets worse.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698655",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A fast heartbeat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699099",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Twitching.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699058",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in thinking clearly and with logic.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699055",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Shakiness, trouble moving around, or stiffness.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699019",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10024152\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695829",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take 30 minutes before meals and at bedtime.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694173",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Oral-disintegrating tablet:",
"        </span>",
"       </b>",
"       Place on your tongue and let it melt. Water is not needed. Do not swallow it whole. Do not chew, break, or crush it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       There is a liquid (solution, syrup) if you cannot swallow pills.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696107",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Those who have feeding tubes may also use the liquid. Flush the feeding tube before and after this drug is given.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705429",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Shot:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695976",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into a muscle or vein.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10024153\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696528",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Many times this drug is given on an as needed basis.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10024158\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705490",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Oral:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705429",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Shot:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699585",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       The shot will be given to you in a hospital or doctor's office. You will not store it at home.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10024159\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10862 Version 37.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-203.80.222.8-3836C529BC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_45_34517=[""].join("\n");
var outline_f33_45_34517=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F195600\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F195601\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024148\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024150\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024149\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024154\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024155\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024157\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024152\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024153\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024158\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024159\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?0/13/216?source=related_link\">",
"      Metoclopramide: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?0/47/759?source=related_link\">",
"      Metoclopramide: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f33_45_34518="Carotid endarterectomy PI";
var content_f33_45_34518=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F52730&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F52730&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 502px\">",
"   <div class=\"ttl\">",
"    Carotid artery surgery (endarterectomy)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 482px; height: 594px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    During carotid artery surgery, also called \"endarterectomy,\" the doctor clamps the carotid artery above and below the area that has plaque. Then the doctor cuts open the artery and removes the plaque. Next, he or she sews the artery back together and unclamps the artery.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: What To Expect During Carotid Endarterectomy. Diseases and Conditions Index. National Heart Lung and Blood Institute.",
"     <a href=\"file://www.nhlbi.nih.gov/health/dci/Diseases/carend/carend_during.html\">",
"      file://www.nhlbi.nih.gov/health/dci/Diseases/carend/carend_during.html",
"     </a>",
"     (Accessed December 3, 2010).",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_45_34518=[""].join("\n");
var outline_f33_45_34518=null;
var title_f33_45_34519="Uterosacral ligm plication";
var content_f33_45_34519=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F66363%7EOBGYN%2F74027&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F66363%7EOBGYN%2F74027&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Uterosacral ligament plication during laparoscopic hysterectomy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 288px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Thomas Lyons, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Uterosacral ligament plication during laparoscopic hysterectomy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 288px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Thomas Lyons, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_45_34519=[""].join("\n");
var outline_f33_45_34519=null;
var title_f33_45_34520="Treatment of nodular lymphocyte-predominant Hodgkin lymphoma";
var content_f33_45_34520=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment of nodular lymphocyte-predominant Hodgkin lymphoma",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/45/34520/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/45/34520/contributors\">",
"     Peter M Mauch, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/45/34520/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/45/34520/contributors\">",
"     Arnold S Freedman, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/45/34520/contributors\">",
"     Julie R Park, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/45/34520/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/45/34520/contributors\">",
"     Rebecca F Connor, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?33/45/34520/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 27, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) is an uncommon subtype of Hodgkin lymphoma (HL). This disorder is differentiated from all other forms of HL, which are commonly referred to as classical Hodgkin lymphomas (CHL), by characteristic pathologic and clinical features.",
"   </p>",
"   <p>",
"    NLPHL represents a more indolent disease than CHL, and is therefore managed uniquely. Since this disease is rare, most information concerning treatment and outcome has come from reports of single institutions or pooled, multi-institutional retrospective analyses.",
"   </p>",
"   <p>",
"    Treatment and prognosis of NLPHL are reviewed here. The epidemiology, pathogenesis, clinical presentation, pathology, and diagnosis of NLPHL are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/41/33432?source=see_link\">",
"     \"Clinical manifestations, pathologic features, and diagnosis of nodular lymphocyte-predominant Hodgkin lymphoma\"",
"    </a>",
"    .) Treatment of the other Hodgkin lymphoma subtypes is discussed separately. (See related topic reviews).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     STAGING",
"    </span>",
"    &nbsp;&mdash;&nbsp;After the diagnosis of NLPHL is confirmed, the patient should undergo a work-up and staging evaluation similar to that performed for patients with CHL. Staging is performed using the Ann Arbor staging system with Cotswolds modifications (",
"    <a class=\"graphic graphic_table graphicRef66651 \" href=\"mobipreview.htm?19/23/19836\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/45/34520/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. This system is described at length separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/37/14935?source=see_link\">",
"     \"Staging and prognosis of Hodgkin lymphoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/41/33432?source=see_link\">",
"     \"Clinical manifestations, pathologic features, and diagnosis of nodular lymphocyte-predominant Hodgkin lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Historically, patients with NLPHL have been treated like patients with CHL, and many of the large randomized studies that have guided treatment of patients with HL have included small numbers of patients with NLPHL. However, we now know that NLPHL differs from CHL both in its response to treatment as well as its prognosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/45/34520/abstract/3\">",
"     3",
"    </a>",
"    ]. We have developed an understanding that patients with NLPHL may not require as aggressive therapies and that the treatment standard of chemotherapy followed by involved-field RT that has been used in CHL may not be appropriate for NLPHL. Our approach is generally consistent with that proposed by the National Comprehensive Care Network (NCCN)&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/45/34520/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     STAGE IA/IIA DISEASE",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Overview",
"    </span>",
"    &nbsp;&mdash;&nbsp;The current treatment strategy for patients with stage",
"    <span class=\"nowrap\">",
"     I/II",
"    </span>",
"    NLPHL without B symptoms involves local-regional radiation therapy with 30 to 36 Gy. Doses of 30 Gy are generally considered sufficient in patients whose nodal disease has been completely excised surgically.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Natural history",
"    </span>",
"    &nbsp;&mdash;&nbsp;The indolent nature and favorable prognosis of NLPHL are illustrated by published reports of patients who did not undergo further therapy following diagnosis but still enjoyed excellent overall survival. However, these reports must be interpreted cautiously because of a possible inaccurate diagnosis due to the absence of immunophenotyping, the small patient numbers, and likelihood for selection bias. As an example, in a series from 1983 of 51 patients diagnosed with NLPHL, most of whom were stage IA, 31 did not receive any treatment other than tumor excision, with actuarial survival rates at 5 and 10 years of 93 and 80 percent, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/45/34520/abstract/5\">",
"     5",
"    </a>",
"    ]. Of the 31 untreated patients, only 7 had died with one death due to HL and two to autopsy-confirmed NHL. This report and another similar report indicate that some patients with early stage disease have enjoyed long-term survival with no treatment other than the original lymph node resection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/45/34520/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Surgical excision alone",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no data in adults concerning the efficacy of surgical excision alone. By comparison, several pediatric study groups have reported small nonrandomized series in which children and adolescents received only careful follow-up after initial lymph node resection in an attempt to avoid toxicities that can be associated with treatment (eg, growth retardation, infertility, hypothyroidism, cardiopulmonary complications, secondary malignancy) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/45/34520/abstract/7-9\">",
"     7-9",
"    </a>",
"    ]. The largest of these series from the European Network group reported data from 58 children (54 with stage IA disease), who were initially treated with resection alone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/45/34520/abstract/9\">",
"     9",
"    </a>",
"    ]. After a median follow-up of 43 months, all of the children were alive, with an estimated 50-month progression-free survival of 57 percent. Of the 18 stage IA patients who developed recurrence after initial resection, all were restaged as either IA or IIA.",
"   </p>",
"   <p>",
"    However, the current use of limited fields and lower doses of radiation make the potential adverse long-term effects of treatment less concerning.",
"   </p>",
"   <p>",
"    Observation without treatment following excision is still considered experimental, and should be reserved for highly selected patients&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/45/34520/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Radiation therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of radiation therapy alone for early stage NLPHL has been evaluated retrospectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/45/34520/abstract/10-14\">",
"     10-14",
"    </a>",
"    ]. The following is an overview of some of the studies that have evaluated this treatment approach.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A retrospective study from the Australasian Radiation Oncology Lymphoma Group described the outcomes of 202 patients with stage I-II lymphocyte-predominant Hodgkin lymphoma (LPHL) treated with radiation therapy (RT) alone at nine centers [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/45/34520/abstract/10\">",
"       10",
"      </a>",
"      ]. Each center was responsible for pathologic review for determination of study eligibility. However, pathologic data was available for only 120 of these patients, specimens were not centrally reviewed, and patients with nodular, diffuse, and nodular-diffuse LPHL were not individually analyzed.",
"      <br/>",
"      <br/>",
"      In this study, RT fields were full mantle (52 percent), less than a full mantle (24 percent), full inverted-Y (17 percent), less than a full inverted-Y (3 percent), and total lymphoid (3 percent). The median RT dose was 36 Gy. Results included:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      At a median follow-up of 15 years, the 10- and 15-year overall survival rates were 88 and 83 percent, respectively. Freedom from disease progression at 10 and 15 years were 88 and 82 percent, respectively.",
"     </li>",
"     <li>",
"      On multivariate analysis, the number of sites of involvement was found to be an independent prognostic factor for disease progression. Those patients with one or two sites of involvement were at a significantly lower risk of progression following RT than those with three or more sites of involvement.",
"     </li>",
"     <li>",
"      In the subset of 146 patients with supradiaphragmatic disease without mediastinal involvement who were treated with supradiaphragmatic fields only, there was no statistically significant difference in the risk of progression between patients who received mediastinal irradiation compared with those who did not.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Another retrospective study of 42 patients with NLPHL included 22 patients with stage IA disease who were treated with involved-field radiation therapy (35 Gy) alone [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/45/34520/abstract/11\">",
"       11",
"      </a>",
"      ]. All patients achieved a complete response. Four patients relapsed, but all were successfully salvaged with combination chemotherapy consisting of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/52/35654?source=see_link\">",
"       chlorambucil",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?4/3/4152?source=see_link\">",
"       vinblastine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/45/24279?source=see_link\">",
"       procarbazine",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/48/33536?source=see_link\">",
"       prednisolone",
"      </a>",
"      .",
"     </li>",
"     <li>",
"      An observational study of 113 patients with stage",
"      <span class=\"nowrap\">",
"       I/II",
"      </span>",
"      NLPHL treated at a single center included 93 patients treated with RT alone [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/45/34520/abstract/14\">",
"       14",
"      </a>",
"      ]. Among these patients, 25 received limited-field RT, 35 received regional field, and 46 received extended field RT. Among those treated with RT alone, the rates of progression-free survival at 10 years were 89 and 72 percent for those with stage I or II disease, respectively. Corresponding 10-year survival rates were 96 and 100 percent, respectively. Progression-free and overall survival rates were similar among the three RT groups. Patients treated with chemotherapy alone had a higher rate of progression than those whose treatment included RT.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These data tend to support the notion, as discussed below, that patients with early stage NLPHL may be adequately treated with less than full mantle fields without compromising disease control.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Reduced volume RT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Reduced volume radiation therapy is becoming better accepted as the treatment of choice in patients with stage I-II NLPHL. A combined subset analysis of three selected retrospective studies gives insight into the outcome following RT alone in a total of 131 patients with stage I-II NLPHL [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/45/34520/abstract/15-17\">",
"     15-17",
"    </a>",
"    ]. The combined recurrence rate following more limited mantle or regional RT was 19 percent (14 of 73 patients), which was similar to a recurrence rate of 16 percent (9 of 58 patients) following the use of more extensive subtotal- or total-lymphoid RT.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     RT technique",
"    </span>",
"    &nbsp;&mdash;&nbsp;In general, regional field radiotherapy utilizing doses of 30 to 36 Gy is considered appropriate therapy for patients with stage I-II NLPHL. Doses of 30 Gy are generally sufficient in patients whose nodal disease has been completely excised. This technique treats not only the involved node but also the regional lymphatics. Guidelines for border design are well described elsewhere [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/45/34520/abstract/18\">",
"     18",
"    </a>",
"    ], but the following principles apply:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Since the mediastinum is infrequently involved, the design of fields above the diaphragm often includes a central block to protect the heart.",
"     </li>",
"     <li>",
"      CT-based simulation with three-dimensional (3-D) conformal treatment planning improves accuracy in demarcating nodal disease and ideally ensures that the fields provide adequate dosimetric coverage of the clinical target volume. The contoured tumor volumes do not act as a boundary in the design of conformal fields; instead, involved-field borders are created to treat the nodal region while ensuring that the tumor volumes are not inadvertently blocked or left in a low-dose region near the block edge.",
"     </li>",
"     <li>",
"      Intensity-modulated radiation therapy (IMRT) that allows for even more conformal dose distributions through the use of multiple beam arrangements with active beam modulation during treatment delivery with dynamic multi-leaf collimators has provided an important treatment approach for patients with a number of different cancers. However, there is little role for this technique in NLPHL as the required doses are low, more than just the tumor mass needs to be treated, and IMRT theoretically treats a larger amount of normal tissue to low doses. This may have negative implications in potentially increasing the late risk of second cancers. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?31/55/32630?source=see_link\">",
"       \"Intensity-modulated radiation therapy\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     RT with or without chemotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prognosis of patients with NLPHL treated with moderate dose RT with or without chemotherapy is favorable. However, studies directly comparing these two approaches are limited in number. Representative studies are presented below.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the European Task Force on Lymphomas (ETFL) study, patients with stage I NLPHL were treated with either radiation therapy (RT) alone (88 percent) or RT combined with chemotherapy (12 percent). The corresponding figures for patients with stage II disease were 57 percent and 38 percent, respectively. The eight-year overall survival and freedom from treatment failure (FFTF) were 99 percent and 85 percent for patients with stage I disease and 94 percent and 71 percent for patients with stage II disease, respectively [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/45/34520/abstract/19\">",
"       19",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A retrospective report from the German Hodgkin Study Group (GHSG) analyzed the treatment outcome of 131 patients with clinical stage IA NLPHL without risk factors (ie, bulky disease more than 10 cm or B symptoms) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/45/34520/abstract/20\">",
"       20",
"      </a>",
"      ]. Forty-five patients received extended-field (EF) RT, 45 patients received involved-field (IF) RT, and 41 patients received combined modality treatment (two to four cycles of ABVD followed by",
"      <span class=\"nowrap\">",
"       EF/IF-RT).",
"      </span>",
"      Estimated 24-month freedom from treatment failure rates were 100, 92, and 97 percent, respectively for the three treatment groups. However, the median follow-up in each group varied, and in the IF-RT group the median follow-up was only 17 months, an insufficient follow-up time in a disease in which late relapses may occur.",
"     </li>",
"     <li>",
"      A retrospective study from the M.D. Anderson Cancer Center compared the outcome in 48 patients with stage I-II NLPHL who were treated with RT alone (n = 37) or combined modality therapy (n = 11) and found that the addition of chemotherapy did not improve relapse-free or overall survival at a median follow-up of 9.3 years [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/45/34520/abstract/21\">",
"       21",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A prospective randomized trial evaluated the role of radiation therapy (30 Gy to extended field plus 10 Gy to involved field) with or without two cycles of ABVD chemotherapy in patients with newly diagnosed stage I-II Hodgkin lymphoma without risk factors [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/45/34520/abstract/22\">",
"       22",
"      </a>",
"      ]. A subset analysis of 64 patients with NLPHL showed a nonsignificant trend toward better freedom from treatment failure in the combined modality treatment group (7-year FFTF of 96 versus 83 percent) but no difference in overall survival.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These data, although limited, tend to support the concept of limited treatment (ie, RT only) in early stage favorable NLPHL.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Chemotherapy alone",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is a paucity of data regarding the use of chemotherapy alone in this disease.",
"   </p>",
"   <p>",
"    A case series of seven children with stage I-II NLPHL treated with six cycles of EBVD chemotherapy without radiation showed a 100 percent complete remission rate but a 43 percent relapse rate at a median follow-up time of four years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/45/34520/abstract/23\">",
"     23",
"    </a>",
"    ]. All of these relapses were salvaged with further chemotherapy without radiation.",
"   </p>",
"   <p>",
"    A second series of 37 patients with NLPHL enrolled on prospective clinical trials of chemotherapy reported treatment failure rates of 75 and 32 percent for patients who received",
"    <span class=\"nowrap\">",
"     ABVD/EVA",
"    </span>",
"    (9 of12 patients) or MOPP-based therapy (8 of 25 patients), respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/45/34520/abstract/24\">",
"     24",
"    </a>",
"    ]. Although the data are sparse, these results suggest that ABVD alone for NLPHL is less effective than when used for classical Hodgkin lymphoma.",
"   </p>",
"   <p>",
"    A retrospective analysis reviewed 42 cases of childhood NLPHL treated with either radiation therapy alone (35 Gy) or combination chemotherapy (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/52/35654?source=see_link\">",
"     chlorambucil",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/3/4152?source=see_link\">",
"     vinblastine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/45/24279?source=see_link\">",
"     procarbazine",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/48/33536?source=see_link\">",
"     prednisolone",
"    </a>",
"    ) for stage IA disease or the same combination chemotherapy for higher stage disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/45/34520/abstract/11\">",
"     11",
"    </a>",
"    ]. Patients were stage IA (57 percent), IIA (26 percent), IIIA (9 percent), IIIB (2 percent), and IVA (6 percent). All patients achieved a complete response. At a median follow-up of 8.9 years, six patients relapsed, four of whom had been treated with radiation alone and two with chemotherapy alone. Five of the six relapsed patients were salvaged with second line chemotherapy and were alive and disease free 3 to 10 years after recurrence. The 5-year and 10-year relapse-free survival rates were 87 percent and 82 percent, respectively.",
"   </p>",
"   <p>",
"    The use of chemotherapy alone for early stage NLPHL is not recommended outside a clinical trial. The use of immunotherapy is discussed below. (See",
"    <a class=\"local\" href=\"#H18\">",
"     'Rituximab'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Recurrent disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients treated for NLPHL tend to develop late recurrences at sites distant from the original regions of presentation and can relapse repeatedly [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/45/34520/abstract/16,25,26\">",
"     16,25,26",
"    </a>",
"    ]. Retrospective studies show that the freedom from treatment failure rates decline post-treatment from 5 years (range 67 to 100 percent) to 10 years (45 to 88 percent) to 15 years (71 to 82 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/45/34520/abstract/10,15,16,19,20,27-32\">",
"     10,15,16,19,20,27-32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Fortunately, patients who experience distant relapse can generally be salvaged with repeat treatment with involved-field RT to areas of nodal relapse or chemotherapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/45/34520/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Treatment related complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;The late morbidity associated with RT in patients with NLPHL may contribute significantly to the causes of death in these patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/45/34520/abstract/10,15,16,27,28,30,33-35\">",
"     10,15,16,27,28,30,33-35",
"    </a>",
"    ]. Unfortunately, death as a result of a second malignancy (6 percent) can be as common as death from HL (6 percent) and death from other causes (6 percent). Cardiac disease was also an important competing cause of mortality in these patients (4 percent). Thus, the long-term follow-up of these patients is critical, to monitor for disease recurrence, screen for second malignancies, and reduce other risk factors for the development of cardiovascular disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/45/34520/abstract/36,37\">",
"     36,37",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/21/34137?source=see_link\">",
"     \"Cardiotoxicity of radiation therapy for malignancy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/26/35242?source=see_link\">",
"     \"Second malignancies after treatment of classical Hodgkin lymphoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/19/30007?source=see_link\">",
"     \"Monitoring of the patient with classical Hodgkin lymphoma during and after treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Three-dimensional conformal radiotherapy with the use of CT-based simulation allows the radiation oncologist to limit the dose to normal tissue structures that do not harbor cancer cells. With time we may see a decrease in treatment related complications as the amount of normal tissue exposed to radiation decreases.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     STAGE IB/IIB DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although the presence of B symptoms is unusual in early stage disease, there are some data to suggest that these patients need more aggressive therapy than patients with stage IA-IIA disease. A retrospective multicenter study examined the long term outcome after radiotherapy alone in 202 patients with stage I-II lymphocyte-predominant Hodgkin lymphoma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/45/34520/abstract/10\">",
"     10",
"    </a>",
"    ]. Although only 3 percent of these patients had B symptoms, their presence resulted in significantly decreased overall survival and freedom from progression (HR 14.4; 95% CI 3.8-54.2).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     STAGE III/IV DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately one-quarter of patients with NLPHL will present with stage III or IV disease. These patients have a significantly worse prognosis than patients with earlier stage disease and warrant more aggressive therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Chemotherapy and RT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The best data on the treatment of patients with stage III-IV NLPHL are derived from the ETFL study [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/45/34520/abstract/19\">",
"     19",
"    </a>",
"    ]. In this study clinical data and biopsy material was collected from 426 patients with presumed NLPHL based upon the Rye classification system [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/45/34520/abstract/19\">",
"     19",
"    </a>",
"    ]. After the biopsy specimens were meticulously reviewed using the stringent morphologic and immunophenotypic criteria of the REAL classification system, 51 percent were confirmed to be NLPHL, while the remainder were reclassified. This study showed that the clinical outcome for patients with advanced stage NLPHL is similar to that of patients with advanced CHL. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/41/33432?source=see_link&amp;anchor=H14#H14\">",
"     \"Clinical manifestations, pathologic features, and diagnosis of nodular lymphocyte-predominant Hodgkin lymphoma\", section on 'Diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Of the 219 cases confirmed to be LPHD by REAL classification, 53, 28, 14, and 6 percent were stage I, II, III, and IV, respectively. Thirteen percent had bulky disease and 10 percent had B symptoms.",
"     </li>",
"     <li>",
"      Patients with stage III or IV disease were treated with radiation alone (19 and 5 percent, respectively), chemotherapy alone (41 and 63 percent respectively) or combined modality treatment (41 and 32 percent, respectively). Most of the patients were treated during the 1980s on protocol chemotherapy regimens that were MOPP-like (49 percent) or",
"      <span class=\"nowrap\">",
"       MOPP/ABVD-like",
"      </span>",
"      (36 percent). The specifics of the radiation therapy were not defined. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?38/54/39786?source=see_link\">",
"       \"Initial treatment of advanced (stage III-IV) classical Hodgkin lymphoma\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patients were followed for a median of 6.8 years for LPHL. Across all stages, primary therapy resulted in complete remission in 210 patients (96 percent), partial remission in 6 patients (3 percent), and progressive disease or no change in 3 patients (1 percent). Forty-five patients (21 percent) relapsed with 12 patients relapsing more than once. Thirty-one patients (14 percent) died.",
"     </li>",
"     <li>",
"      For stage III patients, eight-year Hodgkin lymphoma specific survival and failure-free survival were 94 percent and 62 percent, respectively. For stage IV patients, eight-year Hodgkin lymphoma specific survival and failure-free survival were 41 percent and 24 percent, respectively. These rates were similar between LPHL and LRCHL and were not significantly better stage for stage than those for CHD.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There are extremely limited data concerning the relative effectiveness of various chemotherapeutic regimens when used for the initial treatment or relapse of NLPHL. In one study, 8 of 12 patients treated with MOPP or a MOPP-like regimen achieved a durable first or second complete remission without additional treatment, while only two of six patients treated initially or at first relapse with",
"    <span class=\"nowrap\">",
"     ABVD/EVA",
"    </span>",
"    achieved a similar response [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/45/34520/abstract/15\">",
"     15",
"    </a>",
"    ]. Given the potential toxicities associated with alkylating agent-based chemotherapy, it is wise to use chemotherapy only in the setting of advanced or recurrent disease. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/54/39786?source=see_link\">",
"     \"Initial treatment of advanced (stage III-IV) classical Hodgkin lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Rituximab",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"     Rituximab",
"    </a>",
"    , a monoclonal antibody directed against the CD20 surface antigen, has been effective in treating a variety of B-cell lymphoid malignancies that express CD20. There has been increasing interest in exploring rituximab as a potential therapy for NLPHL, given that the neoplastic cell in this disorder expresses CD20 and that rituximab is associated with fewer side effects than conventional chemotherapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/45/34520/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are preliminary data to support",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    's efficacy in NLPHL. Small phase II studies of single agent rituximab have demonstrated high response rate and remission rate in both untreated and previously treated patients with NLPHL [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/45/34520/abstract/39-41\">",
"     39-41",
"    </a>",
"    ]. As an example, a GHSG phase II trial of rituximab (375",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    weekly for four doses) in 29 adults with stage IA NLPHL reported an overall response rate of 100 percent (86 percent complete) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/45/34520/abstract/40\">",
"     40",
"    </a>",
"    ]. At a median follow-up of 43 months, progression-free survival at 36 months was 81 percent. Patients who relapsed were able to achieve a complete response with radiation",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    chemotherapy.",
"   </p>",
"   <p>",
"    Given the paucity of data, prospective studies are needed to establish the role of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    , alone or in combination, in the management of NLPHL.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Palliative RT",
"    </span>",
"    &nbsp;&mdash;&nbsp;RT can be given for palliation to patients with advanced NLPHL with bulky sites of disease causing discomfort, pain, or compromise of critical organs. Conventional courses of RT to a dose of 30 to 36 Gy usually provide rapid and durable regression of disease. The radiation therapist must be cautious not to exceed normal tissue tolerance in the treatment fields, particularly in patients who may have received multiple prior courses of RT.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;In general the prognosis of patients with NLPHL is better than that of patients with CHL. This is likely related to the distribution of disease stage, since patients with NLPHL are less likely to present with advanced stage disease, B symptoms, or bulky disease, all of which are poor prognostic features. Two major studies that provide insight into prognosis of NLPHL are summarized below:",
"   </p>",
"   <p>",
"    The German Hodgkin's Lymphoma Study Group (GHSG) provided four-year follow-up data on 394 patients with NLPHL treated between 1988 and 2002 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/45/34520/abstract/3,42\">",
"     3,42",
"    </a>",
"    ]. Patients fell into three groups: 63 percent with \"early stage disease\" (ie, stage I or II disease and none of the following risk factors: large mediastinal masses, extranodal disease, splenomegaly, elevated erythrocyte sedimentation rate, or three or more nodal sites), 16 percent \"intermediate stage\" (ie, stage I or II with at least one of the above risk factors), and 21 percent \"advanced stage\" (stage IIB with risk factors or stage III or IV).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Early stage disease was treated with radiation or ABVD plus radiation with 91 percent of patients achieving a complete remission. Intermediate stage disease was treated with chemotherapy (ABVD, BEACOPP,",
"      <span class=\"nowrap\">",
"       COPP/ABVD,",
"      </span>",
"      or",
"      <span class=\"nowrap\">",
"       COPP/ABV/IMEP)",
"      </span>",
"      plus radiation therapy with 86 percent of patients achieving a complete remission. Advanced stage disease was treated with chemotherapy (BEACOPP,",
"      <span class=\"nowrap\">",
"       COPP/ABVD,",
"      </span>",
"      or",
"      <span class=\"nowrap\">",
"       COPP/ABV/IMEP)",
"      </span>",
"      plus radiation therapy with 77 percent of patients achieving a complete remission.",
"     </li>",
"     <li>",
"      The four-year freedom from treatment failure (FFTF) rates were 93, 87, and 77 percent for patients in the early, intermediate, and advanced stages, respectively [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/45/34520/abstract/3\">",
"       3",
"      </a>",
"      ]. These rates did not differ significantly, stage for stage, from those seen in the patients with CHL. Overall survival (OS) at four years was 96 percent.",
"     </li>",
"     <li>",
"      Thirty-one deaths occurred among the LPHD patients. Eight deaths (26 percent) were due to HL, 10 deaths (32 percent) were from secondary malignancies including",
"      <span class=\"nowrap\">",
"       leukemia/MDS,",
"      </span>",
"      NHL, and solid tumors.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A study from the European task force on lymphoma of 219 patients confirmed to have NLPHL by the REAL classification system and treated with radiation, chemotherapy, or a combined modality approach reported estimated rates of OS at eight years of 85, 71, 62, and 24 percent for patients with stage I, II, III, and IV disease, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/45/34520/abstract/19\">",
"     19",
"    </a>",
"    ]. Corresponding rates of FFTF were 99, 94, 94, and 41 percent.",
"   </p>",
"   <p>",
"    Together, these data are consistent with those from other retrospective studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/45/34520/abstract/10,11,15,18,19,27-32\">",
"     10,11,15,18,19,27-32",
"    </a>",
"    ]. As noted above, patients with stages I to III disease have relapse rates ranging from 15 to 38 percent, but have overall survivals in the range of 94 to 99 percent, since relapses are almost always responsive to further treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Transformation to NHL",
"    </span>",
"    &nbsp;&mdash;&nbsp;The cause of death of patients with NLPHL is often NHL, other cancers, or complications of treatment rather than HL [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/45/34520/abstract/43-45\">",
"     43-45",
"    </a>",
"    ]. Patients with NLPHL have a slightly higher risk of development of NHL (2 to 5 percent) than patients with other types of HL [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/45/34520/abstract/25,43-47\">",
"     25,43-47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Transformation to a large cell lymphoma is most common with a 10-year cumulative rate of approximately 12 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/45/34520/abstract/25\">",
"     25",
"    </a>",
"    ]. Most cases studied have a B-cell immunophenotype, with monotypic Ig expression in about 30 to 50 percent. In some cases, a clonal relationship between the NLPHL and the large cell lymphoma has been shown by molecular genetic analysis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/45/34520/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In one study, patients with diffuse large B cell lymphoma (DLBCL) arising in the context of nodular lymphocyte-predominant Hodgkin lymphoma, and who were treated aggressively with curative chemotherapy for DLBCL, appeared to have similar survival outcomes as those who were diagnosed with de novo DLBCL [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/45/34520/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      While current treatment of early stage classical Hodgkin lymphoma (CHL) most often involves the use of combination chemotherapy plus involved-field radiation therapy, there are little data to support a similar treatment approach in nodular lymphocyte predominant Hodgkin lymphoma (NLPHL).",
"     </li>",
"     <li>",
"      Treatment of patients with stage I-II NLPHL should be with local-regional radiation therapy alone. We recommend utilizing doses of 30 to 36 Gy (",
"      <a class=\"grade\" href=\"._grade_3?title=Grade 1C\">",
"       Grade 1C",
"      </a>",
"      ). Doses of 30 Gy are generally considered sufficient in patients whose nodal disease has been completely excised surgically (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Stage IA/IIA disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with advanced stage disease (ie, stage",
"      <span class=\"nowrap\">",
"       III/IV)",
"      </span>",
"      respond to treatment in a similar fashion to patients with CHL and identical clinical stage. We recommend treating such patients according to protocols used in CHL (",
"      <a class=\"grade\" href=\"._grade_3?title=Grade 1C\">",
"       Grade 1C",
"      </a>",
"      ).These treatment regimens are discussed separately. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Stage III/IV disease'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?38/54/39786?source=see_link\">",
"       \"Initial treatment of advanced (stage III-IV) classical Hodgkin lymphoma\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Approximately 15 to 30 percent of patients with NLPHL relapse. Relapsed disease tends to be responsive to further chemotherapy",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      involved field radiation. Patients with relapsed disease should be restaged and treated accordingly. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Prognosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      As treatment for Hodgkin lymphoma has become more successful, patients are experiencing long term complications from their treatment (eg, secondary malignancies, cardiac disease, hypothyroidism). This emphasizes the need for long-term follow-up of these patients, both to monitor for disease recurrence as well as to screen for second malignancies and treatment related complications. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Treatment related complications'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?33/21/34137?source=see_link\">",
"       \"Cardiotoxicity of radiation therapy for malignancy\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?34/26/35242?source=see_link\">",
"       \"Second malignancies after treatment of classical Hodgkin lymphoma\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?29/19/30007?source=see_link\">",
"       \"Monitoring of the patient with classical Hodgkin lymphoma during and after treatment\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/45/34520/abstract/1\">",
"      Carbone PP, Kaplan HS, Musshoff K, et al. Report of the Committee on Hodgkin's Disease Staging Classification. Cancer Res 1971; 31:1860.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/45/34520/abstract/2\">",
"      Lister TA, Crowther D, Sutcliffe SB, et al. Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting. J Clin Oncol 1989; 7:1630.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/45/34520/abstract/3\">",
"      Nogov&aacute; L, Reineke T, Brillant C, et al. Lymphocyte-predominant and classical Hodgkin's lymphoma: a comprehensive analysis from the German Hodgkin Study Group. J Clin Oncol 2008; 26:434.",
"     </a>",
"    </li>",
"    <li>",
"     National Comprehensive Cancer Network (NCCN) guidelines. Available at: www.nccn.org (Accessed on May 15, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/45/34520/abstract/5\">",
"      Miettinen M, Franssila KO, Sax&eacute;n E. Hodgkin's disease, lymphocytic predominance nodular. Increased risk for subsequent non-Hodgkin's lymphomas. Cancer 1983; 51:2293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/45/34520/abstract/6\">",
"      Hansmann ML, Zwingers T, B&ouml;ske A, et al. Clinical features of nodular paragranuloma (Hodgkin's disease, lymphocyte predominance type, nodular). J Cancer Res Clin Oncol 1984; 108:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/45/34520/abstract/7\">",
"      Pellegrino B, Terrier-Lacombe MJ, Oberlin O, et al. Lymphocyte-predominant Hodgkin's lymphoma in children: therapeutic abstention after initial lymph node resection--a Study of the French Society of Pediatric Oncology. J Clin Oncol 2003; 21:2948.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/45/34520/abstract/8\">",
"      Murphy SB, Morgan ER, Katzenstein HM, Kletzel M. Results of little or no treatment for lymphocyte-predominant Hodgkin disease in children and adolescents. J Pediatr Hematol Oncol 2003; 25:684.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/45/34520/abstract/9\">",
"      Mauz-K&ouml;rholz C, Gorde-Grosjean S, Hasenclever D, et al. Resection alone in 58 children with limited stage, lymphocyte-predominant Hodgkin lymphoma-experience from the European network group on pediatric Hodgkin lymphoma. Cancer 2007; 110:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/45/34520/abstract/10\">",
"      Wirth A, Yuen K, Barton M, et al. Long-term outcome after radiotherapy alone for lymphocyte-predominant Hodgkin lymphoma: a retrospective multicenter study of the Australasian Radiation Oncology Lymphoma Group. Cancer 2005; 104:1221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/45/34520/abstract/11\">",
"      Hall GW, Katzilakis N, Pinkerton CR, et al. Outcome of children with nodular lymphocyte predominant Hodgkin lymphoma - a Children's Cancer and Leukaemia Group report. Br J Haematol 2007; 138:761.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/45/34520/abstract/12\">",
"      Chera BS, Olivier K, Morris CG, et al. Clinical presentation and outcomes of lymphocyte-predominant Hodgkin disease at the University of Florida. Am J Clin Oncol 2007; 30:601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/45/34520/abstract/13\">",
"      Haas RL, Girinsky T, Aleman BM, et al. Low-dose involved-field radiotherapy as alternative treatment of nodular lymphocyte predominance Hodgkin's lymphoma. Int J Radiat Oncol Biol Phys 2009; 74:1199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/45/34520/abstract/14\">",
"      Chen RC, Chin MS, Ng AK, et al. Early-stage, lymphocyte-predominant Hodgkin's lymphoma: patient outcomes from a large, single-institution series with long follow-up. J Clin Oncol 2010; 28:136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/45/34520/abstract/15\">",
"      Bodis S, Kraus MD, Pinkus G, et al. Clinical presentation and outcome in lymphocyte-predominant Hodgkin's disease. J Clin Oncol 1997; 15:3060.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/45/34520/abstract/16\">",
"      Regula DP Jr, Hoppe RT, Weiss LM. Nodular and diffuse types of lymphocyte predominance Hodgkin's disease. N Engl J Med 1988; 318:214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/45/34520/abstract/17\">",
"      Schlembach PJ, Wilder RB, Jones D, et al. Radiotherapy alone for lymphocyte-predominant Hodgkin's disease. Cancer J 2002; 8:377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/45/34520/abstract/18\">",
"      Yahalom J, Mauch P. The involved field is back: issues in delineating the radiation field in Hodgkin's disease. Ann Oncol 2002; 13 Suppl 1:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/45/34520/abstract/19\">",
"      Diehl V, Sextro M, Franklin J, et al. Clinical presentation, course, and prognostic factors in lymphocyte-predominant Hodgkin's disease and lymphocyte-rich classical Hodgkin's disease: report from the European Task Force on Lymphoma Project on Lymphocyte-Predominant Hodgkin's Disease. J Clin Oncol 1999; 17:776.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/45/34520/abstract/20\">",
"      Nogov&aacute; L, Reineke T, Eich HT, et al. Extended field radiotherapy, combined modality treatment or involved field radiotherapy for patients with stage IA lymphocyte-predominant Hodgkin's lymphoma: a retrospective analysis from the German Hodgkin Study Group (GHSG). Ann Oncol 2005; 16:1683.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/45/34520/abstract/21\">",
"      Wilder RB, Schlembach PJ, Jones D, et al. European Organization for Research and Treatment of Cancer and Groupe d'Etude des Lymphomes de l'Adulte very favorable and favorable, lymphocyte-predominant Hodgkin disease. Cancer 2002; 94:1731.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/45/34520/abstract/22\">",
"      Engert A, Franklin J, Eich HT, et al. Two cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine plus extended-field radiotherapy is superior to radiotherapy alone in early favorable Hodgkin's lymphoma: final results of the GHSG HD7 trial. J Clin Oncol 2007; 25:3495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/45/34520/abstract/23\">",
"      van Grotel M, Lam KH, de Man R, et al. High relapse rate in children with non-advanced nodular lymphocyte predominant Hodgkin's lymphoma (NLPHL or nodular paragranuloma) treated with chemotherapy only. Leuk Lymphoma 2006; 47:1504.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/45/34520/abstract/24\">",
"      Canellos GP, Mauch P. What is the appropriate systemic chemotherapy for lymphocyte-predominant Hodgkin's lymphoma? J Clin Oncol 2010; 28:e8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/45/34520/abstract/25\">",
"      Biasoli I, Stamatoullas A, Meignin V, et al. Nodular, lymphocyte-predominant Hodgkin lymphoma: a long-term study and analysis of transformation to diffuse large B-cell lymphoma in a cohort of 164 patients from the Adult Lymphoma Study Group. Cancer 2010; 116:631.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/45/34520/abstract/26\">",
"      Jackson C, Sirohi B, Cunningham D, et al. Lymphocyte-predominant Hodgkin lymphoma--clinical features and treatment outcomes from a 30-year experience. Ann Oncol 2010; 21:2061.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/45/34520/abstract/27\">",
"      Borg-Grech A, Radford JA, Crowther D, et al. A comparative study of the nodular and diffuse variants of lymphocyte-predominant Hodgkin's disease. J Clin Oncol 1989; 7:1303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/45/34520/abstract/28\">",
"      Pappa VI, Norton AJ, Gupta RK, et al. Nodular type of lymphocyte predominant Hodgkin's disease. A clinical study of 50 cases. Ann Oncol 1995; 6:559.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/45/34520/abstract/29\">",
"      Crennan E, D'Costa I, Liew KH, et al. Lymphocyte predominant Hodgkin's disease: a clinicopathologic comparative study of histologic and immunophenotypic subtypes. Int J Radiat Oncol Biol Phys 1995; 31:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/45/34520/abstract/30\">",
"      Orlandi E, Lazzarino M, Brusamolino E, et al. Nodular lymphocyte predominance Hodgkin's disease: long-term observation reveals a continuous pattern of recurrence. Leuk Lymphoma 1997; 26:359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/45/34520/abstract/31\">",
"      Ha CS, Kavadi V, Dimopoulos MA, et al. Hodgkin's disease with lymphocyte predominance: long-term results based on current histopathologic criteria. Int J Radiat Oncol Biol Phys 1999; 43:329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/45/34520/abstract/32\">",
"      Feugier P, Labouyrie E, Djeridane M, et al. Comparison of initial characteristics and long-term outcome of patients with lymphocyte-predominant Hodgkin lymphoma and classical Hodgkin lymphoma at clinical stages IA and IIA prospectively treated by brief anthracycline-based chemotherapies plus extended high-dose irradiation. Blood 2004; 104:2675.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/45/34520/abstract/33\">",
"      Trudel MA, Krikorian JG, Neiman RS. Lymphocyte predominance Hodgkin's disease. A clinicopathologic reassessment. Cancer 1987; 59:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/45/34520/abstract/34\">",
"      Tefferi A, Zellers RA, Banks PM, et al. Clinical correlates of distinct immunophenotypic and histologic subcategories of lymphocyte-predominance Hodgkin's disease. J Clin Oncol 1990; 8:1959.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/45/34520/abstract/35\">",
"      Friedman DL, Constine LS. Late effects of treatment for Hodgkin lymphoma. J Natl Compr Canc Netw 2006; 4:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/45/34520/abstract/36\">",
"      Hancock SL, Hoppe RT. Long-Term Complications of Treatment and Causes of Mortality After Hodgkin's Disease. Semin Radiat Oncol 1996; 6:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/45/34520/abstract/37\">",
"      Zs&oacute;fia M, Katalin K, Judit V, et al. What is the price of survival in Hodgkin's lymphoma? Long-term follow-up of cured patients. Hematol Oncol 2007; 25:178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/45/34520/abstract/38\">",
"      Rehwald U, Schulz H, Reiser M, et al. Treatment of relapsed CD20+ Hodgkin lymphoma with the monoclonal antibody rituximab is effective and well tolerated: results of a phase 2 trial of the German Hodgkin Lymphoma Study Group. Blood 2003; 101:420.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/45/34520/abstract/39\">",
"      Schulz H, Rehwald U, Morschhauser F, et al. Rituximab in relapsed lymphocyte-predominant Hodgkin lymphoma: long-term results of a phase 2 trial by the German Hodgkin Lymphoma Study Group (GHSG). Blood 2008; 111:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/45/34520/abstract/40\">",
"      Eichenauer DA, Fuchs M, Pluetschow A, et al. Phase 2 study of rituximab in newly diagnosed stage IA nodular lymphocyte-predominant Hodgkin lymphoma: a report from the German Hodgkin Study Group. Blood 2011; 118:4363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/45/34520/abstract/41\">",
"      Ekstrand BC, Lucas JB, Horwitz SM, et al. Rituximab in lymphocyte-predominant Hodgkin disease: results of a phase 2 trial. Blood 2003; 101:4285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/45/34520/abstract/42\">",
"      Nogov&aacute; L, Reineke T, Josting A, et al. Lymphocyte-predominant and classical Hodgkin's lymphoma--comparison of outcomes. Eur J Haematol Suppl 2005; :106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/45/34520/abstract/43\">",
"      K&uuml;ppers R, Rajewsky K, Zhao M, et al. Hodgkin disease: Hodgkin and Reed-Sternberg cells picked from histological sections show clonal immunoglobulin gene rearrangements and appear to be derived from B cells at various stages of development. Proc Natl Acad Sci U S A 1994; 91:10962.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/45/34520/abstract/44\">",
"      Tamaru J, Hummel M, Zemlin M, et al. Hodgkin's disease with a B-cell phenotype often shows a VDJ rearrangement and somatic mutations in the VH genes. Blood 1994; 84:708.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/45/34520/abstract/45\">",
"      Delabie J, Tierens A, Wu G, et al. Lymphocyte predominance Hodgkin's disease: lineage and clonality determination using a single-cell assay. Blood 1994; 84:3291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/45/34520/abstract/46\">",
"      Coleman M, Kaufmann T, Nisce LZ, Leonard JP. Treatment of nonlaparotomized (clinical) stage I and II Hodgkin's disease patients by extended field and splenic irradiation. Int J Radiat Oncol Biol Phys 2000; 46:1235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/45/34520/abstract/47\">",
"      Chan WC. Cellular origin of nodular lymphocyte-predominant Hodgkin's lymphoma: immunophenotypic and molecular studies. Semin Hematol 1999; 36:242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/45/34520/abstract/48\">",
"      Braeuninger A, K&uuml;ppers R, Strickler JG, et al. Hodgkin and Reed-Sternberg cells in lymphocyte predominant Hodgkin disease represent clonal populations of germinal center-derived tumor B cells. Proc Natl Acad Sci U S A 1997; 94:9337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/45/34520/abstract/49\">",
"      Huang JZ, Weisenburger DD, Vose JM, et al. Diffuse large B-cell lymphoma arising in nodular lymphocyte predominant Hodgkin lymphoma: a report of 21 cases from the Nebraska Lymphoma Study Group. Leuk Lymphoma 2004; 45:1551.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4732 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-118.195.65.248-E943584887-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_45_34520=[""].join("\n");
var outline_f33_45_34520=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H22\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      STAGING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      STAGE IA/IIA DISEASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Overview",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Natural history",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Surgical excision alone",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Radiation therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Reduced volume RT",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - RT technique",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      RT with or without chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Chemotherapy alone",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Recurrent disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Treatment related complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      STAGE IB/IIB DISEASE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      STAGE III/IV DISEASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Chemotherapy and RT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Rituximab",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Palliative RT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Transformation to NHL",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/4732\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/4732|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?19/23/19836\" title=\"table 1\">",
"      Cotswolds system in HL",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/21/34137?source=related_link\">",
"      Cardiotoxicity of radiation therapy for malignancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/41/33432?source=related_link\">",
"      Clinical manifestations, pathologic features, and diagnosis of nodular lymphocyte-predominant Hodgkin lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/54/39786?source=related_link\">",
"      Initial treatment of advanced (stage III-IV) classical Hodgkin lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/55/32630?source=related_link\">",
"      Intensity-modulated radiation therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/19/30007?source=related_link\">",
"      Monitoring of the patient with classical Hodgkin lymphoma during and after treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/26/35242?source=related_link\">",
"      Second malignancies after treatment of classical Hodgkin lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/37/14935?source=related_link\">",
"      Staging and prognosis of Hodgkin lymphoma",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f33_45_34521="Overview and management of lower extremity chronic venous disease";
var content_f33_45_34521=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Overview and management of lower extremity chronic venous disease",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/45/34521/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/45/34521/contributors\">",
"     Patrick C Alguire, MD, FACP",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/45/34521/contributors\">",
"     Sherry Scovell, MD, FACS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/45/34521/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/45/34521/contributors\">",
"     John F Eidt, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/45/34521/contributors\">",
"     Joseph L Mills, Sr, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/45/34521/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/45/34521/contributors\">",
"     Kathryn A Collins, MD, PhD, FACS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?33/45/34521/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 27, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vein related problems may or may not be symptomatic, and include a wide range of clinical signs that vary from minimal superficial venous dilation to chronic skin changes with ulceration. Chronic venous disease refers to a wide spectrum of morphologic (ie, venous dilation)",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    functional abnormalities (eg, venous reflux) of long duration [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/45/34521/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic vein abnormalities are present in up to 50 percent of individuals [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/45/34521/abstract/2-5\">",
"     2-5",
"    </a>",
"    ]. However, estimates of prevalence rates of chronic venous disease vary depending upon the population studied [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/45/34521/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Epidemiologic studies typically focus on defined subsets based upon the visible manifestations of venous disease. Study populations are generally limited to either those with mild venous dilation (telangiectasias, reticular veins), or uncomplicated varicose veins with or without venous reflux, or longstanding venous insufficiency (ie, skin changes, venous ulceration). While it is convenient to stratify the study of venous abnormalities in this manner, it is important to remember that these subsets represent varying levels of disease severity in a spectrum of a single pathology; risk factors for development are the same. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Risk factors'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The prevalence of symptoms and clinical signs of venous disease correlates with the presence of venous reflux identified with duplex ultrasound [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/45/34521/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/43/33462?source=see_link\">",
"     \"Diagnostic evaluation of chronic venous insufficiency\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Telangiectasias &mdash; Telangiectasias and reticular veins are dilated intradermal and subdermal veins, respectively (",
"      <a class=\"graphic graphic_picture graphicRef62119 \" href=\"mobipreview.htm?17/58/18351\">",
"       picture 1",
"      </a>",
"      ). Compared to other levels of venous disease severity, less severe venous abnormalities (ie, telangiectasias and reticular veins) are the most prevalent, occurring in the absence of more significant abnormalities (ie, varicose veins) in 50 to 66 percent of individuals depending upon the population studied [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/45/34521/abstract/6,8\">",
"       6,8",
"      </a>",
"      ]. Women (56 to 71 percent) are more commonly affected than men (36 to 44 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/45/34521/abstract/6,8\">",
"       6,8",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Varicose veins &mdash; Varicose veins are dilated, elongated, tortuous, subcutaneous veins three millimeters or greater in size (",
"      <a class=\"graphic graphic_picture graphicRef56463 graphicRef68551 \" href=\"mobipreview.htm?15/19/15669\">",
"       picture 2A-B",
"      </a>",
"      ). Varicose veins are present in 10 to 30 percent of the general population, with increasing rates in older individuals [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/45/34521/abstract/4,5\">",
"       4,5",
"      </a>",
"      ]. Varicose veins are generally thought to be more common in women than men, however, depending upon the population evaluated, men may have a higher rate [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/45/34521/abstract/3-5,9-11\">",
"       3-5,9-11",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Chronic venous insufficiency &mdash; Chronic venous insufficiency refers to the presence of edema (",
"      <a class=\"graphic graphic_picture graphicRef56758 \" href=\"mobipreview.htm?3/63/4080\">",
"       picture 3",
"      </a>",
"      ), skin changes (",
"      <a class=\"graphic graphic_picture graphicRef76901 \" href=\"mobipreview.htm?25/57/26527\">",
"       picture 4",
"      </a>",
"      ), or ulceration (",
"      <a class=\"graphic graphic_picture graphicRef71020 \" href=\"mobipreview.htm?13/14/13536\">",
"       picture 5",
"      </a>",
"      ) and is most commonly associated with chronic venous reflux [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/45/34521/abstract/12\">",
"       12",
"      </a>",
"      ]. The incidence of venous insufficiency with and without ulceration also increases with age [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/45/34521/abstract/13-20\">",
"       13-20",
"      </a>",
"      ]. It is estimated that six to seven million people in the United States are affected at a given time.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Chronic venous insufficiency and ulceration and symptoms attributable to venous disease may be twice as common in women; however, results may be influenced by female longevity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/45/34521/abstract/18,19,21,22\">",
"     18,19,21,22",
"    </a>",
"    ]. In one population sample, the rate of moderate disease was twice as high among women as men, but the rate of severe disease was higher in men than women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/45/34521/abstract/23\">",
"     23",
"    </a>",
"    ]. This same study found no ethnic differences for prevalence of moderate disease, but severe disease may be less common in African American women. Men who worked as laborers had higher rates of severe disease than non-laborers.",
"   </p>",
"   <p>",
"    Since venous ulceration can be recurrent as well as chronic, studies of point prevalence tend to underestimate the number of cases. Point prevalence estimates of venous ulceration in western nations range from 0.02 to 1 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/45/34521/abstract/18,19,21,24\">",
"     18,19,21,24",
"    </a>",
"    ], while the period prevalence is higher, between 1 and 5 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/45/34521/abstract/12,21\">",
"     12,21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     RISK FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risk factors for the development of chronic venous disease include advancing age, family history of venous disease, ligamentous laxity (eg, hernia, flat feet), prolonged standing, increased body mass index, smoking, sedentary lifestyle, lower extremity trauma, prior venous thrombosis (superficial or deep), the presence of an arteriovenous shunt, some hereditary conditions, high estrogen states, and, in women, pregnancy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/45/34521/abstract/3,4,8,25-31\">",
"     3,4,8,25-31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Despite the well known association, a history of deep venous thrombosis is obtained in less than one-third of patients with severe clinical manifestations of chronic venous disease (ie, edema, ulcer, inflammation) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/45/34521/abstract/21,32,33\">",
"     21,32,33",
"    </a>",
"    ]. Duplex ultrasound in these patients may identify valvular insufficiency, chronic vein wall thickening, or chronic thrombosis indicative of post-thrombotic syndrome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/45/34521/abstract/34-36\">",
"     34-36",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/37/23127?source=see_link\">",
"     \"Post-thrombotic (postphlebitic) syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Many studies have suggested a strong familial component [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/45/34521/abstract/8,10,23\">",
"     8,10,23",
"    </a>",
"    ]. In a case-control study of 67 patients and their parents, the risk for varicose veins was 90 percent when both parents were affected, 25 percent for men and 62 percent for women when one parent was affected, and 20 percent if neither parent had varicose veins [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/45/34521/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Prevalence rates appear to be lower in non-western populations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/45/34521/abstract/38\">",
"     38",
"    </a>",
"    ]. Based upon these observations it is widely thought that factors related to western lifestyle such as prolonged standing and sitting increase the likelihood of the development of chronic venous disease. However, a large population-based study in Scotland that examined multiple potential risk factors found no consistent relationship between varicose veins and these lifestyle risk factors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/45/34521/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Telangiectasias associated with cutaneous pigmentation and atrophy may result from radiation treatments or sequelae. Some disorders are associated with telangiectasias but not of the lower extremities [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/45/34521/abstract/39\">",
"     39",
"    </a>",
"    ]. These include systemic sclerosis, cirrhosis, hereditary hemorrhagic telangiectasia, and ataxia telangiectasia. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/31/31226?source=see_link\">",
"     \"Hereditary hemorrhagic telangiectasia (Osler-Weber-Rendu syndrome)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/60/23497?source=see_link\">",
"     \"Ataxia-telangiectasia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other venous conditions can contribute to the development of venous abnormalities and include venous wall degeneration (ie, venous aneurysm), arteriovenous shunts (eg, traumatic), and non-thrombotic iliac vein obstruction (eg, May-Thurner syndrome) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/45/34521/abstract/30,31\">",
"     30,31",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Progression",
"    </span>",
"    &nbsp;&mdash;&nbsp;The factors responsible for a transition from mild to more severe manifestations are not well known. Disease progression and increasing severity of symptoms appear to be related to the extent of venous valvular incompetence [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/45/34521/abstract/8,9,22,40,41\">",
"     8,9,22,40,41",
"    </a>",
"    ]. Varicose veins tend to remain more stable in the absence of venous reflux. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/22/43365?source=see_link\">",
"     \"Pathophysiology of chronic venous disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The Framingham Study examined men and women for the presence of varicose veins every two years over a 16 year period. Over this time, 396 of 1720 men (23 percent) and 629 of 2102 women (30 percent) who were initially free from the condition developed varicose veins. However, the presence or absence of venous reflux was not evaluated. The two-year incidence of varicose veins was on average 39.4 per 1000 for men and 51.9 per 1000 for women. The incidence was highest in women 40 to 49 years of age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/45/34521/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     CLINICAL EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lower extremity chronic venous disorders encompass an entire spectrum of morphologic and functional abnormalities of the venous system. Symptoms include pain, leg heaviness or aching, swelling, dry skin, tightness, skin irritation, heaviness, muscle cramps, and itching. Clinical signs include dilated veins, edema, lipodermatosclerosis (a fibrosing dermatitis of the subcutaneous tissue), or ulceration. The clinical evaluation of the patient with lower extremity chronic venous disease is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/17/13592?source=see_link\">",
"     \"Clinical evaluation of lower extremity chronic venous disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Classification",
"    </span>",
"    &nbsp;&mdash;&nbsp;The visible signs of chronic venous disorders are categorized as C0 to C6 (CEAP classification) depending on the severity of venous signs, which include: dilated veins (eg, telangiectasia, varicose veins), leg edema, skin changes, or ulceration (",
"    <a class=\"graphic graphic_table graphicRef52388 \" href=\"mobipreview.htm?10/45/10973\">",
"     table 1",
"    </a>",
"    ). Patients are classified as asymptomatic or symptomatic depending on the presence of lower extremity symptoms. The classification of lower extremity chronic venous disorders is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/29/11735?source=see_link&amp;anchor=H6#H6\">",
"     \"Classification of lower extremity chronic venous disorders\", section on 'CEAP classification'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/29/11735?source=see_link&amp;anchor=H31#H31\">",
"     \"Classification of lower extremity chronic venous disorders\", section on 'Measures of clinical severity'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     PATHOPHYSIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Inadequate muscle pump function, incompetent venous valves (reflux), and venous obstruction are causes of elevated venous pressure (venous hypertension). Venous hypertension initiates a sequence of anatomic, physiologic, and histologic changes leading to vein dilation, skin changes, or skin ulceration. The factors that determine whether a given patient will progress from mild to more severe disease are largely unknown. The pathophysiology of chronic venous disease is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/22/43365?source=see_link\">",
"     \"Pathophysiology of chronic venous disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     DIAGNOSTIC EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The severity of both symptoms and signs of venous disease tends to correlate with the degree of venous reflux, which is identified by duplex ultrasound as retrograde or reversed flow of greater than 0.5 seconds duration [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/45/34521/abstract/42,43\">",
"     42,43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The majority of symptomatic patients should undergo venous duplex to evaluate the nature and extent of venous reflux, which impacts the choice of treatment. Any combination of superficial, perforator, or deep venous reflux can be present. The diagnostic evaluation of patients with chronic venous insufficiency is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/43/33462?source=see_link\">",
"     \"Diagnostic evaluation of chronic venous insufficiency\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     MANAGEMENT APPROACH",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients diagnosed with this disorder are managed according to clinical severity and the nature of underlying venous reflux. Treatment goals include improvement of symptoms and appearance, reduction of edema, treatment of lipodermatosclerosis, and healing of ulcers.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Conservative measures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Initial management for the majority of patients with chronic venous disease includes:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Leg elevation, exercise, and compression therapy improve oxygen transport to the skin and subcutaneous tissues, decrease edema, reduce inflammation, and compress dilated veins. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?31/41/32410?source=see_link&amp;anchor=H3#H3\">",
"       \"Medical management of lower extremity chronic venous disease\", section on 'General measures'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?31/41/32410?source=see_link&amp;anchor=H6#H6\">",
"       \"Medical management of lower extremity chronic venous disease\", section on 'Continuous compression therapy'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Skin changes respond to topical dermatologic agents. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?31/41/32410?source=see_link&amp;anchor=H23#H23\">",
"       \"Medical management of lower extremity chronic venous disease\", section on 'Skin care'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Venous ulceration is treated with a combination of ulcer wound management and compression therapy (stockings, bandaging systems). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?31/41/32410?source=see_link&amp;anchor=H28#H28\">",
"       \"Medical management of lower extremity chronic venous disease\", section on 'Ulcer care'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Systemic therapy may be beneficial for patients with symptoms that are refractory to compression therapy or who are unable to tolerate compression therapy. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?31/41/32410?source=see_link&amp;anchor=H13#H13\">",
"       \"Medical management of lower extremity chronic venous disease\", section on 'Systemic agents'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patients with symptoms (eg, lower extremity aching, pain, tightness, skin irritation, heaviness, muscle cramps) or signs of severe venous disease (skin changes, ulcers) unresponsive to medical management (eg, limb elevation, exercise, compression therapy) within six months of initiating therapy are candidates for vein ablation therapy. Specific options for intervention depend upon the presence and location of venous reflux. (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Management of venous reflux'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Ablation therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The goals of ablation therapy in patients with symptomatic venous disease are improvement in symptoms as well as appearance. Superficial vein ablation is thought to produce beneficial effects by reducing venous volume in the limb and thereby the effects of venous hypertension upon the cutaneous tissues [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/45/34521/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Ultimately, the decision to offer ablation therapy depends upon symptom severity, response to medical therapy, extent of disease, patient expectations, and likelihood of providing a durable benefit either with respect to appearance, improvement in symptoms or potential for ulcer healing. For patients with symptomatic varicose veins (eg, pain, itching), a minimum of three months of conservative treatment is warranted prior to proceeding with ablation therapy. Bleeding associated with varicose veins is treated as needed. (See",
"    <a class=\"local\" href=\"#H19\">",
"     'Vein hemorrhage'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Contraindications to lower extremity venous ablation therapies generally include [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/45/34521/abstract/45\">",
"     45",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pregnancy",
"     </li>",
"     <li>",
"      Acute superficial or deep venous thrombosis",
"     </li>",
"     <li>",
"      Moderate to severe peripheral artery disease",
"     </li>",
"     <li>",
"      Advanced generalized systemic disease",
"     </li>",
"     <li>",
"      Joint disease that interferes with mobility",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Several vein ablation techniques are available and are classified by their method of vein destruction: chemical, thermal, or mechanical. The choice of modality depends upon the size of abnormal veins, their location, and presence or absence of venous reflux. Minimally-invasive therapies using chemical (sclerotherapy) or thermal (radiofrequency, laser ablation) means to effect closure of the superficial veins appear to be at least as effective as mechanical removal (surgical stripping). A systematic review found, at three years follow-up, an estimated pooled success of 77 percent (95% CI 69-84), 84 percent (95% CI 75-90), 94 percent (95% CI 87-98), and 78 percent (95% CI, 70-84), for foam sclerotherapy, radiofrequency ablation, endovenous laser therapy and vein stripping, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/45/34521/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Chemical ablation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chemical ablation involves the introduction of an irritant agent into the vein causing endothelial damage by either detergent or osmotic action. Liquid sclerosant preparations are typically used to treat telangiectasias, reticular veins and small varicose veins.",
"   </p>",
"   <p>",
"    Foam preparations were formulated to increase the surface area of the sclerosant and decrease volume of sclerosant needed as applied to the treatment of larger varicosities, incompetent saphenous veins and perforator veins. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/12/13514?source=see_link\">",
"     \"Liquid and foam sclerotherapy techniques for the treatment of lower extremity veins\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Thermal ablation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thermal ablation involves generation of heat at a temperature high enough to denature the proteins that constitute the vein wall. This is accomplished with either the application of light energy (ie, surface laser) to the skin for treatment of smaller dilated veins or introduction of a catheter delivering laser light or radiofrequency energy (endovenous ablation) into the lumen of an incompetent vein (great saphenous, small saphenous) (",
"    <a class=\"graphic graphic_figure graphicRef55019 graphicRef52340 \" href=\"mobipreview.htm?5/25/5527\">",
"     figure 1A-B",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Surface laser therapy is used to manage telangiectasias and reticular veins while endovenous laser or radiofrequency techniques are applied to incompetent saphenous veins (great and small). Smaller radiofrequency probes are available to treat non-saphenous varicose veins and incompetent perforator veins. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/40/17031?source=see_link\">",
"     \"Laser and light therapy of lower extremity telangiectasias, reticular veins and small varicose veins\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/5/30809?source=see_link\">",
"     \"Radiofrequency ablation for the treatment of lower extremity chronic venous disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Mechanical ablation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mechanical ablation involves the physical destruction of a vein with its partial or complete removal. Vein",
"    <span class=\"nowrap\">",
"     ligation/stripping,",
"    </span>",
"    stab phlebectomy, powered phlebectomy, and open or endoscopic perforator ligation are some of the surgical techniques used. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/29/21977?source=see_link\">",
"     \"Open surgical techniques for lower extremity vein ablation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     MANAGEMENT BY CEAP CLINICAL CATEGORY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of venous disease depends on symptoms, extent of lower extremity disease, patient expectations, and likelihood of providing a durable benefit either with respect to appearance or improvement in symptoms. Some individuals with large varicosities do not have significant complaints and may not find the appearance of their veins concerning. Others find even the smallest dilated veins cosmetically troublesome even in the absence of symptoms. Superficial",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    perforator reflux should be treated by ablation before management of visibly dilated veins.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     No visible or palpable signs of venous disease (C0)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with no visible or palpable signs of venous disease who complain of venous symptoms are treated conservatively. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/41/32410?source=see_link\">",
"     \"Medical management of lower extremity chronic venous disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Telangiectasias and reticular veins (C1)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Telangiectasias and reticular veins are dilated intradermal and subdermal veins, respectively (",
"    <a class=\"graphic graphic_picture graphicRef62119 \" href=\"mobipreview.htm?17/58/18351\">",
"     picture 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef86549 \" href=\"mobipreview.htm?9/11/9394\">",
"     picture 6",
"    </a>",
"    ). Asymptomatic patients with only telangiectasias or reticular veins as their only manifestation of venous disease often find the cosmetic appearance of their veins distressing. These veins can be treated with surface laser or injection sclerotherapy without further diagnostic studies as these patients are not as likely as symptomatic patients to have underlying venous reflux [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/45/34521/abstract/6,22\">",
"     6,22",
"    </a>",
"    ]. Residual telangiectasias or reticular veins following successful management of venous reflux are also candidates for sclerotherapy or surface laser therapy.",
"   </p>",
"   <p>",
"    Sclerotherapy is the preferred initial approach for the treatment of most patients with lower extremity telangiectasias, reticular veins, and small varicose veins. The results for sclerotherapy are generally thought to be superior to those of laser therapy; however, the outcome depends on the size of the vein being treated and the presence or absence of underlying reticular veins and skin type. Three small observational studies have compared laser to sclerotherapy for the treatment of telangiectasias: one concluded that laser therapy was less efficacious and more expensive than sclerotherapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/45/34521/abstract/47\">",
"     47",
"    </a>",
"    ], the second demonstrated no differences in the clearance of veins by objective measures, however, patients still favored sclerotherapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/45/34521/abstract/48\">",
"     48",
"    </a>",
"    ], and the third study evaluated combined laser and sclerotherapy approaches and determined that clearance of veins was improved with sclerotherapy followed by laser compared to either laser followed by sclerotherapy, laser alone, or sclerotherapy alone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/45/34521/abstract/49\">",
"     49",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/12/13514?source=see_link\">",
"     \"Liquid and foam sclerotherapy techniques for the treatment of lower extremity veins\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Sclerotherapy and surface laser of telangiectasias and reticular veins are generally considered a cosmetic treatment and are not typically covered by insurance, though occasionally sclerotherapy will be reimbursed when treating veins that have hemorrhaged. The average cost of sclerotherapy and laser therapy in the United States in 2007 was $342 and $400 per session, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/45/34521/abstract/50\">",
"     50",
"    </a>",
"    ]. Typically, several treatment sessions are required.",
"   </p>",
"   <p>",
"    Laser therapy is performed in patients who have failed sclerotherapy, patients with post-sclerotherapy matting, needle phobic patients, and patients allergic to sclerosant agents. Laser is also preferred for vessels located at or below the ankle regions, areas that are more prone to ulceration with sclerotherapy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/40/17031?source=see_link\">",
"     \"Laser and light therapy of lower extremity telangiectasias, reticular veins and small varicose veins\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Varicose veins (C2)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Varicose veins are dilated, elongated, tortuous, subcutaneous veins three millimeters or greater in diameter (",
"    <a class=\"graphic graphic_picture graphicRef56463 graphicRef68551 \" href=\"mobipreview.htm?15/19/15669\">",
"     picture 2A-B",
"    </a>",
"    ). They may involve the saphenous veins (great or small) (",
"    <a class=\"graphic graphic_figure graphicRef55019 graphicRef52340 \" href=\"mobipreview.htm?5/25/5527\">",
"     figure 1A-B",
"    </a>",
"    ), saphenous tributaries, or non saphenous superficial leg veins and may develop with or without the presence of axial vein valvular incompetence.",
"   </p>",
"   <p>",
"    Significant varicosities can occur in the absence of reflux. These patients are typically treated with chemical (ie, sclerotherapy) or mechanical ablation (eg, ambulatory phlebectomy) depending on the size, location, and number of veins involved. Residual or recurrent varicosities following saphenous ablation are treated in the same manner [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/45/34521/abstract/51,52\">",
"     51,52",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/12/13514?source=see_link\">",
"     \"Liquid and foam sclerotherapy techniques for the treatment of lower extremity veins\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/29/21977?source=see_link&amp;anchor=H18#H18\">",
"     \"Open surgical techniques for lower extremity vein ablation\", section on 'Ambulatory phlebectomy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Complications of varicose veins are uncommon but may require immediate attention including potential surgical management. Complications include bleeding and superficial thrombophlebitis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Vein hemorrhage",
"    </span>",
"    &nbsp;&mdash;&nbsp;Telangiectasias, reticular veins, or varicose veins that are superficial or located near bony prominences are prone to hemorrhage. In the setting of recurrent hemorrhage, these patients may be candidates for sclerotherapy or vein",
"    <span class=\"nowrap\">",
"     ligation/excision,",
"    </span>",
"    depending upon the location of the vein. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/12/13514?source=see_link\">",
"     \"Liquid and foam sclerotherapy techniques for the treatment of lower extremity veins\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/29/21977?source=see_link\">",
"     \"Open surgical techniques for lower extremity vein ablation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Sclerotherapy reduces the risk of future hemorrhage at the treated site, even in the presence of venous insufficiency; therefore, duplex examination prior to treatment is not necessary [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/45/34521/abstract/6\">",
"     6",
"    </a>",
"    ]. Once hemorrhage is controlled (ie, elevation of the limb and direct pressure to the bleeding site), duplex examination should be performed to identify any underlying reflux.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Superficial thrombophlebitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Superficial thrombophlebitis is usually self limited and resolves with conservative management. Vein ablation may be required if the patient has significant symptoms refractory to conservative care. Data suggest that",
"    <span class=\"nowrap\">",
"     ligation/stripping",
"    </span>",
"    provides better symptomatic relief and prevents local recurrence compared to no therapy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/25/43417?source=see_link\">",
"     \"Superficial thrombophlebitis of the lower extremity\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/29/21977?source=see_link\">",
"     \"Open surgical techniques for lower extremity vein ablation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Following an episode of thrombophlebitis, recanalized vein is prone to recurrent thrombosis and treatment is indicated. One study found that endovenous ablation can be performed safely and effectively on patients with a history of superficial phlebitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/45/34521/abstract/53\">",
"     53",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/5/30809?source=see_link\">",
"     \"Radiofrequency ablation for the treatment of lower extremity chronic venous disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Surgical ablation (eg, high ligation of the saphenous vein at the saphenofemoral junction) has been advocated in patients who develop extension of thrombus up to but not into the common femoral vein and in those with contraindications to anticoagulation. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/29/21977?source=see_link\">",
"     \"Open surgical techniques for lower extremity vein ablation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Advanced venous disease (C3-6)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with signs and symptoms of edema (",
"    <a class=\"graphic graphic_picture graphicRef56758 \" href=\"mobipreview.htm?3/63/4080\">",
"     picture 3",
"    </a>",
"    ), skin changes (",
"    <a class=\"graphic graphic_picture graphicRef76901 \" href=\"mobipreview.htm?25/57/26527\">",
"     picture 4",
"    </a>",
"    ), or ulceration (C3-6) (",
"    <a class=\"graphic graphic_picture graphicRef71020 \" href=\"mobipreview.htm?13/14/13536\">",
"     picture 5",
"    </a>",
"    ) are initially managed conservatively with elevation, compression therapy, and",
"    <span class=\"nowrap\">",
"     skin/ulcer",
"    </span>",
"    care. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Conservative measures'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Patients who are refractory to conservative measures may be candidates for more aggressive treatment and comprehensive lower extremity duplex examination should be obtained. The majority of these patients will exhibit some degree of venous reflux and ablation therapy may be indicated. (See",
"    <a class=\"local\" href=\"#H22\">",
"     'Management of venous reflux'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     MANAGEMENT OF VENOUS REFLUX",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presence of reflux increases recurrence rates of both dilated veins and ulcers; therefore, superficial and perforator reflux should be treated prior to treating telangiectasias, reticular veins and varicose veins.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Superficial reflux",
"    </span>",
"    &nbsp;&mdash;&nbsp;Symptomatic patients with saphenous venous reflux are candidates for saphenous ablation by chemical, thermal, or mechanical means. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/12/13514?source=see_link\">",
"     \"Liquid and foam sclerotherapy techniques for the treatment of lower extremity veins\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/5/30809?source=see_link\">",
"     \"Radiofrequency ablation for the treatment of lower extremity chronic venous disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/29/21977?source=see_link\">",
"     \"Open surgical techniques for lower extremity vein ablation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with telangiectasias, reticular veins or varicosities should undergo saphenous (great or small) (",
"    <a class=\"graphic graphic_figure graphicRef55019 graphicRef52340 \" href=\"mobipreview.htm?5/25/5527\">",
"     figure 1A-B",
"    </a>",
"    ) ablation prior to further management of their visibly dilated veins. Following successful ablation of the great saphenous vein, telangiectasias, telangiectatic matting, reticular veins, and smaller varicosities can become more prominent, but usually improve over time. Therefore, delaying treatment of these smaller veins will minimize the number of veins that need treatment.",
"   </p>",
"   <p>",
"    Management of larger non-saphenous varicosities can be also be delayed; however, it is equally appropriate to perform phlebectomy concurrently with saphenous ablation.",
"   </p>",
"   <p>",
"    Up to 20 percent of patients with venous ulceration have isolated saphenous incompetence [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/45/34521/abstract/54\">",
"     54",
"    </a>",
"    ]. Elimination of saphenous reflux in these patients while not altering ulcer healing significantly reduces ulcer recurrence compared with compression therapy alone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/45/34521/abstract/13-15,55,56\">",
"     13-15,55,56",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/41/32410?source=see_link\">",
"     \"Medical management of lower extremity chronic venous disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A meta-analysis evaluating stripping, foam sclerotherapy, and endovenous therapies in the treatment of the saphenous vein concluded that minimally invasive therapies were as effective as surgical stripping with long-term success rates of 78 to 84 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/45/34521/abstract/57\">",
"     57",
"    </a>",
"    ]. Postoperative pain is generally less, and return to work quicker with minimally invasive therapies compared with conventional surgery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/45/34521/abstract/58\">",
"     58",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/12/13514?source=see_link\">",
"     \"Liquid and foam sclerotherapy techniques for the treatment of lower extremity veins\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/5/30809?source=see_link\">",
"     \"Radiofrequency ablation for the treatment of lower extremity chronic venous disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/29/21977?source=see_link\">",
"     \"Open surgical techniques for lower extremity vein ablation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Perforator reflux",
"    </span>",
"    &nbsp;&mdash;&nbsp;Symptomatic patients whose physical examination and duplex study are consistent with perforator reflux as a source for recurrent, tributary veins or venous ulceration are candidates for perforator ablation.",
"   </p>",
"   <p>",
"    Perforator reflux when identified in isolation (ie, no saphenous or deep venous reflux) may give rise to clusters of varicose veins. These perforators will often resolve when associated varicose veins are removed. Large diameter residual or recurrent perforators may be suitable for perforator ablation.",
"   </p>",
"   <p>",
"    Ultrasound-guided sclerotherapy with the injection of the sclerosant at the level of refluxing perforator veins, has also been used to treat the associated clusters of varicose veins [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/45/34521/abstract/16\">",
"     16",
"    </a>",
"    ]. This technique has been used with good long term results and without significant complications but requires an experienced practitioner [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/45/34521/abstract/17\">",
"     17",
"    </a>",
"    ]. Endovenous techniques can also be used to ablate perforator reflux with the use of special probes. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/5/30809?source=see_link\">",
"     \"Radiofrequency ablation for the treatment of lower extremity chronic venous disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/12/13514?source=see_link\">",
"     \"Liquid and foam sclerotherapy techniques for the treatment of lower extremity veins\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    When combined saphenous and perforator reflux are identified, saphenous reflux is treated first. Perforator reflux often resolves following saphenous ablation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/45/34521/abstract/59\">",
"     59",
"    </a>",
"    ]. Perforators identified by duplex following saphenous ablation can be managed concurrently or at a later time with ultrasound-guided sclerotherapy or endovenous methods. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/12/13514?source=see_link\">",
"     \"Liquid and foam sclerotherapy techniques for the treatment of lower extremity veins\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/5/30809?source=see_link\">",
"     \"Radiofrequency ablation for the treatment of lower extremity chronic venous disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For patients with venous ulceration, incompetent perforator veins are less likely to be identified in isolation (incidence 14 percent); however, incompetent perforators can contribute significantly to increased local venous pressure reducing skin perfusion and inhibiting ulcer healing [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/45/34521/abstract/59\">",
"     59",
"    </a>",
"    ]. Minimally invasive techniques are preferred first, however, refractory signs of severe venous disease (skin changes, ulcer) with persistent perforators may require surgery (ie, endoscopic perforator ligation [SEPS]) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/45/34521/abstract/60,61\">",
"     60,61",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/12/13514?source=see_link&amp;anchor=H17#H17\">",
"     \"Liquid and foam sclerotherapy techniques for the treatment of lower extremity veins\", section on 'Perforator ablation'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/5/30809?source=see_link&amp;anchor=H20#H20\">",
"     \"Radiofrequency ablation for the treatment of lower extremity chronic venous disease\", section on 'Specific anatomic considerations'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/29/21977?source=see_link\">",
"     \"Open surgical techniques for lower extremity vein ablation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Deep venous reflux",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with combined deep and superficial venous insufficiency are often not good candidates for ablation therapy due to coexisting medical issues. In this population, varicose vein recurrence and ulcer recurrence rates following intervention are much higher.",
"   </p>",
"   <p>",
"    Because of this and potential for the development of non-healing ulcers, dilated veins in patients with isolated deep venous reflux are rarely treated with surface laser, sclerotherapy or phlebectomy. These patients are managed medically. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/41/32410?source=see_link\">",
"     \"Medical management of lower extremity chronic venous disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, in several studies, deep venous reflux was noted to resolve following saphenous ablation and aggressive management should be considered in patients with refractory symptoms or skin changes, persistent ulcer, or recurrent ulcer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/45/34521/abstract/62,63\">",
"     62,63",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?40/47/41714?source=see_link\">",
"       \"Patient information: Varicose veins and other vein disease in the legs (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?29/32/30210?source=see_link\">",
"       \"Patient information: Vein ablation (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topic (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?34/17/35091?source=see_link\">",
"       \"Patient information: Chronic venous disease (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Visibly dilated lower extremity veins (ie, telangiectasias, reticular veins, or varicose veins) may be indicative of underlying venous reflux, especially when associated with symptoms (aching, swelling, heaviness). However, dilated veins can occur in the absence of symptoms or reflux and are often a source of significant distress to the patient even in the absence of symptoms. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Pathophysiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Symptomatic patients with lower extremity telangiectasias, reticular veins, or varicose veins should undergo further evaluation with venous duplex to identify the presence of superficial or deep venous insufficiency, which alters treatment options. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Diagnostic evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients found to have significant venous reflux, as well as patients with complications (including ulceration, hemorrhage, or recurrent superficial thrombophlebitis) should be referred to a vein specialist for further evaluation and management. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Management Approach'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The goals of treatment are improved symptoms and appearance. Initial treatment for chronic venous disease is conservative and includes leg elevation, exercise and compression therapy. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Conservative measures'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with persistent symptoms (pain, aching, swelling) and signs (telangiectasias, reticular veins, varicose veins, skin changes, ulceration) of venous disease after three months of medical therapy and documented reflux (ie, retrograde flow &gt;0.5 second duration) as a source of their symptoms are candidates for invasive therapies. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Ablation therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest symptomatic patients with telangiectasias, reticular veins, and varicose veins with documented saphenous reflux as a source of their symptoms, undergo saphenous ablation before treatment of their associated telangiectasias, reticular veins, or varicose veins (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Management of saphenous reflux decreases recurrence rates. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Telangiectasias and reticular veins (C1)'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H18\">",
"       'Varicose veins (C2)'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For lower extremity telangiectasias, reticular veins, and small varicose veins large enough to admit a 27 or 30 gauge needle, we suggest sclerotherapy over laser as initial treatment (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Sclerotherapy results in improved clearance of treated veins. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Telangiectasias and reticular veins (C1)'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Laser therapy is the only option for treatment of telangiectasias too small to access, patients allergic to sclerosing agents or afraid of needles, or those who have failed sclerotherapy. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Telangiectasias and reticular veins (C1)'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest endovenous ablation techniques (radiofrequency ablation or endovenous laser ablation) for the saphenous and other axial veins over surgical vein stripping. Endovenous techniques are highly successful in achieving vein closure and have high patient satisfaction rates. (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      )&nbsp;(See",
"      <a class=\"local\" href=\"#H23\">",
"       'Superficial reflux'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Persistent or recurrent perforators identified by duplex following vein ablation can be managed with ultrasound-guided sclerotherapy or endovenous methods. On occasion surgical methods (ie, SEPS) may be required in patients with recurrent or refractory venous ulceration. (See",
"      <a class=\"local\" href=\"#H24\">",
"       'Perforator reflux'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/45/34521/abstract/1\">",
"      Porter JM, Moneta GL. Reporting standards in venous disease: an update. International Consensus Committee on Chronic Venous Disease. J Vasc Surg 1995; 21:635.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/45/34521/abstract/2\">",
"      Zahariev T, Anastassov V, Girov K, et al. Prevalence of primary chronic venous disease: the Bulgarian experience. Int Angiol 2009; 28:303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/45/34521/abstract/3\">",
"      Brand FN, Dannenberg AL, Abbott RD, Kannel WB. The epidemiology of varicose veins: the Framingham Study. Am J Prev Med 1988; 4:96.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/45/34521/abstract/4\">",
"      Callam MJ. Epidemiology of varicose veins. Br J Surg 1994; 81:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/45/34521/abstract/5\">",
"      Evans CJ, Fowkes FG, Ruckley CV, Lee AJ. Prevalence of varicose veins and chronic venous insufficiency in men and women in the general population: Edinburgh Vein Study. J Epidemiol Community Health 1999; 53:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/45/34521/abstract/6\">",
"      Criqui MH, Jamosmos M, Fronek A, et al. Chronic venous disease in an ethnically diverse population: the San Diego Population Study. Am J Epidemiol 2003; 158:448.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/45/34521/abstract/7\">",
"      Labropoulos N, Giannoukas AD, Nicolaides AN, et al. The role of venous reflux and calf muscle pump function in nonthrombotic chronic venous insufficiency. Correlation with severity of signs and symptoms. Arch Surg 1996; 131:403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/45/34521/abstract/8\">",
"      Chiesa R, Marone EM, Limoni C, et al. Chronic venous disorders: correlation between visible signs, symptoms, and presence of functional disease. J Vasc Surg 2007; 46:322.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/45/34521/abstract/9\">",
"      Cesarone MR, Belcaro G, Nicolaides AN, et al. 'Real' epidemiology of varicose veins and chronic venous diseases: the San Valentino Vascular Screening Project. Angiology 2002; 53:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/45/34521/abstract/10\">",
"      Lee AJ, Evans CJ, Allan PL, et al. Lifestyle factors and the risk of varicose veins: Edinburgh Vein Study. J Clin Epidemiol 2003; 56:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/45/34521/abstract/11\">",
"      Carpentier PH, Maricq HR, Biro C, et al. Prevalence, risk factors, and clinical patterns of chronic venous disorders of lower limbs: a population-based study in France. J Vasc Surg 2004; 40:650.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/45/34521/abstract/12\">",
"      Coon WW, Willis PW 3rd, Keller JB. Venous thromboembolism and other venous disease in the Tecumseh community health study. Circulation 1973; 48:839.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/45/34521/abstract/13\">",
"      Barwell JR, Taylor M, Deacon J, et al. Surgical correction of isolated superficial venous reflux reduces long-term recurrence rate in chronic venous leg ulcers. Eur J Vasc Endovasc Surg 2000; 20:363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/45/34521/abstract/14\">",
"      Zamboni P, Cisno C, Marchetti F, et al. Minimally invasive surgical management of primary venous ulcers vs. compression treatment: a randomized clinical trial. Eur J Vasc Endovasc Surg 2003; 25:313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/45/34521/abstract/15\">",
"      Gohel MS, Barwell JR, Taylor M, et al. Long term results of compression therapy alone versus compression plus surgery in chronic venous ulceration (ESCHAR): randomised controlled trial. BMJ 2007; 335:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/45/34521/abstract/16\">",
"      FEGAN WG. Continuous compression technique of injecting varicose veins. Lancet 1963; 2:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/45/34521/abstract/17\">",
"      Labas P, Ohradka B, Cambal M, et al. Long term results of compression sclerotherapy. Bratisl Lek Listy 2003; 104:78.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/45/34521/abstract/18\">",
"      Callam MJ, Ruckley CV, Harper DR, Dale JJ. Chronic ulceration of the leg: extent of the problem and provision of care. Br Med J (Clin Res Ed) 1985; 290:1855.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/45/34521/abstract/19\">",
"      Callam, M. Prevalence of chronic leg ulceration and severe chronic venous disease in western countries. Phlebology 1992; 1(Suppl):6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/45/34521/abstract/20\">",
"      Callam MJ, Harper DR, Dale JJ, Ruckley CV. Chronic ulcer of the leg: clinical history. Br Med J (Clin Res Ed) 1987; 294:1389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/45/34521/abstract/21\">",
"      Baker SR, Stacey MC, Jopp-McKay AG, et al. Epidemiology of chronic venous ulcers. Br J Surg 1991; 78:864.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/45/34521/abstract/22\">",
"      Langer RD, Ho E, Denenberg JO, et al. Relationships between symptoms and venous disease: the San Diego population study. Arch Intern Med 2005; 165:1420.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/45/34521/abstract/23\">",
"      Criqui MH, Denenberg JO, Bergan J, et al. Risk factors for chronic venous disease: the San Diego Population Study. J Vasc Surg 2007; 46:331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/45/34521/abstract/24\">",
"      Cornwall JV, Dor&eacute; CJ, Lewis JD. Leg ulcers: epidemiology and aetiology. Br J Surg 1986; 73:693.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/45/34521/abstract/25\">",
"      Scott TE, LaMorte WW, Gorin DR, Menzoian JO. Risk factors for chronic venous insufficiency: a dual case-control study. J Vasc Surg 1995; 22:622.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/45/34521/abstract/26\">",
"      Fowkes FG, Lee AJ, Evans CJ, et al. Lifestyle risk factors for lower limb venous reflux in the general population: Edinburgh Vein Study. Int J Epidemiol 2001; 30:846.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/45/34521/abstract/27\">",
"      Sadick NS. Predisposing factors of varicose and telangiectatic leg veins. J Dermatol Surg Oncol 1992; 18:883.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/45/34521/abstract/28\">",
"      Iannuzzi A, Panico S, Ciardullo AV, et al. Varicose veins of the lower limbs and venous capacitance in postmenopausal women: relationship with obesity. J Vasc Surg 2002; 36:965.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/45/34521/abstract/29\">",
"      Evans CJ, Fowkes FG, Hajivassiliou CA, et al. Epidemiology of varicose veins. A review. Int Angiol 1994; 13:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/45/34521/abstract/30\">",
"      Browse NL. The etiology of venous ulceration. World J Surg 1986; 10:938.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/45/34521/abstract/31\">",
"      Browse NL, Burnand KG. The cause of venous ulceration. Lancet 1982; 2:243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/45/34521/abstract/32\">",
"      Stacey MC, Burnand KG, Lea Thomas M, Pattison M. Influence of phlebographic abnormalities on the natural history of venous ulceration. Br J Surg 1991; 78:868.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/45/34521/abstract/33\">",
"      Hanrahan LM, Araki CT, Rodriguez AA, et al. Distribution of valvular incompetence in patients with venous stasis ulceration. J Vasc Surg 1991; 13:805.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/45/34521/abstract/34\">",
"      Kahn SR, Hirsch A, Shrier I. Effect of postthrombotic syndrome on health-related quality of life after deep venous thrombosis. Arch Intern Med 2002; 162:1144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/45/34521/abstract/35\">",
"      Kahn SR, Ginsberg JS. Relationship between deep venous thrombosis and the postthrombotic syndrome. Arch Intern Med 2004; 164:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/45/34521/abstract/36\">",
"      Mohr DN, Silverstein MD, Heit JA, et al. The venous stasis syndrome after deep venous thrombosis or pulmonary embolism: a population-based study. Mayo Clin Proc 2000; 75:1249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/45/34521/abstract/37\">",
"      Cornu-Thenard A, Boivin P, Baud JM, et al. Importance of the familial factor in varicose disease. Clinical study of 134 families. J Dermatol Surg Oncol 1994; 20:318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/45/34521/abstract/38\">",
"      Stanhope, J. Varisoe veins in a population of lowland new guinea. Int J Epid 1975; 4:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/45/34521/abstract/39\">",
"      Molho-Pessach V, Agha Z, Libster D, et al. Evidence for clinical and genetic heterogeneity in hereditary benign telangiectasia. J Am Acad Dermatol 2007; 57:814.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/45/34521/abstract/40\">",
"      Sarin S, Shields DA, Farrah J, et al. Does venous function deteriorate in patients waiting for varicose vein surgery? J R Soc Med 1993; 86:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/45/34521/abstract/41\">",
"      Labropoulos N, Leon L, Kwon S, et al. Study of the venous reflux progression. J Vasc Surg 2005; 41:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/45/34521/abstract/42\">",
"      Coleridge-Smith P, Labropoulos N, Partsch H, et al. Duplex ultrasound investigation of the veins in chronic venous disease of the lower limbs--UIP consensus document. Part I. Basic principles. Eur J Vasc Endovasc Surg 2006; 31:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/45/34521/abstract/43\">",
"      Labropoulos N, Tiongson J, Pryor L, et al. Definition of venous reflux in lower-extremity veins. J Vasc Surg 2003; 38:793.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/45/34521/abstract/44\">",
"      Stacey MC, Burnand KG, Layer GT, Pattison M. Calf pump function in patients with healed venous ulcers is not improved by surgery to the communicating veins or by elastic stockings. Br J Surg 1988; 75:436.",
"     </a>",
"    </li>",
"    <li>",
"     Pfeifer, JR. Sclerotherapy in Pfenninger: Procedures for primary care medicine, Mosby-Year Book, Inc 1994.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/45/34521/abstract/46\">",
"      van den Bos R, Arends L, Kockaert M, et al. Endovenous therapies of lower extremity varicosities: a meta-analysis. J Vasc Surg 2009; 49:230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/45/34521/abstract/47\">",
"      Lupton JR, Alster TS, Romero P. Clinical comparison of sclerotherapy versus long-pulsed Nd:YAG laser treatment for lower extremity telangiectases. Dermatol Surg 2002; 28:694.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/45/34521/abstract/48\">",
"      Coles CM, Werner RS, Zelickson BD. Comparative pilot study evaluating the treatment of leg veins with a long pulse ND:YAG laser and sclerotherapy. Lasers Surg Med 2002; 30:154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/45/34521/abstract/49\">",
"      Levy JL, Berwald C. Treatment of vascular abnormalities with a long-pulse diode at 980 nm. J Cosmet Laser Ther 2004; 6:217.",
"     </a>",
"    </li>",
"    <li>",
"     American Board of Plastic Surgery. Available online at: www.abplsurg.org/ModDefault.aspx (Accesssed on March 31, 2009).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/45/34521/abstract/51\">",
"      Galland RB, Magee TR, Lewis MH. A survey of current attitudes of British and Irish vascular surgeons to venous sclerotherapy. Eur J Vasc Endovasc Surg 1998; 16:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/45/34521/abstract/52\">",
"      Tisi PV, Beverley CA. Injection sclerotherapy for varicose veins. Cochrane Database Syst Rev 2002; :CD001732.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/45/34521/abstract/53\">",
"      Puggioni A, Marks N, Hingorani A, et al. The safety of radiofrequency ablation of the great saphenous vein in patients with previous venous thrombosis. J Vasc Surg 2009; 49:1248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/45/34521/abstract/54\">",
"      Gloviczki P, Bergan JJ, Menawat SS, et al. Safety, feasibility, and early efficacy of subfascial endoscopic perforator surgery: a preliminary report from the North American registry. J Vasc Surg 1997; 25:94.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/45/34521/abstract/55\">",
"      Adam DJ, Bello M, Hartshorne T, London NJ. Role of superficial venous surgery in patients with combined superficial and segmental deep venous reflux. Eur J Vasc Endovasc Surg 2003; 25:469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/45/34521/abstract/56\">",
"      Barwell JR, Davies CE, Deacon J, et al. Comparison of surgery and compression with compression alone in chronic venous ulceration (ESCHAR study): randomised controlled trial. Lancet 2004; 363:1854.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/45/34521/abstract/57\">",
"      Van Den Bos RR, Neumann M, De Roos KP, Nijsten T. Endovenous laser ablation-induced complications: review of the literature and new cases. Dermatol Surg 2009; 35:1206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/45/34521/abstract/58\">",
"      Darvall KA, Bate GR, Adam DJ, Bradbury AW. Recovery after ultrasound-guided foam sclerotherapy compared with conventional surgery for varicose veins. Br J Surg 2009; 96:1262.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/45/34521/abstract/59\">",
"      O'Donnell TF Jr. The present status of surgery of the superficial venous system in the management of venous ulcer and the evidence for the role of perforator interruption. J Vasc Surg 2008; 48:1044.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/45/34521/abstract/60\">",
"      Thibault PK, Lewis WA. Recurrent varicose veins. Part 2: Injection of incompetent perforating veins using ultrasound guidance. J Dermatol Surg Oncol 1992; 18:895.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/45/34521/abstract/61\">",
"      Guex JJ. Ultrasound guided sclerotherapy (USGS) for perforating veins (PV). Hawaii Med J 2000; 59:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/45/34521/abstract/62\">",
"      Sales CM, Bilof ML, Petrillo KA, Luka NL. Correction of lower extremity deep venous incompetence by ablation of superficial venous reflux. Ann Vasc Surg 1996; 10:186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/45/34521/abstract/63\">",
"      Puggioni A, Lurie F, Kistner RL, Eklof B. How often is deep venous reflux eliminated after saphenous vein ablation? J Vasc Surg 2003; 38:517.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8181 Version 12.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-213.131.41.98-853D91569B-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_45_34521=[""].join("\n");
var outline_f33_45_34521=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H26\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      RISK FACTORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Progression",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      CLINICAL EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Classification",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      PATHOPHYSIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      DIAGNOSTIC EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      MANAGEMENT APPROACH",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Conservative measures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Ablation therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Chemical ablation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Thermal ablation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Mechanical ablation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      MANAGEMENT BY CEAP CLINICAL CATEGORY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      No visible or palpable signs of venous disease (C0)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Telangiectasias and reticular veins (C1)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Varicose veins (C2)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Vein hemorrhage",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Superficial thrombophlebitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Advanced venous disease (C3-6)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      MANAGEMENT OF VENOUS REFLUX",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Superficial reflux",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Perforator reflux",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Deep venous reflux",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"SURG/8181\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/8181|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?35/46/36579\" title=\"figure 1A\">",
"      Superficial veins of leg anterior view",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?41/42/42671\" title=\"figure 1B\">",
"      Superficial veins of lower leg posterior view",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/8181|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?17/58/18351\" title=\"picture 1\">",
"      Telangiectasia of the lower extremity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?21/63/22514\" title=\"picture 2A\">",
"      Varicose veins of the thigh and calf",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?39/36/40526\" title=\"picture 2B\">",
"      Severe varicose veins",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?3/63/4080\" title=\"picture 3\">",
"      Skin changes of chronic venous insufficiency",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?25/57/26527\" title=\"picture 4\">",
"      Lipodermatosclerosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?13/14/13536\" title=\"picture 5\">",
"      Venous stasis ulcer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?9/11/9394\" title=\"picture 6\">",
"      Corona phlebectasia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/8181|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?10/45/10973\" title=\"table 1\">",
"      CEAP classification for chronic venous disorders",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/60/23497?source=related_link\">",
"      Ataxia-telangiectasia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/29/11735?source=related_link\">",
"      Classification of lower extremity chronic venous disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/17/13592?source=related_link\">",
"      Clinical evaluation of lower extremity chronic venous disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/43/33462?source=related_link\">",
"      Diagnostic evaluation of chronic venous insufficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/31/31226?source=related_link\">",
"      Hereditary hemorrhagic telangiectasia (Osler-Weber-Rendu syndrome)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/40/17031?source=related_link\">",
"      Laser and light therapy of lower extremity telangiectasias, reticular veins and small varicose veins",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/12/13514?source=related_link\">",
"      Liquid and foam sclerotherapy techniques for the treatment of lower extremity veins",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/41/32410?source=related_link\">",
"      Medical management of lower extremity chronic venous disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/29/21977?source=related_link\">",
"      Open surgical techniques for lower extremity vein ablation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/22/43365?source=related_link\">",
"      Pathophysiology of chronic venous disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?34/17/35091?source=related_link\">",
"      Patient information: Chronic venous disease (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?40/47/41714?source=related_link\">",
"      Patient information: Varicose veins and other vein disease in the legs (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?29/32/30210?source=related_link\">",
"      Patient information: Vein ablation (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/37/23127?source=related_link\">",
"      Post-thrombotic (postphlebitic) syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/5/30809?source=related_link\">",
"      Radiofrequency ablation for the treatment of lower extremity chronic venous disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/25/43417?source=related_link\">",
"      Superficial thrombophlebitis of the lower extremity",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f33_45_34522="Depot medroxyprogesterone acetate for contraception";
var content_f33_45_34522=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Depot medroxyprogesterone acetate for contraception",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/45/34522/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/45/34522/contributors\">",
"     Andrew M Kaunitz, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/45/34522/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/45/34522/contributors\">",
"     Mimi Zieman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/45/34522/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/45/34522/contributors\">",
"     Vanessa A Barss, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?33/45/34522/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 12, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Depot",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?1/24/1417?source=see_link\">",
"     medroxyprogesterone acetate",
"    </a>",
"    (DMPA) is an injectable, progestin-only contraceptive that provides highly effective, private, long-acting, reversible contraception and avoids both the need for user action daily or near the time of sexual intercourse and the need for partner cooperation. DMPA is often used by the following groups of women:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Women who do not want to take a hormone pill daily",
"     </li>",
"     <li>",
"      Women who have a contraindication to, or wish to avoid, an estrogen-containing contraceptive",
"     </li>",
"     <li>",
"      Women who would like to avoid regular menses",
"     </li>",
"     <li>",
"      Adolescents who may not consistently remember to use types of contraception that require frequent administration &nbsp;",
"     </li>",
"     <li>",
"      Institutionalized girls and women who have difficulty using other forms of contraception",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other types of progestin-only contraceptives include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Progestin pills (minipills) (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?8/52/9031?source=see_link\">",
"       \"Progestin-only pills (minipills) for contraception\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Progestin implants (eg, Implanon&reg;, Jadelle&reg;) (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?3/27/3512?source=see_link\">",
"       \"Etonogestrel contraceptive implant\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Intrauterine contraception (eg, Mirena&reg;) (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?31/19/32058?source=see_link\">",
"       \"Overview of intrauterine contraception\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     FORMULATIONS AND PHARMACOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;DMPA is available in two formulations: 150",
"    <span class=\"nowrap\">",
"     mg/1",
"    </span>",
"    mL for intramuscular injection (IM) and 104",
"    <span class=\"nowrap\">",
"     mg/0.65",
"    </span>",
"    mL for subcutaneous (SC) injection. The drug is given every three months because low solubility of the microcrystals at the injection site allows pharmacologically active drug levels to persist and remain effective for several months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/45/34522/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Following a single intramuscular dose of DMPA, the drug level increases for approximately three weeks, reaching a peak blood concentration of up to 7",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    for a few days [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/45/34522/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. The level then declines until it becomes undetectable between 120 and 200 days following injection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/45/34522/abstract/3\">",
"     3",
"    </a>",
"    ], but there is considerable inter-individual variability in serum levels. Ovulation resumes at DMPA levels &lt;0.1",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/45/34522/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The formulation for subcutaneous injection provides slower and more sustained absorption of the progestin than conventional intramuscular DMPA. This enables a 30 percent lower dose of progestin (104 versus 150 mg), but with the same duration of effect as conventional DMPA. Administration via the SC route is less painful than IM injection and potentially may allow patient self-administration [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/45/34522/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. DMPA given IM is available as a generic formulation, which is less costly than the SC formulation (www.drugstore.com: $95 versus $113). Otherwise, the benefits and risks are similar for IM and SC administration.",
"   </p>",
"   <p>",
"    Serum progesterone levels are low (&lt;0.4",
"    <span class=\"nowrap\">",
"     ng/mL)",
"    </span>",
"    for several months following an injection of DMPA since ovulation is suppressed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/45/34522/abstract/1\">",
"     1",
"    </a>",
"    ]. Estrogen levels vary, but most women have lower levels than normally cycling women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/45/34522/abstract/1,6\">",
"     1,6",
"    </a>",
"    ]. Women who have used DMPA for several years have serum estradiol levels between 10 and 92",
"    <span class=\"nowrap\">",
"     pg/mL",
"    </span>",
"    (mean about 40",
"    <span class=\"nowrap\">",
"     pg/mL)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/45/34522/abstract/1\">",
"     1",
"    </a>",
"    ]. Although the endometrium becomes atrophic, vasomotor symptoms are uncommon and the vaginal epithelium remains moist and well rugated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     MECHANISMS OF ACTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Progestins can prevent pregnancy via several mechanisms. DMPA primarily acts by inhibition of gonadotropin secretion, thereby inhibiting follicular maturation and ovulation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/45/34522/abstract/7\">",
"     7",
"    </a>",
"    ]. The inhibition of ovarian function results in a hypoestrogenic state, which inhibits endometrial proliferation and renders the endometrium less receptive to implantation. Another contraceptive effect is progestin's ability to cause changes in cervical mucus (becomes thick with reduced permeability to sperm) and tubal motility (reduced ciliary action) that are unfavorable to sperm migration, thus inhibiting fertilization.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     EFFICACY",
"    </span>",
"    &nbsp;&mdash;&nbsp;For the 150 mg IM injection, failure rates in clinical trials ranged from 0.0 to",
"    <span class=\"nowrap\">",
"     0.7/100",
"    </span>",
"    woman-years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/45/34522/abstract/8\">",
"     8",
"    </a>",
"    ]. The typical-user failure rate is",
"    <span class=\"nowrap\">",
"     3/100",
"    </span>",
"    woman-years in the first year of use, which reflects pregnancies in users who do not return for their injections as scheduled (see",
"    <a class=\"local\" href=\"#H7\">",
"     'Repeat injections'",
"    </a>",
"    below) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/45/34522/abstract/9\">",
"     9",
"    </a>",
"    ]. In a study assessing failure rates among women choosing various reversible contraceptives, the three-year cumulative failure rate in women who chose DMPA and returned consistently and on time for injections was 0.7 percent, a failure rate comparable to that of intrauterine devices and the contraceptive implant [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/45/34522/abstract/10\">",
"     10",
"    </a>",
"    ]. Because progestin levels are high, efficacy is not reduced by high body weight [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/45/34522/abstract/11,12\">",
"     11,12",
"    </a>",
"    ] or use of concurrent medications [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/45/34522/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For the 104 mg SC injection, no contraceptive failures were reported in phase III clinical trials [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/45/34522/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. This formulation is relatively new; typical-user failure rates are not yet available, but are expected to be similar to the IM preparation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     ADMINISTRATION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26226348\">",
"    <span class=\"h2\">",
"     Medical eligibility criteria",
"    </span>",
"    &nbsp;&mdash;&nbsp;DMPA can be initiated without a pelvic or breast examination and without any routine laboratory tests. Medical eligibility criteria are listed in the table (",
"    <a class=\"graphic graphic_table graphicRef74890 \" href=\"mobipreview.htm?12/13/12506\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Although allergy to any hormonal contraceptive is rare, anaphylaxis to DMPA has been reported [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/45/34522/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Contraindications specific to DMPA (150 mg intramuscular injection or 104 mg subcutaneous injection) include current use of aminoglutethimide (usually for the treatment of Cushing's syndrome), pregnancy planned within the next year (because a delay in return in fertility occurs with DMPA), known fragility fracture(s) (ie, fracture caused by an injury that would be insufficient to fracture normal bone: the result of reduced compressive",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    torsional strength of bone), and known osteoporosis or strong risk factors for fracture, eg, hypothalamic amenorrhea, anorexia nervosa, rheumatoid arthritis, chronic glucocorticoid therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26226355\">",
"    <span class=\"h2\">",
"     Timing of injections",
"    </span>",
"    &nbsp;&mdash;&nbsp;Timing of DMPA injections is summarized in the table (",
"    <a class=\"graphic graphic_table graphicRef69414 \" href=\"mobipreview.htm?20/61/21468\">",
"     table 2",
"    </a>",
"    ) and described below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Initial injection",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       First day of menses",
"      </strong>",
"      - The ideal time to initiate DMPA is within seven days of the onset of menses. This approach increases the certainty that the patient is not pregnant at the time of injection and prevents ovulation during the first month of use, so that back-up contraception is unnecessary. Most women have pharmacologically active drug levels and relatively impermeable cervical mucus within 24 hours after injection [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/45/34522/abstract/17\">",
"       17",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Quick start",
"      </strong>",
"      - Several studies have initiated DMPA on the day the patient is first seen for contraception, rather than waiting until her next menses begins [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/45/34522/abstract/18-21\">",
"       18-21",
"      </a>",
"      ], as long as pregnancy can be excluded with reasonable certainty by history or pregnancy testing. This \"same day\" \"quick start\" or \"Depo-now\" approach facilitates DMPA initiation for many users, and thus may prevent some pregnancies [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/45/34522/abstract/22\">",
"       22",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      <strong>",
"       More than seven days from start of menses",
"      </strong>",
"      - If DMPA is initiated more than seven days after the first day of the woman's menstrual period and she has had unprotected intercourse during the cycle, clinicians and patients must recognize that there is a small chance of luteal phase pregnancy despite a negative pregnancy test prior to the injection. We suggest these women receive emergency contraception if intercourse occurred within the previous 120 hours, and we advise them to use back-up contraception for seven days after DMPA injection [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/45/34522/abstract/23\">",
"       23",
"      </a>",
"      ] since ovulation may occur within 24 hours of the initial injection, and we counsel them to have a repeat pregnancy test in two to three weeks.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Switching from another method",
"      </strong>",
"      &ndash; Begin DMPA while the woman is still using hormonal contraception (pill, patch, ring) or within seven days of the last day of active hormone use (",
"      <a class=\"graphic graphic_table graphicRef77410 \" href=\"mobipreview.htm?4/46/4846\">",
"       table 3",
"      </a>",
"      ). If switching from intrauterine contraception, the injection should be given before removal of the intrauterine device. A condom should be used as a back-up if the first injection is not given within seven days of menses onset.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There is no evidence that inadvertent administration of DMPA during pregnancy increases the risk of congenital anomalies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/45/34522/abstract/24,25\">",
"     24,25",
"    </a>",
"    ]. In the US Planned Parenthood National database for 1994 to 1998, 402 DMPA users became pregnant and many of these women received more than one dose of DMPA while pregnant [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/45/34522/abstract/24\">",
"     24",
"    </a>",
"    ]. No fetal anomalies were reported; however, birth outcome data were incomplete.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Repeat injections",
"    </span>",
"    &nbsp;&mdash;&nbsp;DMPA users should be encouraged to return every 12 weeks for repeat injections.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Women who return late for a repeat injection",
"      </strong>",
"      &mdash; Women using injectable birth control who present late for follow-up injections should not be turned away solely because they are not on time. After a 150 mg injection, ovulation does not occur for at least 14 weeks. Therefore, a two-week \"grace period\" (repeat injection without pregnancy testing) is appropriate for women receiving injections every three months. In women more than two weeks late for their injection, we suggest a pregnancy test before administering DMPA [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/45/34522/abstract/7\">",
"       7",
"      </a>",
"      ]. The literature supports this approach (ie, two-week grace period) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/45/34522/abstract/26\">",
"       26",
"      </a>",
"      ]; however, the package labeling is conservative and recommends excluding pregnancy prior to reinjection in women more than one week late for their injection (ie, more than 13 weeks from their last injection).",
"      <br/>",
"      <br/>",
"      As a result of a study showing that contraceptive efficacy is maintained with a grace period as long as four weeks [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/45/34522/abstract/27\">",
"       27",
"      </a>",
"      ], the World Health Organization (WHO) adopted a longer grace period in its updated guideline [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/45/34522/abstract/9\">",
"       9",
"      </a>",
"      ]. In this study of 2290 women in developing countries who underwent 13,608 DMPA cycles, the pregnancy risk per 100 women-years was statistically similar for users who were \"on time\" for their injection (0.6, 95% CI 0.33-0.92; 12,508 cycles), users who were two weeks late for their injection (0.0; 95% CI 0.0-1.88; 739 cycles), and users who were four weeks late for their injection (0.4; 95% CI 0.01-2.29; 893 cycles) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/45/34522/abstract/27\">",
"       27",
"      </a>",
"      ]. A limitation of these data is that more than one third of the women in the study were lactating, placing them at low baseline risk for conception.",
"      <br/>",
"      <br/>",
"      Because pregnancy testing may not be readily available in low resource countries, expanding the grace period to four weeks is reasonable in such settings. In high resource countries, we continue to encourage women to return on time and allow a two-week grace period, and require documentation of a negative pregnancy test in women who present more than 14 weeks after their last injection.",
"     </li>",
"     <li>",
"      <strong>",
"       Women who return early for a repeat injection",
"      </strong>",
"      &mdash; If it is necessary for a patient to move up the date of her DMPA injection, a repeat injection may be given up to two weeks early (10 weeks after the previous DMPA injection) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/45/34522/abstract/28\">",
"       28",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Switching from DMPA to another method",
"    </span>",
"    &nbsp;&mdash;&nbsp;In women who wish to change from DMPA to another form of contraception, the new method should be started no later than 12 to 14 weeks after the previous injection. This ensures that the woman is not pregnant at the time she initiates a new contraceptive method.",
"   </p>",
"   <p>",
"    With long-term use of DMPA, most users become amenorrheic. Initiation of contraception should not be delayed until resumption of menses. Amenorrhea after discontinuing DMPA injections does not mean the woman is protected against pregnancy if she has unprotected intercourse.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26226042\">",
"    <span class=\"h1\">",
"     COUNSELING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Proactive, candid counseling on both the side effects of DMPA, especially bleeding irregularities, and the need for timed injections is important because women who are well-informed when they choose this method of contraception are much more likely to become satisfied users with high continuation rates [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/45/34522/abstract/20,29-33\">",
"     20,29-33",
"    </a>",
"    ]. In a randomized trial, women who received information on risks, benefits, and overall characteristics of DMPA at each visit and counseling that emphasized that potential side effects were not harmful were much less likely to discontinue the method within 12 months than the usual care group (OR 0.27, 95% CI 0.16-0.44) and much less likely to discontinue the method because of menstrual disturbances (OR 0.20, 95% CI 0.11-0.37) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/45/34522/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     SIDE EFFECTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Side effects usually decrease or stop within the first few months after starting injections. A change in uterine bleeding pattern is the best documented and most common side effect in DMPA users. Side effects associated with DMPA use were illustrated in a clinical trial in which over 3900 DMPA users were followed for up to seven years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/45/34522/abstract/3\">",
"     3",
"    </a>",
"    ]. The following side effects were reported by more than 5 percent of subjects: menstrual irregularities (unscheduled bleeding or amenorrhea), weight changes, headache, abdominal pain or discomfort, nervousness, dizziness, and asthenia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Menstrual changes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Menstrual changes occur in all women using DMPA and are the most frequent reason for discontinuation. In many cases, women become anxious over menstrual changes because of concerns that the changes are due to pregnancy or gynecologic disease. Conscientious patient education before initiation of DMPA, as well as supportive follow-up, can markedly reduce these concerns. Women who will not tolerate the menstrual changes that inevitably accompany use of DMPA should be counseled to choose an alternative contraceptive.",
"   </p>",
"   <p>",
"    During the first months of use, episodes of unpredictable bleeding and spotting lasting seven days or longer are common. The frequency and duration of such unscheduled bleeding decrease with increasing duration of use.",
"   </p>",
"   <p>",
"    If persistent spotting or unscheduled bleeding in the first few months of use is unacceptable to a DMPA user who otherwise wishes to continue using this method, one option is to administer oral or transdermal estrogen supplements. The efficacy of supplemental estrogen for prevention or treatment of active unscheduled bleeding in DMPA users is unclear. Trials have reported discordant findings. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/10/22698?source=see_link&amp;anchor=H4#H4\">",
"     \"Management of unscheduled bleeding in women using contraception\", section on 'Depot medroxyprogesterone acetate (DMPA)'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If bothersome spotting",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    unscheduled bleeding persist after several injections of DMPA, further evaluation is not necessary unless indicated based on history (bleeding pattern was abnormal prior to contraceptive use), symptoms (menorrhagia, pain, vaginal discharge), or national cervical cancer screening guidelines, even if the unscheduled bleeding persists for the duration of contraceptive use. If a treatable abnormality is not found and the patient remains dissatisfied with the menstrual changes caused by DMPA, then she may be better served by another contraceptive method. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/10/22698?source=see_link&amp;anchor=H3#H3\">",
"     \"Management of unscheduled bleeding in women using contraception\", section on 'General approach'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    With increasing duration of use, amenorrhea becomes increasingly prevalent. A systematic review calculated the weighted prevalence of amenorrhea over successive 90-day periods and found rates of 12, 25, 37, and 46 percent, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/45/34522/abstract/34\">",
"     34",
"    </a>",
"    ]. With ongoing use, the rate of amenorrhea increases to 75 percent. As long as women understand that absence of bleeding represents an expected and reversible phenomenon associated with DMPA use, amenorrhea (along with a reduction or elimination of menstrual cramps) can be viewed as one of the advantages of using this method [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/45/34522/abstract/20,35-39\">",
"     20,35-39",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Weight changes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Observational studies have reported variable effects of DMPA on weight gain. Some studies found nonsignificant changes in weight among women who used DMPA for up to one year [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/45/34522/abstract/40-43\">",
"     40-43",
"    </a>",
"    ]; others described weight gain ranging from 3 to 6 kg [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/45/34522/abstract/44-48\">",
"     44-48",
"    </a>",
"    ] or an increase in BMI [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/45/34522/abstract/49\">",
"     49",
"    </a>",
"    ]. One of these studies, for example, followed 703 women (African American, white, and Hispanic) for three years after beginning use of oral contraception, DMPA, or nonhormonal contraception [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/45/34522/abstract/48\">",
"     48",
"    </a>",
"    ]. DMPA users increased their weight (+5.1 kg), body fat (+4.1 kg), percent body fat (+3.4 percent), and central to peripheral fat ratio (+0.1) significantly more than users of oral contraception and nonhormonal contraception. In other studies, a greater than 5 percent increase in weight during the first six months of DMPA use was predictive of higher weight gain over time with continued use (eg, 0.35",
"    <span class=\"nowrap\">",
"     kg/month",
"    </span>",
"    compared with 0.08",
"    <span class=\"nowrap\">",
"     kg/month",
"    </span>",
"    in women with &lt;5 percent early weight gain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/45/34522/abstract/50\">",
"     50",
"    </a>",
"    ]) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/45/34522/abstract/50,51\">",
"     50,51",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It appears that large weight gain is more likely in certain subgroups, such as adolescents (especially overweight adolescents), and normal weight and overweight adult women, and less likely among obese adult women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/45/34522/abstract/52-54\">",
"     52-54",
"    </a>",
"    ]. A systematic review found that obese adolescent, but not obese adult, DMPA users gained more weight than normal weight users [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/45/34522/abstract/52\">",
"     52",
"    </a>",
"    ]. However, even nonobese adolescent DMPA users appear to gain more weight than adolescent nonusers or oral contraceptive users [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/45/34522/abstract/53\">",
"     53",
"    </a>",
"    ]. Weight gain on DMPA may mitigate loss of BMD among adolescent users [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/45/34522/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The weight changes reported with DMPA use in observational studies may have resulted from demographic differences in the study populations and the differing susceptibilities of these populations to weight gain. Randomized trials, although not definitive, have not reported significant weight gain in DMPA users. One randomized trial compared the effects of intramuscular DMPA and saline injections on food intake, resting energy expenditure, and body weight [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/45/34522/abstract/55\">",
"     55",
"    </a>",
"    ]. DMPA did not increase appetite or weight in normal weight women observed during the two menstrual cycles before, and first menstrual cycle following, the initial injection. Two randomized trials comparing a subcutaneous formulation of DMPA and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/41/4760?source=see_link\">",
"     leuprolide",
"    </a>",
"    in women with symptomatic endometriosis found no difference in the impact of these drugs on weight over 6 to 12 months of use [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/45/34522/abstract/56,57\">",
"     56,57",
"    </a>",
"    ]. However, the results of these trials are not generalizable since the first trial involved only 20 volunteers who received only one injection of DMPA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/45/34522/abstract/55\">",
"     55",
"    </a>",
"    ] and the other two trials had controls whom were given leuprolide rather than another contraceptive drug or no contraceptive drug.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Headache",
"    </span>",
"    &nbsp;&mdash;&nbsp;DMPA appears to trigger headache as a side effect in susceptible patients, but natural progesterone and oral progestins have been reported to reduce the frequency of migraine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/45/34522/abstract/58,59\">",
"     58,59",
"    </a>",
"    ]. A history of headache is not a contraindication to DMPA use (",
"    <a class=\"graphic graphic_table graphicRef74890 \" href=\"mobipreview.htm?12/13/12506\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Mood changes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Observational studies have not reported any consistent effects of DMPA on mood [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/45/34522/abstract/60-63\">",
"     60-63",
"    </a>",
"    ]. We feel that progestins may cause or exacerbate depressive symptoms in certain subpopulations of women, including those with a history of premenstrual syndrome or mood disorders [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/45/34522/abstract/41,64,65\">",
"     41,64,65",
"    </a>",
"    ]. Therefore, we suggest that clinicians follow such women closely when any progestin-based therapy is initiated, but we do not feel a history of depression is a contraindication to use of DMPA (",
"    <a class=\"graphic graphic_table graphicRef74890 \" href=\"mobipreview.htm?12/13/12506\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26226460\">",
"    <span class=\"h2\">",
"     Other",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dizziness, bloating, and decreased libido are other reported side effects.",
"   </p>",
"   <p>",
"    Two to 20 percent of patients using the subcutaneous formulation have reported a dent, dimple, or lump at the injection site (termed",
"    <span class=\"nowrap\">",
"     granuloma/atrophy),",
"    </span>",
"    or other minor site reactions (redness, pruritus, bruising, or blistering) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/45/34522/abstract/4,5,14,66\">",
"     4,5,14,66",
"    </a>",
"    ]. The natural history of",
"    <span class=\"nowrap\">",
"     granuloma/atrophy",
"    </span>",
"    is unclear; resolution is possible as with other forms of lipoatrophy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     RISKS AND BENEFITS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Benefits",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7898312\">",
"    <span class=\"h3\">",
"     Management of comorbid conditions",
"    </span>",
"    &nbsp;&mdash;&nbsp;DMPA has been used to manage a variety of gynecologic and nongynecologic disorders:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The tendency of DMPA to cause amenorrhea makes it a particularly appropriate contraceptive choice for women with menorrhagia, dysmenorrhea, or iron-deficiency anemia [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/45/34522/abstract/67-70\">",
"       67-70",
"      </a>",
"      ]. There are no data from randomized trials regarding the impact of DMPA on menorrhagia in women with intramural fibroids; however, substantial clinical experience over two decades indicates that some women with",
"      <span class=\"nowrap\">",
"       menorrhagia/anemia",
"      </span>",
"      associated with intramural fibroids become amenorrheic during use of DMPA.",
"     </li>",
"     <li>",
"      DMPA may prevent development of hemorrhagic corpus luteum cysts in women who are anticoagulated [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/45/34522/abstract/71\">",
"       71",
"      </a>",
"      ]. Although direct evidence is sparse, subcutaneous and intramuscular injections do not appear to increase the risk of local hematoma formation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/45/34522/abstract/72\">",
"       72",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      DMPA transforms proliferative into secretory endometrium, thus it protects against development of endometrial hyperplasia.",
"     </li>",
"     <li>",
"      DMPA users have a decreased risk of developing pelvic inflammatory disease [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/45/34522/abstract/67\">",
"       67",
"      </a>",
"      ]. This may be related to changes in cervical mucus, decreased menstrual blood flow,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      a reduction in retrograde menstruation.",
"     </li>",
"     <li>",
"      Women using hormonal contraception, including DMPA, are at very low risk of conceiving ectopic, as well as intrauterine, pregnancies.",
"     </li>",
"     <li>",
"      Progestins inhibit endometriotic tissue growth by directly causing initial decidualization and eventual atrophy and by inhibiting pituitary gonadotropin secretion and ovarian estrogen production. Randomized trials have shown that DMPA is more effective than estrogen-progestin contraceptives and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?26/0/26629?source=see_link\">",
"       danazol",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/45/34522/abstract/73\">",
"       73",
"      </a>",
"      ], and is as effective as",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?4/41/4760?source=see_link\">",
"       leuprolide",
"      </a>",
"      for treatment of pain associated with endometriosis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/45/34522/abstract/56,57\">",
"       56,57",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      DMPA is a useful means of suppressing menstrual bleeding and managing menstrual hygiene in individuals with special needs (eg, cognitive impairment, military personnel, athletes) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/45/34522/abstract/74\">",
"       74",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Use of DMPA has been associated with fewer painful crises in women with sickle cell disease [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/45/34522/abstract/75\">",
"       75",
"      </a>",
"      ] and appears to be a safe and effective contraceptive method in this population [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/45/34522/abstract/76\">",
"       76",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The efficacy of DMPA's contraceptive protection does not appear attenuated by the use of enzyme-inducing anticonvulsants [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/45/34522/abstract/13\">",
"       13",
"      </a>",
"      ], and DMPA may have intrinsic anticonvulsant properties [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/45/34522/abstract/77,78\">",
"       77,78",
"      </a>",
"      ]. For these reasons, DMPA might be a good contraceptive of choice for many women with seizure disorders (",
"      <a class=\"graphic graphic_table graphicRef74890 \" href=\"mobipreview.htm?12/13/12506\">",
"       table 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      DMPA is an effective treatment of menopausal vasomotor symptoms in women who need to avoid estrogen therapy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/45/34522/abstract/79\">",
"       79",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7898336\">",
"    <span class=\"h3\">",
"     Drug interactions",
"    </span>",
"    &nbsp;&mdash;&nbsp;A benefit of DMPA use is the lack of drug interactions compared to other types of hormonal contraception (",
"    <a class=\"graphic graphic_table graphicRef74890 \" href=\"mobipreview.htm?12/13/12506\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7897960\">",
"    <span class=\"h2\">",
"     Risks",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Cancer risk",
"    </span>",
"    &nbsp;&mdash;&nbsp;WHO examined the risk of endometrial, ovarian, liver, and cervical carcinoma in DMPA-users [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/45/34522/abstract/80-82\">",
"     80-82",
"    </a>",
"    ]. In large case control studies, DMPA decreased the prevalence of endometrial cancer by 80 percent, and was associated with a greater protective effect against endometrial cancer than oral contraceptives. DMPA did not increase the risk of ovarian, cervical, or liver cancer.",
"   </p>",
"   <p>",
"    Studies evaluating the relationship between DMPA use and breast cancer risk have been generally reassuring and have",
"    <strong>",
"     not",
"    </strong>",
"    observed an increase in risk [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/45/34522/abstract/83-86\">",
"     83-86",
"    </a>",
"    ], with two exceptions (RR 2.6, 95% CI 1.4-4.7 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/45/34522/abstract/87\">",
"     87",
"    </a>",
"    ] and 2.2, 95% CI 1.2-4.2 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/45/34522/abstract/88\">",
"     88",
"    </a>",
"    ]). In the first of these studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/45/34522/abstract/87\">",
"     87",
"    </a>",
"    ], the authors considered their findings inconclusive given the small number of DMPA users and the lack of a dose-response relationship. In the second study [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/45/34522/abstract/88\">",
"     88",
"    </a>",
"    ], the increase in risk was limited to current users with &ge;12 months of use. The findings of this latter study, conducted in the Seattle, Washington area and based on 1028 cases of breast cancer, directly conflict with those of the Women&rsquo;s CARE Study [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/45/34522/abstract/85\">",
"     85",
"    </a>",
"    ], conducted by the Centers for Disease Control (CDC) and based on 4575 cases. In contrast with the Washington State study, the Women&rsquo;s CARE study found that use of DMPA was not associated with an elevated risk of breast cancer in",
"    <span class=\"nowrap\">",
"     current/recent",
"    </span>",
"    users or in women who had initiated DMPA five years prior. Neither study verified hormone use by review of medical",
"    <span class=\"nowrap\">",
"     records/prescriptions.",
"    </span>",
"   </p>",
"   <p>",
"    Theoretically, it is possible that prolonged ovulation suppression associated with DMPA might provide protection against ovarian cancer, as seen with oral contraceptives [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/45/34522/abstract/35,67,89,90\">",
"     35,67,89,90",
"    </a>",
"    ]. In the largest case-control study of this issue, use of DMPA was associated with protection against epithelial ovarian cancer (OR 0.61, 95% CI 0.44-0.85) and the magnitude of protection was similar to that seen with oral contraceptives [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/45/34522/abstract/91\">",
"     91",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Cardiovascular risk",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is some evidence that long-term DMPA use induces moderately unfavorable changes in lipid metabolism and reduces peripheral arterial hyperemia-induced flow-mediated dilatation (FMD) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/45/34522/abstract/92-96\">",
"     92-96",
"    </a>",
"    ], but does not increase production of coagulation factors and has no adverse effect on blood pressure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/45/34522/abstract/97-99\">",
"     97-99",
"    </a>",
"    ]. The clinical implications, if any, of the combination of these changes in healthy young women are unknown.",
"   </p>",
"   <p>",
"    Findings from observational studies are illustrated by the following examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One large epidemiological study did not observe a statistically significant increase in adverse cardiovascular effects (venous thrombosis, stroke, acute myocardial infarction) related to past or current DMPA use, although a small nonsignificant increase in OR for venous thromboembolism (VTE) was observed (OR 2.2, 95%CI 0.7-7.3) compared to nonusers of any type of steroid hormone contraceptive [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/45/34522/abstract/100\">",
"       100",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A case control study observed a significantly increased risk of VTE in DMPA users compared with nonusers of hormonal contraception (OR 3.6, 95% CI 1.8-7.1), but there were only 35 women with VTE in this study and the data were not adjusted for weight, family history, or smoking status, which were different between groups. An additional concern with this study was that only approximately 1 percent of reproductive age women used DMPA for contraception, raising the possibility of selection bias (DMPA users may be at substantially higher baseline risk for VTE than nonusers of injectable contraception) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/45/34522/abstract/101\">",
"       101",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The American College of Obstetricians and Gynecologists (ACOG) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/45/34522/abstract/102\">",
"     102",
"    </a>",
"    ] and the CDC (",
"    <a class=\"graphic graphic_table graphicRef74890 \" href=\"mobipreview.htm?12/13/12506\">",
"     table 1",
"    </a>",
"    ) consider DMPA an acceptable contraceptive option for women with an uncomplicated history of VTE in whom use of estrogen-progestin contraceptives is contraindicated. In these women, the advantages of using the method generally outweigh the theoretical or proven risks. This recommendation differs from package labeling for DMPA, which indicates that a prior history of VTE is a contraindication to DMPA use. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/5/18522?source=see_link\">",
"     \"Overview of the use of estrogen-progestin contraceptives\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For women with multiple risk factors for arterial cardiovascular disease (eg, smoking, older age, diabetes, hypertension that is poorly controlled or associated with vascular disease), women with a history of stroke or ischemic heart disease, and women with a current VTE, WHO and the CDC classify DMPA as Category 3, indicating that the risks of use may exceed the benefits. This classification reflects theoretical concerns related to the reduction in plasma high-density lipoprotein levels associated with DMPA use and weak evidence of an increased risk of VTE in users. However, lipid changes associated with use of hormonal contraceptives have not been linked to adverse clinical cardiovascular outcomes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/45/34522/abstract/103\">",
"     103",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The CDC categorizes current VTE as &ldquo;a condition for which the advantages of using the method generally outweigh the theoretical or proven risks&rdquo; (",
"    <a class=\"graphic graphic_table graphicRef74890 \" href=\"mobipreview.htm?12/13/12506\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Reduction in bone mineral density",
"    </span>",
"    &nbsp;&mdash;&nbsp;A primary concern regarding the safety of long-term use of DMPA is its effect on bone density. One of the contraceptive actions of DMPA results from suppression of gonadotropin secretion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/45/34522/abstract/1\">",
"     1",
"    </a>",
"    ], which in turn suppresses ovarian estradiol production [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/45/34522/abstract/104\">",
"     104",
"    </a>",
"    ]. In hypoestrogenic states, bone resorption exceeds bone formation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/45/34522/abstract/105\">",
"     105",
"    </a>",
"    ], resulting in a decline in bone mineral density (BMD). Compared to nonusers, BMD at the hip and spine of DMPA users decreases by 0.5 to 3.5 percent after one year and 5.7 to 7.5 percent after two years of use [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/45/34522/abstract/106\">",
"     106",
"    </a>",
"    ]. The rate of loss is not linear; the greatest loss is during the first one to two years of use (",
"    <a class=\"graphic graphic_figure graphicRef61971 \" href=\"mobipreview.htm?42/11/43197\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/45/34522/abstract/107-112\">",
"     107-112",
"    </a>",
"    ]. The SC and IM formulations have similar effects [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/45/34522/abstract/15\">",
"     15",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/21/9562?source=see_link\">",
"     \"Drugs that affect bone metabolism\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Observations of reduced BMD in current DMPA users have led to concerns that DMPA-induced bone loss might increase the long-term risk of fractures years after discontinuation of the drug, particularly in two groups of women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/45/34522/abstract/113\">",
"     113",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Young women, who have not yet attained their peak bone mass",
"     </li>",
"     <li>",
"      Perimenopausal women, who may be starting to lose bone mass and who may have reached menopause by the time of DMPA discontinuation, with no opportunity to regain the lost bone mass.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The best available data show that DMPA use does not reduce peak bone mass and does not increase the risk of osteoporotic fracture in later life in women at average risk of osteoporosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/45/34522/abstract/114\">",
"     114",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Several observational studies have reported an increased risk of fracture in current DMPA users compared with non-users [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/45/34522/abstract/115-119\">",
"     115-119",
"    </a>",
"    ]. However, DMPA users differ behaviorally in a variety of ways from non-users and these differences may impact their risk of traumatic fractures, thus it is difficult to draw clinical inferences from these findings. A retrospective cohort study provided reassuring data: DMPA users had higher incident fracture risk than never users before beginning DMPA (incidence rate ratio 1.28) and after beginning DMPA (incidence rate ratio 1.23), but the fracture risk in DMPA users did not increase significantly after starting DMPA (incidence rate ratio before and after starting DMPA: 1.08, 95% CI 0.92&ndash;1.26) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/45/34522/abstract/119\">",
"     119",
"    </a>",
"    ]. Long-term prospective data are not available.",
"   </p>",
"   <p>",
"    Despite the lack of a proven increase in fracture rate, in 2004, the Food and Drug Administration issued a black box warning on DMPA package labeling: \"Women who use DMPA may lose significant bone mineral density. Bone loss is greater with increasing duration of use and may not be completely reversible. It is unknown if use of DMPA during adolescence or early adulthood, a critical period of bone accretion, will reduce peak bone mass and increase the risk for osteoporotic fracture in later life. DMPA should be used as a long-term birth control method (eg, longer than two years) only if other birth control methods are inadequate.\" The addition of this warning to DMPA's package labeling appears to have led some clinicians in the United States to restrict the duration of DMPA use in their patients and to order BMD testing in women using DMPA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/45/34522/abstract/120\">",
"     120",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The clinical significance of decreased BMD in current DMPA users is unknown. Studies involving premenopausal women and adolescents treated with DMPA for up to five years showed that the decline in BMD associated with the drug was substantially reversed after discontinuation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/45/34522/abstract/56,57,108-111,121-132\">",
"     56,57,108-111,121-132",
"    </a>",
"    ]. Reversal at the spine occurred sooner, and appeared to be more complete, than reversal at the hip.",
"   </p>",
"   <p>",
"    The impact of DMPA use on BMD is illustrated by the following studies, which are representative examples of the literature on this subject:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Women 25 to 35 years of age",
"      </strong>",
"      &mdash; An FDA-mandated manufacturer-sponsored study represents the largest and longest controlled study assessing BMD in women using DMPA (150 mg formulation) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/45/34522/abstract/121\">",
"       121",
"      </a>",
"      ]. This was a seven-year open-label, prospective, matched-cohort study which assessed BMD, body weight, lipid profiles, and biochemical markers of bone metabolism. Subjects were women aged 25 to 35 years using DMPA or nonhormonal contraception who were matched for race, age, and current smoking status. A total of 608 women were enrolled, including 248 in the DMPA group and 360 in the nonhormonal group. Change in BMD was assessed for up to 4.6 years (240 weeks) of treatment and up to 1.8 years (96 weeks) of post-treatment follow-up in subjects who received at least one dose of DMPA. BMD was measured at the lumbar spine and the hip by dual-energy X-ray absorptiometry at baseline, weeks 24 and 48, then every 48 weeks through week 240, and in the post-treatment phase at weeks 24, 48, and 96. Of the women enrolled, 42 (17 percent) in the DMPA group and 118 (33 percent) in the nonhormonal group completed the 4.6-year (240-week) treatment period. Post-treatment data were available for 91 women, including women who discontinued DMPA prior to week 240; of these, 44 (48 percent) had all follow-up assessments performed.",
"      <br/>",
"      <br/>",
"      Consistent with other published studies, BMD in DMPA users decreased from baseline by 5.2 percent in the total hip and 5.4 percent in the lumbar spine, with the rate of BMD decline in the DMPA group most rapid in the first year of treatment. Recovery in BMD occurred after DMPA discontinuation. Post-treatment follow-up at 96 weeks indicated an overall mean decline from baseline of -0.20 percent in total hip BMD and -1.19 percent in the lumbar spine BMD. After adjustment for baseline differences, the BMD differences between the DMPA and nonhormonal groups were of borderline significance (-2.08 percent, P = 0.047) for the hip and significant (-2.04 percent, P = 0.017) for the lumbar spine. Significant BMD recovery post-treatment began as early as 24 weeks at all anatomic sites. At the end of the post-treatment follow-up, none of the subjects in the DMPA group had a loss of &ge;10 percent in either total hip or lumbar spine BMD.",
"      <br/>",
"      <br/>",
"      BMD recovery appeared to be ongoing at 96 weeks. Limiting the post-treatment period of BMD observation to two years likely explains why full recovery was not observed [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/45/34522/abstract/108\">",
"       108",
"      </a>",
"      ]. Fracture rates among study participants were low and similar in the DMPA users and non-users.",
"     </li>",
"     <li>",
"      <strong>",
"       Adolescents",
"      </strong>",
"      &mdash; A population-based prospective cohort study was conducted to follow BMD in 170 adolescent girls, aged 14 to 18 years (including 80 who used DMPA contraception at baseline) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/45/34522/abstract/125\">",
"       125",
"      </a>",
"      ]. BMD was measured every six months for 24 to 36 months at the hip, spine, and whole body, and mean BMD changes were compared between girls who used DMPA, those who discontinued use during the study, and girls who had not used DMPA.",
"      <br/>",
"      <br/>",
"      Use of DMPA was associated with BMD loss during use; however, recovery of BMD was complete within 12 months following DMPA discontinuation. Among girls using DMPA, BMD declined significantly relative to nonusers at the hip and spine (-1.81 percent versus -0.19 percent, and -0.97 percent versus 1.32 percent, respectively). More rapid BMD loss was observed in new users than in those who had been using DMPA for longer than six months. Discontinuation of DMPA was associated with significant increases in BMD relative to non-users at all anatomical sites.",
"      <br/>",
"      <br/>",
"      A prospective multicenter study that examined variables that predict increased risk of BMD loss over 5 percent found that lower BMI, lower calcium intake, and greater alcohol use were significantly associated with greater BMD loss in adolescents using DMPA [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/45/34522/abstract/133\">",
"       133",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h4\">",
"     Conclusions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although there is an association between current DMPA use and decreased BMD, there is no high quality evidence of a significant increase in risk of fractures in DMPA users [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/45/34522/abstract/134\">",
"     134",
"    </a>",
"    ]. In particular, there are few data on the effect of BMD changes in younger women on their short- or long-term fracture risk [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/45/34522/abstract/135,136\">",
"     135,136",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We, and others, including ACOG, the Society for Adolescent Medicine, WHO, and the Society of Obstetricians and Gynaecologists of Canada [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/45/34522/abstract/102,106,135-138\">",
"     102,106,135-138",
"    </a>",
"    ], believe that the advantages of DMPA use as a contraceptive generally outweigh the theoretical concerns regarding skeletal harm. Accordingly, skeletal health concerns should not restrict initiation or continuation of DMPA in adolescent girls, women 18 to 45 years of age, or older reproductive age women (age more than 45 years). The available evidence also does not justify limiting the duration of DMPA therapy, which may be continued for decades.",
"   </p>",
"   <p>",
"    Given that the effect of DMPA on BMD is similar to that with pregnancy (decrease in BMD of 2 to 8 percent) or lactation (decrease in BMD of 3 to 5 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/45/34522/abstract/106\">",
"     106",
"    </a>",
"    ]), use of DMPA is not an indication for BMD testing either before, during, or in follow-up of its administration [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/45/34522/abstract/102,137\">",
"     102,137",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some clinicians prescribe supplemental hormone replacement doses of oral or transdermal estrogen in long-term DMPA users who have additional risk factors for low BMD. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/25/6553?source=see_link\">",
"     \"Epidemiology and etiology of premenopausal osteoporosis\"",
"    </a>",
"    .) This approach is based on data from randomized trials in which menopausal doses of estrogen supplements given to adolescent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/45/34522/abstract/139\">",
"     139",
"    </a>",
"    ] and adult DMPA users [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/45/34522/abstract/140\">",
"     140",
"    </a>",
"    ] prevented declines in BMD. These studies provided evidence that the loss in BMD was estrogen related and that the effects of estrogen on bone metabolism were not impaired by DMPA. We feel there is insufficient evidence to make specific clinical recommendations regarding estrogen supplementation for DMPA users, in part, because it appears that estrogen from an exogenous (supplemental estrogen) or endogenous (ovarian) source results in similar recovery of BMD following DMPA discontinuation.",
"   </p>",
"   <p>",
"    There are no data on use of other antiresorptive agents (eg, bisphosphonates, calcitonin, selective estrogen receptor modulators) to prevent bone loss in DMPA users. We recommend not using them for this indication [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/45/34522/abstract/141\">",
"     141",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Providers should advise DMPA users to ensure adequate intake of calcium and vitamin D and to engage in regular exercise to promote bone health, which is good advice for all women, regardless of their contraceptive choice. Providers should also use clinical judgment when deciding whether to use DMPA versus an alternative contraceptive in women with risk factors for osteoporosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Lack of protection from sexually transmitted infections",
"    </span>",
"    &nbsp;&mdash;&nbsp;Use of DMPA does not protect users from acquiring sexually transmitted infections (STIs). Whether it increases the risk of acquiring these infections is less clear.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h4\">",
"     Effect on HIV acquisition and transmission",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some studies have found no association between use of hormonal contraception, particularly DMPA, and acquisition of HIV infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/45/34522/abstract/142-144\">",
"     142-144",
"    </a>",
"    ], while others have reported hormonal contraception, especially DMPA, increased the risk of HIV acquisition in females [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/45/34522/abstract/145-147\">",
"     145-147",
"    </a>",
"    ]. These studies also reported increased cervical HIV shedding, thus potentially facilitating transmission of the disease from the female to the male partner.",
"   </p>",
"   <p>",
"    One explanation for a possible association between use of hormonal contraception and HIV may be that women using hormonal contraception may be less likely to consistently use condoms than women using condoms alone for contraception, potentially biasing the findings of these studies. This and other challenges in interpreting the existing literature highlight the need for more prospective (preferably randomized) studies of HIV acquisition and transmission rates in women using and not using hormonal contraception. Until those data are available, we agree with the World Health Organization and CDC assessments that women at high risk of and living with HIV can continue to use all existing hormonal contraceptive methods without restriction (",
"    <a class=\"graphic graphic_table graphicRef75345 \" href=\"mobipreview.htm?38/20/39245\">",
"     table 4",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef74890 \" href=\"mobipreview.htm?12/13/12506\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/45/34522/abstract/148,149\">",
"     148,149",
"    </a>",
"    ]. In women at risk, condoms (male or female) and other HIV preventive measures should always be used to protect against transmission or acquisition of sexually transmitted diseases.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h4\">",
"     Effect on chlamydia and gonorrhea acquisition",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some studies have observed an increased risk of chlamydia and gonorrhea infection in DMPA users compared to oral contraceptive users, contraceptive nonusers, or the general population [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/45/34522/abstract/107,150-153\">",
"     107,150-153",
"    </a>",
"    ]. However, these differences usually disappear after adjustment for relevant behavioral factors and rates of new versus existing infection.",
"   </p>",
"   <p>",
"    The hypothesis that long-acting progestins promote transmission of STIs was based on two studies in Rhesus monkeys in whom progestins caused vaginal mucosal thinning, hyperplasia of cervical columnar cells, and cervical ectopy; however, these changes were not found in women given progestins [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/45/34522/abstract/154\">",
"     154",
"    </a>",
"    ]. Moreover, progestins thicken cervical mucus, and thickened cervical mucus may reduce the risk of ascending infection and development of pelvic inflammatory disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3193608\">",
"    <span class=\"h3\">",
"     Change in glucose/insulin",
"    </span>",
"    &nbsp;&mdash;&nbsp;A study that measured fasting glucose and insulin levels over three years in 240 white, African-American, and Hispanic women receiving DMPA found some women experienced mild increases in fasting insulin and glucose levels (3",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    and 4 units, respectively, over baseline values); however, these changes probably are not clinically important [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/45/34522/abstract/155\">",
"     155",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     RETURN TO FERTILITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although DMPA does not permanently impact endocrine function, return of fertility may be delayed. Within 10 months of the last injection, 50 percent of women who discontinue DMPA to become pregnant will conceive; in a small proportion of women, however, fertility is not reestablished until 18 months after the last injection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/45/34522/abstract/156\">",
"     156",
"    </a>",
"    ]. The persistence of ovulation suppression following DMPA discontinuation is not related to the duration of use, but is related to weight [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/45/34522/abstract/156\">",
"     156",
"    </a>",
"    ]. Women with lower body weights conceive sooner after discontinuing DMPA than women with higher body weights.",
"   </p>",
"   <p>",
"    Before initiating DMPA contraception, clinicians should counsel candidates about the possible prolonged duration of contraceptive action. Women who may want to become pregnant within the next one or two years should choose an alternative contraceptive.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7898424\">",
"    <span class=\"h1\">",
"     SPECIAL POPULATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Adolescents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rates of oral contraceptive failure and discontinuation can be exceedingly high among adolescents. In contrast, DMPA provides highly effective and acceptable contraception in this population [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/45/34522/abstract/37,157-162\">",
"     37,157-162",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A study of postpartum teens found that DMPA users were more likely to continue their contraception than oral contraceptive users (55 versus 27 percent), and had lower rates of repeat pregnancy (3 versus 24 percent) during a minimum of 12 months follow-up [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/45/34522/abstract/163\">",
"     163",
"    </a>",
"    ]. Some experts in adolescent gynecology suggest that long-acting progestin methods, coupled with condoms for protection against sexually transmitted infections, should be considered contraceptives of first choice for sexually active teens [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/45/34522/abstract/158,164\">",
"     158,164",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The effect of DMPA on BMD was discussed above. (See",
"    <a class=\"local\" href=\"#H18\">",
"     'Reduction in bone mineral density'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Perimenopausal women",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women can safely continue use of DMPA until they become menopausal. Because long-term DMPA users are amenorrheic, perimenopausal DMPA users will not experience the irregular bleeding that characteristically accompanies the perimenopausal transition. Likewise, such women may not experience vasomotor symptoms, which are suppressed by DMPA use. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/53/25434?source=see_link\">",
"     \"Menopausal hot flashes\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The median age of menopause (when contraception is no longer needed) is 51 to 52 years, meaning that 50 percent of women of this age are still ovulatory. By age 55, in contrast, at least 80 percent of women are menopausal [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/45/34522/abstract/165,166\">",
"     165,166",
"    </a>",
"    ]. Therefore, it is reasonable to continue DMPA without gonadotropin testing until the patient is in her mid-50s. At that time, contraception can be discontinued.",
"   </p>",
"   <p>",
"    Although serum follicle-stimulating hormone (FSH) concentrations increase across the menopausal transition, a single elevated FSH level is not useful in determining menopausal status in any woman because FSH levels vary from cycle to cycle and may fluctuate between the normal premenopausal and postmenopausal ranges [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/45/34522/abstract/167\">",
"     167",
"    </a>",
"    ]. FSH testing is even less useful in DMPA users because DMPA suppresses FSH production, thus menopausal DMPA users may have FSH levels in the premenopausal range related to DMPA. These relationships were illustrated in a study of 82 amenorrheic long-term DMPA users age 40 to 55 years who had FSH testing every 90 days immediately before their DMPA injection: 41 percent of women with a high initial FSH level subsequently had a low FSH level [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/45/34522/abstract/168\">",
"     168",
"    </a>",
"    ]. If FSH is measured in a DMPA user &ge;age 50 years, the level is most informative of menopausal status if measured immediately before the next DMPA injection is due [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/45/34522/abstract/169\">",
"     169",
"    </a>",
"    ] and is in the menopausal range on two consecutive occasions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/45/34522/abstract/168\">",
"     168",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The effect of DMPA on BMD was discussed above (see",
"    <a class=\"local\" href=\"#H18\">",
"     'Reduction in bone mineral density'",
"    </a>",
"    above).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     After abortion or delivery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Use of DMPA after abortion or delivery, and in breastfeeding women, is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/8/24713?source=see_link\">",
"     \"Postpartum and postabortion contraception\"",
"    </a>",
"    .).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     When estrogen is contraindicated",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although clinicians should familiarize themselves with the contraindications listed on package labeling for all medications they prescribe, progestin-only hormonal methods appear to be reasonable contraceptive choices for many women with relative contraindications to estrogen-containing contraceptives (",
"    <a class=\"graphic graphic_table graphicRef74890 \" href=\"mobipreview.htm?12/13/12506\">",
"     table 1",
"    </a>",
"    ). Many of the contraindications listed in the package insert were established for combined estrogen-progestin oral contraceptives and then extrapolated to progestin-only methods because clinical trials have not evaluated the safety of the latter in women with contraindications to estrogen. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/7/39034?source=see_link\">",
"     \"Risks and side effects associated with estrogen-progestin contraceptives\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h1\">",
"     COST",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to enhancing quality of life by allowing couples to choose whether and when they wish to bear children, effective contraception saves healthcare costs. An analysis of nine contraceptive methods found that, over a five-year period, DMPA and intrauterine contraception were the most cost-effective reversible contraceptives [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/45/34522/abstract/170\">",
"     170",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?13/56/14211?source=see_link\">",
"       \"Patient information: Choosing birth control (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?21/32/22021?source=see_link\">",
"       \"Patient information: Hormonal methods of birth control (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?8/60/9157?source=see_link\">",
"       \"Patient information: Birth control; which method is right for me? (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Depot",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?1/24/1417?source=see_link\">",
"       medroxyprogesterone acetate",
"      </a>",
"      (DMPA) injection is an excellent method of contraception for women who desire a long-term, reversible contraceptive method. It is highly effective, private, and avoids the need for compliance daily or near the time of sexual intercourse. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H4\">",
"       'Efficacy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      DMPA can be initiated without a pelvic or breast examination and without any routine laboratory tests. Medical eligibility criteria are listed in the table (",
"      <a class=\"graphic graphic_table graphicRef74890 \" href=\"mobipreview.htm?12/13/12506\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H26226348\">",
"       'Medical eligibility criteria'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The ideal time to initiate DMPA is within seven days of the onset of menses or before discontinuing another method of contraception, but it can be started at almost any time. The dose is repeated every three months, with a two-week grace period. We suggest performing a pregnancy test before administering DMPA in women more than two weeks late for their injection. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Administration'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Thorough counseling about side effects, particularly the high frequency of amenorrhea and unscheduled bleeding, is important to enhance continuation of the method. (See",
"      <a class=\"local\" href=\"#H26226042\">",
"       'Counseling'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H9\">",
"       'Side effects'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Menstrual changes occur in all women using DMPA and are the most frequent cause for discontinuation. During the first months of use, episodes of irregular bleeding and spotting lasting seven days or longer are common. The frequency and duration of such bleeding decrease with increasing duration of use. After one year of use, 50 percent of women experience amenorrhea, and with ongoing use, the rate of amenorrhea increases to 75 percent. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Menstrual changes'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There is an association between current DMPA use and decreased bone mineral density; losses in bone mineral density are temporary and reverse after discontinuation of DMPA. There is no evidence of an increase in risk of fractures. We believe that, in all age groups, the advantages of DMPA use as a contraceptive generally outweigh the theoretical concerns regarding skeletal harm. We suggest not avoiding DMPA as a contraceptive option in adolescent girls and older reproductive age women (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Reduction in bone mineral density'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In contrast to package labeling, we do not suggest avoiding DMPA as a contraceptive option in women with an uncomplicated past history of venous thrombosis (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). However, for women with multiple risk factors for arterial cardiovascular disease (eg, smoking, older age, diabetes, hypertension that is poorly controlled or associated with vascular disease), women with a history of stroke or ischemic heart disease, and women with current venous thrombosis, the risks of DMPA use may exceed the benefits. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Cardiovascular risk'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Return of fertility may be delayed after discontinuing DMPA, but within 10 months of the last injection, 50 percent of women who are trying to conceive will become pregnant; in a small proportion of women, however, fertility is not reestablished until 18 months after the last injection. (See",
"      <a class=\"local\" href=\"#H24\">",
"       'Return to fertility'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/45/34522/abstract/1\">",
"      Mishell DR Jr. Pharmacokinetics of depot medroxyprogesterone acetate contraception. J Reprod Med 1996; 41:381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/45/34522/abstract/2\">",
"      Ortiz A, Hirol M, Stanczyk FZ, et al. Serum medroxyprogesterone acetate (MPA) concentrations and ovarian function following intramuscular injection of depo-MPA. J Clin Endocrinol Metab 1977; 44:32.",
"     </a>",
"    </li>",
"    <li>",
"     HIGHLIGHTS OF PRESCRIBING INFORMATION. DEPO-PROVERA CI (medroxyprogesterone acetate) injectable suspension, for intramuscular use file://contraception.about.com/gi/o.htm?zi=1/XJ&amp;zTi=1&amp;sdn=contraception&amp;cdn=health&amp;tm=55&amp;f=10&amp;su=p284.12.336.ip_p1051.2.336.ip_&amp;tt=3&amp;bt=0&amp;bts=0&amp;zu=http%3A//media.pfizer.com/files/products/uspi_depo_provera_contraceptive.pdf (Accessed on October 18, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/45/34522/abstract/4\">",
"      Prabhakaran S, Sweet A. Self-administration of subcutaneous depot medroxyprogesterone acetate for contraception: feasibility and acceptability. Contraception 2012; 85:453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/45/34522/abstract/5\">",
"      Cameron ST, Glasier A, Johnstone A. Pilot study of home self-administration of subcutaneous depo-medroxyprogesterone acetate for contraception. Contraception 2012; 85:458.",
"     </a>",
"    </li>",
"    <li>",
"     Speroff, L, Darney, PD. Injectable contraception. In: A Clinical Guide for Contraception. Philadelphia, Pa: Lippincott Williams &amp; Wilkins; 2011: chap 6.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/45/34522/abstract/7\">",
"      Kaunitz AM. Long-acting injectable contraception with depot medroxyprogesterone acetate. Am J Obstet Gynecol 1994; 170:1543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/45/34522/abstract/8\">",
"      Trussell J. Contraceptive failure in the United States. Contraception 2004; 70:89.",
"     </a>",
"    </li>",
"    <li>",
"     World Health Organization Department of Reproductive Health and Research and Johns Hopkins Bloomberg School of Public Health. Family Planning: A Global Handbook for Providers (2008 update). Baltimore and Geneva, 2008.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/45/34522/abstract/10\">",
"      Winner B, Peipert JF, Zhao Q, et al. Effectiveness of long-acting reversible contraception. N Engl J Med 2012; 366:1998.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/45/34522/abstract/11\">",
"      Leiman G. Depo-medroxyprogesterone acetate as a contraceptive agent: its effect on weight and blood pressure. Am J Obstet Gynecol 1972; 114:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/45/34522/abstract/12\">",
"      Segall-Gutierrez P, Taylor D, Liu X, et al. Follicular development and ovulation in extremely obese women receiving depo-medroxyprogesterone acetate subcutaneously. Contraception 2010; 81:487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/45/34522/abstract/13\">",
"      Sapire, KE. Letter to the Editor: Depo-Provera and carbamazepine. Br J Fam Plann 1990; 15:130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/45/34522/abstract/14\">",
"      Jain J, Jakimiuk AJ, Bode FR, et al. Contraceptive efficacy and safety of DMPA-SC. Contraception 2004; 70:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/45/34522/abstract/15\">",
"      Kaunitz AM, Darney PD, Ross D, et al. Subcutaneous DMPA vs. intramuscular DMPA: a 2-year randomized study of contraceptive efficacy and bone mineral density. Contraception 2009; 80:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/45/34522/abstract/16\">",
"      Lestishock L, Pariseau C, Rooholamini S, Ammerman S. Anaphylaxis from depot medroxyprogesterone acetate in an adolescent girl. Obstet Gynecol 2011; 118:443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/45/34522/abstract/17\">",
"      Petta CA, Faundes A, Dunson TR, et al. Timing of onset of contraceptive effectiveness in Depo-Provera users: Part I. Changes in cervical mucus. Fertil Steril 1998; 69:252.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/45/34522/abstract/18\">",
"      Sneed R, Westhoff C, Morroni C, Tiezzi L. A prospective study of immediate initiation of depo medroxyprogesterone acetate contraceptive injection. Contraception 2005; 71:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/45/34522/abstract/19\">",
"      Balkus J, Miller L. Same-day administration of depot-medroxyprogesterone acetate injection: a retrospective chart review. Contraception 2005; 71:395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/45/34522/abstract/20\">",
"      Nelson AL, Katz T. Initiation and continuation rates seen in 2-year experience with Same Day injections of DMPA. Contraception 2007; 75:84.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/45/34522/abstract/21\">",
"      Rickert VI, Tiezzi L, Lipshutz J, et al. Depo Now: preventing unintended pregnancies among adolescents and young adults. J Adolesc Health 2007; 40:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/45/34522/abstract/22\">",
"      Lopez LM, Newmann SJ, Grimes DA, et al. Immediate start of hormonal contraceptives for contraception. Cochrane Database Syst Rev 2012; 12:CD006260.",
"     </a>",
"    </li>",
"    <li>",
"     World Health Organization. Selected practice recommendations for contraceptive use. 2nd edition, 2004. file://whqlibdoc.who.int/publications/2004/9241562846.pdf (Accessed on June 03, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/45/34522/abstract/24\">",
"      Borgatta L, Murthy A, Chuang C, et al. Pregnancies diagnosed during Depo-Provera use. Contraception 2002; 66:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/45/34522/abstract/25\">",
"      Brent RL. Nongenital malformations following exposure to progestational drugs: the last chapter of an erroneous allegation. Birth Defects Res A Clin Mol Teratol 2005; 73:906.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/45/34522/abstract/26\">",
"      Fotherby K, Koetsawang S, Mathrubutham M. Pharmacokinetic study of different doses of Depo Provera. Contraception 1980; 22:527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/45/34522/abstract/27\">",
"      Steiner MJ, Kwok C, Stanback J, et al. Injectable contraception: what should the longest interval be for reinjections? Contraception 2008; 77:410.",
"     </a>",
"    </li>",
"    <li>",
"     World Health Organization. Selected Practice Recommendations for Contraceptive use, 2nd ed, 2004. p.55.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/45/34522/abstract/29\">",
"      Lei ZW, Wu SC, Garceau RJ, et al. Effect of pretreatment counseling on discontinuation rates in Chinese women given depo-medroxyprogesterone acetate for contraception. Contraception 1996; 53:357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/45/34522/abstract/30\">",
"      Hubacher D, Goco N, Gonzalez B, Taylor D. Factors affecting continuation rates of DMPA. Contraception 1999; 60:345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/45/34522/abstract/31\">",
"      Canto De Cetina TE, Canto P, Ordo&ntilde;ez Luna M. Effect of counseling to improve compliance in Mexican women receiving depot-medroxyprogesterone acetate. Contraception 2001; 63:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/45/34522/abstract/32\">",
"      Westfall JM, Main DS, Barnard L. Continuation rates among injectable contraceptive users. Fam Plann Perspect 1996; 28:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/45/34522/abstract/33\">",
"      Polaneczky M, Guarnaccia M, Alon J, Wiley J. Early experience with the contraceptive use of depot medroxyprogesterone acetate in an inner-city clinic population. Fam Plann Perspect 1996; 28:174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/45/34522/abstract/34\">",
"      Hubacher D, Lopez L, Steiner MJ, Dorflinger L. Menstrual pattern changes from levonorgestrel subdermal implants and DMPA: systematic review and evidence-based comparisons. Contraception 2009; 80:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/45/34522/abstract/35\">",
"      Kaunitz AM. Menstruation: choosing whether...and when. Contraception 2000; 62:277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/45/34522/abstract/36\">",
"      Glasier AF, Smith KB, van der Spuy ZM, et al. Amenorrhea associated with contraception-an international study on acceptability. Contraception 2003; 67:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/45/34522/abstract/37\">",
"      Smith, RD, Cromer, BA, Hayes, MA, et al. Medroxyprogesterone acetate (Depo-Provera) use in adolescents: Uterine bleeding and blood pressure patterns, patient satisfaction, and continuation rates. Adolesc Pediatr Gynecol 1993; 8:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/45/34522/abstract/38\">",
"      Nelson AL. Counseling issues and management of side effects for women using depot medroxyprogesterone acetate contraception. J Reprod Med 1996; 41:391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/45/34522/abstract/39\">",
"      Nelson, AS, Zieman, M. DMPA: Has it been a decade already? The Female Patient 2002; 27:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/45/34522/abstract/40\">",
"      Mainwaring R, Hales HA, Stevenson K, et al. Metabolic parameter, bleeding, and weight changes in U.S. women using progestin only contraceptives. Contraception 1995; 51:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/45/34522/abstract/41\">",
"      Moore LL, Valuck R, McDougall C, Fink W. A comparative study of one-year weight gain among users of medroxyprogesterone acetate, levonorgestrel implants, and oral contraceptives. Contraception 1995; 52:215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/45/34522/abstract/42\">",
"      Risser WL, Gefter LR, Barratt MS, Risser JM. Weight change in adolescents who used hormonal contraception. J Adolesc Health 1999; 24:433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/45/34522/abstract/43\">",
"      Danli S, Qingxiang S, Guowei S. A multicentered clinical trial of the long-acting injectable contraceptive Depo Provera in Chinese women. Contraception 2000; 62:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/45/34522/abstract/44\">",
"      Matson SC, Henderson KA, McGrath GJ. Physical findings and symptoms of depot medroxyprogesterone acetate use in adolescent females. J Pediatr Adolesc Gynecol 1997; 10:18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/45/34522/abstract/45\">",
"      Espey E, Steinhart J, Ogburn T, Qualls C. Depo-provera associated with weight gain in Navajo women. Contraception 2000; 62:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/45/34522/abstract/46\">",
"      Templeman C, Boyd H, Hertweck SP. Depomedroxyprogesterone acetate use and weight gain among adolescents. J Pediatr Adolesc Gynecol 2000; 13:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/45/34522/abstract/47\">",
"      Mangan SA, Larsen PG, Hudson S. Overweight teens at increased risk for weight gain while using depot medroxyprogesterone acetate. J Pediatr Adolesc Gynecol 2002; 15:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/45/34522/abstract/48\">",
"      Berenson AB, Rahman M. Changes in weight, total fat, percent body fat, and central-to-peripheral fat ratio associated with injectable and oral contraceptive use. Am J Obstet Gynecol 2009; 200:329.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/45/34522/abstract/49\">",
"      Pantoja M, Medeiros T, Baccarin MC, et al. Variations in body mass index of users of depot-medroxyprogesterone acetate as a contraceptive. Contraception 2010; 81:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/45/34522/abstract/50\">",
"      Le YC, Rahman M, Berenson AB. Early weight gain predicting later weight gain among depot medroxyprogesterone acetate users. Obstet Gynecol 2009; 114:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/45/34522/abstract/51\">",
"      Bonny AE, Secic M, Cromer B. Early weight gain related to later weight gain in adolescents on depot medroxyprogesterone acetate. Obstet Gynecol 2011; 117:793.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/45/34522/abstract/52\">",
"      Curtis KM, Ravi A, Gaffield ML. Progestogen-only contraceptive use in obese women. Contraception 2009; 80:346.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/45/34522/abstract/53\">",
"      Beksinska ME, Smit JA, Kleinschmidt I, et al. Prospective study of weight change in new adolescent users of DMPA, NET-EN, COCs, nonusers and discontinuers of hormonal contraception. Contraception 2010; 81:30.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/45/34522/abstract/54\">",
"      Lopez LM, Edelman A, Chen-Mok M, et al. Progestin-only contraceptives: effects on weight. Cochrane Database Syst Rev 2011; :CD008815.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/45/34522/abstract/55\">",
"      Pelkman CL, Chow M, Heinbach RA, Rolls BJ. Short-term effects of a progestational contraceptive drug on food intake, resting energy expenditure, and body weight in young women. Am J Clin Nutr 2001; 73:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/45/34522/abstract/56\">",
"      Crosignani PG, Luciano A, Ray A, Bergqvist A. Subcutaneous depot medroxyprogesterone acetate versus leuprolide acetate in the treatment of endometriosis-associated pain. Hum Reprod 2006; 21:248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/45/34522/abstract/57\">",
"      Schlaff WD, Carson SA, Luciano A, et al. Subcutaneous injection of depot medroxyprogesterone acetate compared with leuprolide acetate in the treatment of endometriosis-associated pain. Fertil Steril 2006; 85:314.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/45/34522/abstract/58\">",
"      Kaunitz AM. Injectable depot medroxyprogesterone acetate contraception: an update for U.S. clinicians. Int J Fertil Womens Med 1998; 43:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/45/34522/abstract/59\">",
"      Martin VT, Behbehani M. Ovarian hormones and migraine headache: understanding mechanisms and pathogenesis--part 2. Headache 2006; 46:365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/45/34522/abstract/60\">",
"      Civic D, Scholes D, Ichikawa L, et al. Depressive symptoms in users and non-users of depot medroxyprogesterone acetate. Contraception 2000; 61:385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/45/34522/abstract/61\">",
"      Westhoff C. Depot medroxyprogesterone acetate contraception. Metabolic parameters and mood changes. J Reprod Med 1996; 41:401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/45/34522/abstract/62\">",
"      Westhoff C, Truman C, Kalmuss D, et al. Depressive symptoms and Depo-Provera. Contraception 1998; 57:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/45/34522/abstract/63\">",
"      Gupta N, O'Brien R, Jacobsen LJ, et al. Mood changes in adolescents using depot-medroxyprogesterone acetate for contraception: a prospective study. J Pediatr Adolesc Gynecol 2001; 14:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/45/34522/abstract/64\">",
"      Bj&ouml;rn I, Bixo M, N&ouml;jd KS, et al. Negative mood changes during hormone replacement therapy: a comparison between two progestogens. Am J Obstet Gynecol 2000; 183:1419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/45/34522/abstract/65\">",
"      North American Menopause Society. Role of progestogen in hormone therapy for postmenopausal women: position statement of The North American Menopause Society. Menopause 2003; 10:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/45/34522/abstract/66\">",
"      Halpern V, Lopez LM, Grimes DA, Gallo MF. Strategies to improve adherence and acceptability of hormonal methods of contraception. Cochrane Database Syst Rev 2011; :CD004317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/45/34522/abstract/67\">",
"      Cullins VE. Noncontraceptive benefits and therapeutic uses of depot medroxyprogesterone acetate. J Reprod Med 1996; 41:428.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/45/34522/abstract/68\">",
"      Muse K. Hormonal manipulation in the treatment of premenstrual syndrome. Clin Obstet Gynecol 1992; 35:658.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/45/34522/abstract/69\">",
"      Johnson SR. Premenstrual syndrome, premenstrual dysphoric disorder, and beyond: a clinical primer for practitioners. Obstet Gynecol 2004; 104:845.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/45/34522/abstract/70\">",
"      K&uuml;&ccedil;&uuml;k T, Ertan K. Continuous oral or intramuscular medroxyprogesterone acetate versus the levonorgestrel releasing intrauterine system in the treatment of perimenopausal menorrhagia: a randomized, prospective, controlled clinical trial in female smokers. Clin Exp Obstet Gynecol 2008; 35:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/45/34522/abstract/71\">",
"      S&ouml;nmezer M, Atabeko��lu C, Cengiz B, et al. Depot-medroxyprogesterone acetate in anticoagulated patients with previous hemorrhagic corpus luteum. Eur J Contracept Reprod Health Care 2005; 10:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/45/34522/abstract/72\">",
"      Culwell KR, Curtis KM. Use of contraceptive methods by women with current venous thrombosis on anticoagulant therapy: a systematic review. Contraception 2009; 80:337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/45/34522/abstract/73\">",
"      Vercellini P, De Giorgi O, Oldani S, et al. Depot medroxyprogesterone acetate versus an oral contraceptive combined with very-low-dose danazol for long-term treatment of pelvic pain associated with endometriosis. Am J Obstet Gynecol 1996; 175:396.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/45/34522/abstract/74\">",
"      Elkins TE, Gafford LS, Wilks CS, et al. A model clinic approach to the reproductive health concerns of the mentally handicapped. Obstet Gynecol 1986; 68:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/45/34522/abstract/75\">",
"      De Ceulaer K, Gruber C, Hayes R, Serjeant GR. Medroxyprogesterone acetate and homozygous sickle-cell disease. Lancet 1982; 2:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/45/34522/abstract/76\">",
"      Manchikanti A, Grimes DA, Lopez LM, Schulz KF. Steroid hormones for contraception in women with sickle cell disease. Cochrane Database Syst Rev 2007; :CD006261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/45/34522/abstract/77\">",
"      Mattson RH, Cramer JA, Caldwell BV, Siconolfi BC. Treatment of seizures with medroxyprogesterone acetate: preliminary report. Neurology 1984; 34:1255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/45/34522/abstract/78\">",
"      Frederiksen MC. Depot medroxyprogesterone acetate contraception in women with medical problems. J Reprod Med 1996; 41:414.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/45/34522/abstract/79\">",
"      North American Menopause Society. Treatment of menopause-associated vasomotor symptoms: position statement of The North American Menopause Society. Menopause 2004; 11:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/45/34522/abstract/80\">",
"      Depot-medroxyprogesterone acetate (DMPA) and risk of endometrial cancer. The WHO Collaborative Study of Neoplasia and Steroid Contraceptives. Int J Cancer 1991; 49:186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/45/34522/abstract/81\">",
"      Depot-medroxyprogesterone acetate (DMPA) and risk of epithelial ovarian cancer. The WHO Collaborative Study of Neoplasia and Steroid Contraceptives. Int J Cancer 1991; 49:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/45/34522/abstract/82\">",
"      Depot-medroxyprogesterone acetate (DMPA) and risk of invasive squamous cell cervical cancer. The WHO Collaborative Study of Neoplasia and Steroid Contraceptives. Contraception 1992; 45:299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/45/34522/abstract/83\">",
"      Breast cancer and depot-medroxyprogesterone acetate: a multinational study. WHO Collaborative Study of Neoplasia and Steroid Contraceptives. Lancet 1991; 338:833.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/45/34522/abstract/84\">",
"      Shapiro S, Rosenberg L, Hoffman M, et al. Risk of breast cancer in relation to the use of injectable progestogen contraceptives and combined estrogen/progestogen contraceptives. Am J Epidemiol 2000; 151:396.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/45/34522/abstract/85\">",
"      Strom BL, Berlin JA, Weber AL, et al. Absence of an effect of injectable and implantable progestin-only contraceptives on subsequent risk of breast cancer. Contraception 2004; 69:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/45/34522/abstract/86\">",
"      Paul C, Skegg DC, Spears GF. Depot medroxyprogesterone (Depo-Provera) and risk of breast cancer. BMJ 1989; 299:759.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/45/34522/abstract/87\">",
"      Lee NC, Rosero-Bixby L, Oberle MW, et al. A case-control study of breast cancer and hormonal contraception in Costa Rica. J Natl Cancer Inst 1987; 79:1247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/45/34522/abstract/88\">",
"      Li CI, Beaber EF, Tang MT, et al. Effect of depo-medroxyprogesterone acetate on breast cancer risk among women 20 to 44 years of age. Cancer Res 2012; 72:2028.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/45/34522/abstract/89\">",
"      Eaton SB, Pike MC, Short RV, et al. Women's reproductive cancers in evolutionary context. Q Rev Biol 1994; 69:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/45/34522/abstract/90\">",
"      Liang AP, Levenson AG, Layde PM, et al. Risk of breast, uterine corpus, and ovarian cancer in women receiving medroxyprogesterone injections. JAMA 1983; 249:2909.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/45/34522/abstract/91\">",
"      Wilailak S, Vipupinyo C, Suraseranivong V, et al. Depot medroxyprogesterone acetate and epithelial ovarian cancer: a multicentre case-control study. BJOG 2012; 119:672.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/45/34522/abstract/92\">",
"      Kongsayreepong R, Chutivongse S, George P, et al. A multicentre comparative study of serum lipids and apolipoproteins in long-term users of DMPA and a control group of IUD users. World Health Organization. Task Force on Long-Acting Systemic Agents for Fertility Regulation Special Programme of Research, Development and Research Training in Human Reproduction. Contraception 1993; 47:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/45/34522/abstract/93\">",
"      Enk L, Landgren BM, Lindberg UB, et al. A prospective, one-year study on the effects of two long acting injectable contraceptives (depot-medroxyprogesterone acetate and norethisterone oenanthate) on serum and lipoprotein lipids. Horm Metab Res 1992; 24:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/45/34522/abstract/94\">",
"      Berenson AB, Rahman M, Wilkinson G. Effect of injectable and oral contraceptives on serum lipids. Obstet Gynecol 2009; 114:786.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/45/34522/abstract/95\">",
"      Lizarelli PM, Martins WP, Vieira CS, et al. Both a combined oral contraceptive and depot medroxyprogesterone acetate impair endothelial function in young women. Contraception 2009; 79:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/45/34522/abstract/96\">",
"      Yadav BK, Gupta RK, Gyawali P, et al. Effects of long-term use of depo-medroxyprogesterone acetate on lipid metabolism in Nepalese women. Korean J Lab Med 2011; 31:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/45/34522/abstract/97\">",
"      Goldstein J, Cushman M, Badger GJ, Johnson JV. Effect of depomedroxyprogesterone acetate on coagulation parameter: a pilot study. Fertil Steril 2007; 87:1267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/45/34522/abstract/98\">",
"      Taneepanichskul S, Reinprayoon D, Jaisamrarn U. Effects of DMPA on weight and blood pressure in long-term acceptors. Contraception 1999; 59:301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/45/34522/abstract/99\">",
"      Whigham KA, Howie PW, Mack A, Prentice CR. The effect of an injectable progestogen contraceptive on blood coagulation and fibrinolysis. Br J Obstet Gynaecol 1979; 86:806.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/45/34522/abstract/100\">",
"      Cardiovascular disease and use of oral and injectable progestogen-only contraceptives and combined injectable contraceptives. Results of an international, multicenter, case-control study. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Contraception 1998; 57:315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/45/34522/abstract/101\">",
"      van Hylckama Vlieg A, Helmerhorst FM, Rosendaal FR. The risk of deep venous thrombosis associated with injectable depot-medroxyprogesterone acetate contraceptives or a levonorgestrel intrauterine device. Arterioscler Thromb Vasc Biol 2010; 30:2297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/45/34522/abstract/102\">",
"      ACOG Committee on Practice Bulletins-Gynecology. ACOG practice bulletin. No. 73: Use of hormonal contraception in women with coexisting medical conditions. Obstet Gynecol 2006; 107:1453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/45/34522/abstract/103\">",
"      Grimes DA, Schulz KF. Surrogate end points in clinical research: hazardous to your health. Obstet Gynecol 2005; 105:1114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/45/34522/abstract/104\">",
"      Clark MK, Sowers M, Levy BT, Tenhundfeld P. Magnitude and variability of sequential estradiol and progesterone concentrations in women using depot medroxyprogesterone acetate for contraception. Fertil Steril 2001; 75:871.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/45/34522/abstract/105\">",
"      Gbolade BA. Depo-Provera and bone density. J Fam Plann Reprod Health Care 2002; 28:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/45/34522/abstract/106\">",
"      American College of Obstetricians and Gynecologists Committee on Gynecologic Practice. ACOG Committee Opinion No. 415: Depot medroxyprogesterone acetate and bone effects. Obstet Gynecol 2008; 112:727.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/45/34522/abstract/107\">",
"      Baeten JM, Nyange PM, Richardson BA, et al. Hormonal contraception and risk of sexually transmitted disease acquisition: results from a prospective study. Am J Obstet Gynecol 2001; 185:380.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/45/34522/abstract/108\">",
"      Scholes D, LaCroix AZ, Ichikawa LE, et al. Injectable hormone contraception and bone density: results from a prospective study. Epidemiology 2002; 13:581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/45/34522/abstract/109\">",
"      Clark MK, Sowers MR, Nichols S, Levy B. Bone mineral density changes over two years in first-time users of depot medroxyprogesterone acetate. Fertil Steril 2004; 82:1580.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/45/34522/abstract/110\">",
"      Clark MK, Sowers M, Levy B, Nichols S. Bone mineral density loss and recovery during 48 months in first-time users of depot medroxyprogesterone acetate. Fertil Steril 2006; 86:1466.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/45/34522/abstract/111\">",
"      Ulrich CM, Georgiou CC, Snow-Harter CM, Gillis DE. Bone mineral density in mother-daughter pairs: relations to lifetime exercise, lifetime milk consumption, and calcium supplements. Am J Clin Nutr 1996; 63:72.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/45/34522/abstract/112\">",
"      Cromer BA, Bonny AE, Stager M, et al. Bone mineral density in adolescent females using injectable or oral contraceptives: a 24-month prospective study. Fertil Steril 2008; 90:2060.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/45/34522/abstract/113\">",
"      Westhoff C. Depot-medroxyprogesterone acetate injection (Depo-Provera): a highly effective contraceptive option with proven long-term safety. Contraception 2003; 68:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/45/34522/abstract/114\">",
"      Kaunitz AM, Arias R, McClung M. Bone density recovery after depot medroxyprogesterone acetate injectable contraception use. Contraception 2008; 77:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/45/34522/abstract/115\">",
"      Lappe JM, Stegman MR, Recker RR. The impact of lifestyle factors on stress fractures in female Army recruits. Osteoporos Int 2001; 12:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/45/34522/abstract/116\">",
"      Watson KC, Lentz MJ, Cain KC. Associations between fracture incidence and use of depot medroxyprogesterone acetate and anti-epileptic drugs in women with developmental disabilities. Womens Health Issues 2006; 16:346.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/45/34522/abstract/117\">",
"      Vestergaard P, Rejnmark L, Mosekilde L. The effects of depot medroxyprogesterone acetate and intrauterine device use on fracture risk in Danish women. Contraception 2008; 78:459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/45/34522/abstract/118\">",
"      Meier C, Brauchli YB, Jick SS, et al. Use of depot medroxyprogesterone acetate and fracture risk. J Clin Endocrinol Metab 2010; 95:4909.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/45/34522/abstract/119\">",
"      Lanza LL, McQuay LJ, Rothman KJ, et al. Use of Depot Medroxyprogesterone Acetate Contraception and Incidence of Bone Fracture. Obstet Gynecol 2013; 121:593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/45/34522/abstract/120\">",
"      Paschall S, Kaunitz AM. Depo-Provera and skeletal health: a survey of Florida obstetrics and gynecologist physicians. Contraception 2008; 78:370.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/45/34522/abstract/121\">",
"      Kaunitz AM, Miller PD, Rice VM, et al. Bone mineral density in women aged 25-35 years receiving depot medroxyprogesterone acetate: recovery following discontinuation. Contraception 2006; 74:90.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/45/34522/abstract/122\">",
"      Cundy T, Cornish J, Roberts H, et al. Spinal bone density in women using depot medroxyprogesterone contraception. Obstet Gynecol 1998; 92:569.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/45/34522/abstract/123\">",
"      Cundy T, Evans M, Roberts H, et al. Bone density in women receiving depot medroxyprogesterone acetate for contraception. BMJ 1991; 303:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/45/34522/abstract/124\">",
"      Petitti DB, Piaggio G, Mehta S, et al. Steroid hormone contraception and bone mineral density: a cross-sectional study in an international population. The WHO Study of Hormonal Contraception and Bone Health. Obstet Gynecol 2000; 95:736.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/45/34522/abstract/125\">",
"      Scholes D, LaCroix AZ, Ichikawa LE, et al. Change in bone mineral density among adolescent women using and discontinuing depot medroxyprogesterone acetate contraception. Arch Pediatr Adolesc Med 2005; 159:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/45/34522/abstract/126\">",
"      Orr-Walker BJ, Evans MC, Ames RW, et al. The effect of past use of the injectable contraceptive depot medroxyprogesterone acetate on bone mineral density in normal post-menopausal women. Clin Endocrinol (Oxf) 1998; 49:615.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/45/34522/abstract/127\">",
"      Rosenberg L, Zhang Y, Constant D, et al. Bone status after cessation of use of injectable progestin contraceptives. Contraception 2007; 76:425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/45/34522/abstract/128\">",
"      Berenson AB, Breitkopf CR, Grady JJ, et al. Effects of hormonal contraception on bone mineral density after 24 months of use. Obstet Gynecol 2004; 103:899.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/45/34522/abstract/129\">",
"      Cromer BA, Stager M, Bonny A, et al. Depot medroxyprogesterone acetate, oral contraceptives and bone mineral density in a cohort of adolescent girls. J Adolesc Health 2004; 35:434.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/45/34522/abstract/130\">",
"      Sanches L, Marchi NM, Castro S, et al. Forearm bone mineral density in postmenopausal former users of depot medroxyprogesterone acetate. Contraception 2008; 78:365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/45/34522/abstract/131\">",
"      Harel Z, Johnson CC, Gold MA, et al. Recovery of bone mineral density in adolescents following the use of depot medroxyprogesterone acetate contraceptive injections. Contraception 2010; 81:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/45/34522/abstract/132\">",
"      Viola AS, Castro S, Marchi NM, et al. Long-term assessment of forearm bone mineral density in postmenopausal former users of depot medroxyprogesterone acetate. Contraception 2011; 84:122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/45/34522/abstract/133\">",
"      Harel Z, Wolter K, Gold MA, et al. Biopsychosocial variables associated with substantial bone mineral density loss during the use of depot medroxyprogesterone acetate in adolescents: adolescents who lost 5% or more from baseline vs. those who lost less than 5%. Contraception 2010; 82:503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/45/34522/abstract/134\">",
"      Curtis KM, Martins SL. Progestogen-only contraception and bone mineral density: a systematic review. Contraception 2006; 73:470.",
"     </a>",
"    </li>",
"    <li>",
"     World Health Organization. WHO Statement on Hormonal Contraception and Bone Health 2005; 1-2.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/45/34522/abstract/136\">",
"      Black A, Ad Hoc DMPA Committee of the Society of Obstetricians and Gynaecologists of Canada. Canadian contraception consensus--update on Depot Medroxyprogesterone Acetate (dmpa). J Obstet Gynaecol Can 2006; 28:305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/45/34522/abstract/137\">",
"      Cromer BA, Scholes D, Berenson A, et al. Depot medroxyprogesterone acetate and bone mineral density in adolescents--the Black Box Warning: a Position Paper of the Society for Adolescent Medicine. J Adolesc Health 2006; 39:296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/45/34522/abstract/138\">",
"      Guilbert ER, Brown JP, Kaunitz AM, et al. The use of depot-medroxyprogesterone acetate in contraception and its potential impact on skeletal health. Contraception 2009; 79:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/45/34522/abstract/139\">",
"      Cromer BA, Lazebnik R, Rome E, et al. Double-blinded randomized controlled trial of estrogen supplementation in adolescent girls who receive depot medroxyprogesterone acetate for contraception. Am J Obstet Gynecol 2005; 192:42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/45/34522/abstract/140\">",
"      Cundy T, Ames R, Horne A, et al. A randomized controlled trial of estrogen replacement therapy in long-term users of depot medroxyprogesterone acetate. J Clin Endocrinol Metab 2003; 88:78.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/45/34522/abstract/141\">",
"      Aries, RD, Kaunitz, AM, McClung, MR. Depot medroxyprogesterone acetate and bone density. Dialogues in contraception 2007; 11:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/45/34522/abstract/142\">",
"      Myer L, Denny L, Wright TC, Kuhn L. Prospective study of hormonal contraception and women's risk of HIV infection in South Africa. Int J Epidemiol 2007; 36:166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/45/34522/abstract/143\">",
"      Kleinschmidt I, Rees H, Delany S, et al. Injectable progestin contraceptive use and risk of HIV infection in a South African family planning cohort. Contraception 2007; 75:461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/45/34522/abstract/144\">",
"      Morrison CS, Richardson BA, Mmiro F, et al. Hormonal contraception and the risk of HIV acquisition. AIDS 2007; 21:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/45/34522/abstract/145\">",
"      Mostad SB, Overbaugh J, DeVange DM, et al. Hormonal contraception, vitamin A deficiency, and other risk factors for shedding of HIV-1 infected cells from the cervix and vagina. Lancet 1997; 350:922.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/45/34522/abstract/146\">",
"      Wang CC, McClelland RS, Overbaugh J, et al. The effect of hormonal contraception on genital tract shedding of HIV-1. AIDS 2004; 18:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/45/34522/abstract/147\">",
"      Heffron R, Donnell D, Rees H, et al. Use of hormonal contraceptives and risk of HIV-1 transmission: a prospective cohort study. Lancet Infect Dis 2011.",
"     </a>",
"    </li>",
"    <li>",
"     WHO Technical Statement. Hormonal contraception and HIV. February 2012. file://www.who.int/reproductivehealth/topics/family_planning/hc_hiv/en/index.html (Accessed on March 06, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/45/34522/abstract/149\">",
"      Centers for Disease Control and Prevention (CDC). Update to CDC's U.S. Medical Eligibility Criteria for Contraceptive Use, 2010: revised recommendations for the use of hormonal contraception among women at high risk for HIV infection or infected with HIV. MMWR Morb Mortal Wkly Rep 2012; 61:449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/45/34522/abstract/150\">",
"      Overton ET, Shacham E, Singhatiraj E, Nurutdinova D. Incidence of sexually transmitted infections among HIV-infected women using depot medroxyprogesterone acetate contraception. Contraception 2008; 78:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/45/34522/abstract/151\">",
"      Morrison CS, Bright P, Wong EL, et al. Hormonal contraceptive use, cervical ectopy, and the acquisition of cervical infections. Sex Transm Dis 2004; 31:561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/45/34522/abstract/152\">",
"      Clark RA, Kissinger P, Williams T. Contraceptive and sexually transmitted diseases protection among adult and adolescent women infected with human immunodeficiency virus. Int J STD AIDS 1996; 7:439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/45/34522/abstract/153\">",
"      Lavreys L, Chohan V, Overbaugh J, et al. Hormonal contraception and risk of cervical infections among HIV-1-seropositive Kenyan women. AIDS 2004; 18:2179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/45/34522/abstract/154\">",
"      Mauck CK, Callahan MM, Baker J, et al. The effect of one injection of Depo-Provera on the human vaginal epithelium and cervical ectopy. Contraception 1999; 60:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/45/34522/abstract/155\">",
"      Berenson AB, van den Berg P, Williams KJ, Rahman M. Effect of injectable and oral contraceptives on glucose and insulin levels. Obstet Gynecol 2011; 117:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/45/34522/abstract/156\">",
"      Schwallie PC, Assenzo JR. The effect of depo-medroxyprogesterone acetate on pituitary and ovarian function, and the return of fertility following its discontinuation: a review. Contraception 1974; 10:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/45/34522/abstract/157\">",
"      Cromer BA, Smith RD, Blair JM, et al. A prospective study of adolescents who choose among levonorgestrel implant (Norplant), medroxyprogesterone acetate (Depo-Provera), or the combined oral contraceptive pill as contraception. Pediatrics 1994; 94:687.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/45/34522/abstract/158\">",
"      Davis AJ. Use of depot medroxyprogesterone acetate contraception in adolescents. J Reprod Med 1996; 41:407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/45/34522/abstract/159\">",
"      O'Dell, C, Forke, C, Polaneczky, M, et al. Depo-Provera vs. oral contraceptive use by postpartum adolescents (abstr). J Adolesc Health 1997; 20:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/45/34522/abstract/160\">",
"      Chotnopparatpattara P, Taneepanichskul S. Use of depot medroxyprogesterone acetate in Thai adolescents. Contraception 2000; 62:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/45/34522/abstract/161\">",
"      Kaunitz AM. Long-acting hormonal contraceptives--indispensable in preventing teen pregnancy. J Adolesc Health 2007; 40:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/45/34522/abstract/162\">",
"      Tolaymat LL, Kaunitz AM. Long-acting contraceptives in adolescents. Curr Opin Obstet Gynecol 2007; 19:453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/45/34522/abstract/163\">",
"      Templeman CL, Cook V, Goldsmith LJ, et al. Postpartum contraceptive use among adolescent mothers. Obstet Gynecol 2000; 95:770.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/45/34522/abstract/164\">",
"      Stevens-Simon C, Kelly L, Kulick R. A village would be nice but...it takes a long-acting contraceptive to prevent repeat adolescent pregnancies. Am J Prev Med 2001; 21:60.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/45/34522/abstract/165\">",
"      McKinlay SM, Bifano NL, McKinlay JB. Smoking and age at menopause in women. Ann Intern Med 1985; 103:350.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/45/34522/abstract/166\">",
"      Stanford JL, Hartge P, Brinton LA, et al. Factors influencing the age at natural menopause. J Chronic Dis 1987; 40:995.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/45/34522/abstract/167\">",
"      Bastian LA, Smith CM, Nanda K. Is this woman perimenopausal? JAMA 2003; 289:895.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/45/34522/abstract/168\">",
"      Juliato CT, Fernandes A, Marchi NM, et al. Usefulness of FSH measurements for determining menopause in long-term users of depot medroxyprogesterone acetate over 40 years of age. Contraception 2007; 76:282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/45/34522/abstract/169\">",
"      P&eacute;rez-Palacios G, Fern&aacute;ndez-Aparicio MA, Medina M, et al. On the mechanism of action of progestins. Acta Endocrinol (Copenh) 1981; 97:320.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/45/34522/abstract/170\">",
"      Chiou CF, Trussell J, Reyes E, et al. Economic analysis of contraceptives for women. Contraception 2003; 68:3.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5468 Version 24.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-183.166.191.243-382E3F64B8-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_45_34522=[""].join("\n");
var outline_f33_45_34522=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H33\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      FORMULATIONS AND PHARMACOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      MECHANISMS OF ACTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      EFFICACY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      ADMINISTRATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26226348\">",
"      Medical eligibility criteria",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26226355\">",
"      Timing of injections",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Initial injection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Repeat injections",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Switching from DMPA to another method",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26226042\">",
"      COUNSELING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      SIDE EFFECTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Menstrual changes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Weight changes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Headache",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Mood changes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26226460\">",
"      Other",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      RISKS AND BENEFITS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Benefits",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7898312\">",
"      - Management of comorbid conditions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7898336\">",
"      - Drug interactions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7897960\">",
"      Risks",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Cancer risk",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Cardiovascular risk",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Reduction in bone mineral density",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Conclusions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Lack of protection from sexually transmitted infections",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Effect on HIV acquisition and transmission",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Effect on chlamydia and gonorrhea acquisition",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3193608\">",
"      - Change in glucose/insulin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      RETURN TO FERTILITY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7898424\">",
"      SPECIAL POPULATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Adolescents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Perimenopausal women",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      After abortion or delivery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      When estrogen is contraindicated",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      COST",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"OBGYN/5468\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/5468|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?42/11/43197\" title=\"figure 1\">",
"      Progestin effect on BMD 2",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/5468|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?12/13/12506\" title=\"table 1\">",
"      CDC Medical Eligibility Criteria for Contraceptive Use",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?20/61/21468\" title=\"table 2\">",
"      DMPA injection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?4/46/4846\" title=\"table 3\">",
"      Switching between different methods of contraception",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?38/20/39245\" title=\"table 4\">",
"      WHO MEC for women with HIV AIDS",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/21/9562?source=related_link\">",
"      Drugs that affect bone metabolism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/25/6553?source=related_link\">",
"      Epidemiology and etiology of premenopausal osteoporosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/27/3512?source=related_link\">",
"      Etonogestrel contraceptive implant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/10/22698?source=related_link\">",
"      Management of unscheduled bleeding in women using contraception",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/53/25434?source=related_link\">",
"      Menopausal hot flashes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/19/32058?source=related_link\">",
"      Overview of intrauterine contraception",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/5/18522?source=related_link\">",
"      Overview of the use of estrogen-progestin contraceptives",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?8/60/9157?source=related_link\">",
"      Patient information: Birth control; which method is right for me? (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?13/56/14211?source=related_link\">",
"      Patient information: Choosing birth control (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?21/32/22021?source=related_link\">",
"      Patient information: Hormonal methods of birth control (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/8/24713?source=related_link\">",
"      Postpartum and postabortion contraception",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/52/9031?source=related_link\">",
"      Progestin-only pills (minipills) for contraception",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/7/39034?source=related_link\">",
"      Risks and side effects associated with estrogen-progestin contraceptives",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f33_45_34523="Paracentesis checklist";
var content_f33_45_34523=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F73987&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F73987&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Paracentesis checklist",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Supplies needed for diagnostic and therapeutic paracentesis:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Patient consent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Obtain the ultrasound machine as needed",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Order labs in advance so that labels are available once you have the fluid",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Red top tube",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Purple top tube (or other tube depending on the lab)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        One pair of blood culture bottles (one aerobic and one anaerobic)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Skin anesthesia needle 25 to 27 gauge, as on a tuberculin syringe",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        18 ga 1 inch x 2 or 3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        22 ga 1 to 1.5 inch needle if available",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        22 ga 3.5 inch spinal needle",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Syringes - 3, 5, 20 mL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lidocaine 1 percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        4x4 sterile gauze sponges x 2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Non-sterile gown",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sterile and nonsterile gloves",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Iodine or other skin sterilizer",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Alcohol wipes x 3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Simple bandage",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_45_34523=[""].join("\n");
var outline_f33_45_34523=null;
var title_f33_45_34524="Commonly missed conditions";
var content_f33_45_34524=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F76615&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F76615&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Commonly missed conditions in patients with intellectual disability",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Psychiatric disorders",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Depression",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Schizophrenia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Bipolar affective disorder",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Anxiety disorders",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Post-traumatic stress disorder",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Gastrointestinal disorders",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Constipation/atonic bowel",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Bowel obstruction",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Reflux oesophagitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        H. Pylori infection",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Undescended testis/hypogonadism",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Unrecognized pain or infection",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Dental pathology",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Chest infection",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Urinary tract infection",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Medication issues",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Overuse of tranquilizers",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Unrecognized side effects of medication",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Epilepsy management",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Inadequate review of anticonvulsant medication",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Failure to consider medication interactions and toxicity",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Sensory impairment",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hearing impairment",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Visual impairment",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ear and eye pathology",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Health maintenance activities",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Immunization",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Screening for infectious conditions including hepatitis B",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Nutritional assessment (exclude malnutrition and obesity)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Breast checks and Pap tests",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Blood pressure and skin checks",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Screening for osteoporosis and vitamin D deficiency where appropriate",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Physical activity assessment",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Lennox N, Eastgate G. Adults with intellectual disability and the GP. Aust Fam Physician 2004; 33:601. Copyright to Australian Family Physician. Reproduced with permission. Permission to reproduce must be sought from the publisher, The Royal Australian College of General Practitioners.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_45_34524=[""].join("\n");
var outline_f33_45_34524=null;
var title_f33_45_34525="Probability RDS by FLM and GA";
var content_f33_45_34525=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F72799&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=11\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F72799&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=11\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Absolute risk of RDS based on TDx FLM II ratio (mg/g) and GA*",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" colspan=\"1\" rowspan=\"2\">",
"        FLM",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"11\" rowspan=\"1\">",
"        GA, wk",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        29",
"       </td>",
"       <td class=\"subtitle2\">",
"        30",
"       </td>",
"       <td class=\"subtitle2\">",
"        31",
"       </td>",
"       <td class=\"subtitle2\">",
"        32",
"       </td>",
"       <td class=\"subtitle2\">",
"        33",
"       </td>",
"       <td class=\"subtitle2\">",
"        34",
"       </td>",
"       <td class=\"subtitle2\">",
"        35",
"       </td>",
"       <td class=\"subtitle2\">",
"        36",
"       </td>",
"       <td class=\"subtitle2\">",
"        37",
"       </td>",
"       <td class=\"subtitle2\">",
"        38",
"       </td>",
"       <td class=\"subtitle2\">",
"        39",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        10",
"       </td>",
"       <td>",
"        98%",
"       </td>",
"       <td>",
"        97%",
"       </td>",
"       <td>",
"        96%",
"       </td>",
"       <td>",
"        95%",
"       </td>",
"       <td>",
"        92%",
"       </td>",
"       <td>",
"        89%",
"       </td>",
"       <td>",
"        85%",
"       </td>",
"       <td>",
"        80%",
"       </td>",
"       <td>",
"        73%",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        20",
"       </td>",
"       <td>",
"        94%",
"       </td>",
"       <td>",
"        92%",
"       </td>",
"       <td>",
"        89%",
"       </td>",
"       <td>",
"        85%",
"       </td>",
"       <td>",
"        80%",
"       </td>",
"       <td>",
"        73%",
"       </td>",
"       <td>",
"        65%",
"       </td>",
"       <td>",
"        57%",
"       </td>",
"       <td>",
"        47%",
"       </td>",
"       <td>",
"        38%",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        30",
"       </td>",
"       <td>",
"        85%",
"       </td>",
"       <td>",
"        79%",
"       </td>",
"       <td>",
"        73%",
"       </td>",
"       <td>",
"        65%",
"       </td>",
"       <td>",
"        56%",
"       </td>",
"       <td>",
"        47%",
"       </td>",
"       <td>",
"        38%",
"       </td>",
"       <td>",
"        30%",
"       </td>",
"       <td>",
"        23%",
"       </td>",
"       <td>",
"        17%",
"       </td>",
"       <td>",
"        12%",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        40",
"       </td>",
"       <td>",
"        64%",
"       </td>",
"       <td>",
"        55%",
"       </td>",
"       <td>",
"        46%",
"       </td>",
"       <td>",
"        37%",
"       </td>",
"       <td>",
"        29%",
"       </td>",
"       <td>",
"        22%",
"       </td>",
"       <td>",
"        17%",
"       </td>",
"       <td>",
"        12%",
"       </td>",
"       <td>",
"        8.7%",
"       </td>",
"       <td>",
"        6.2%",
"       </td>",
"       <td>",
"        4.4%",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        50",
"       </td>",
"       <td>",
"        37%",
"       </td>",
"       <td>",
"        29%",
"       </td>",
"       <td>",
"        22%",
"       </td>",
"       <td>",
"        16%",
"       </td>",
"       <td>",
"        12%",
"       </td>",
"       <td>",
"        8.5%",
"       </td>",
"       <td>",
"        6.1%",
"       </td>",
"       <td>",
"        4.3%",
"       </td>",
"       <td>",
"        3.0%",
"       </td>",
"       <td>",
"        2.1%",
"       </td>",
"       <td>",
"        1.5%",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        60",
"       </td>",
"       <td>",
"        16%",
"       </td>",
"       <td>",
"        12%",
"       </td>",
"       <td>",
"        8.4%",
"       </td>",
"       <td>",
"        6.0%",
"       </td>",
"       <td>",
"        4.2%",
"       </td>",
"       <td>",
"        3.0%",
"       </td>",
"       <td>",
"        2.1%",
"       </td>",
"       <td>",
"        1.4%",
"       </td>",
"       <td>",
"        1.0%",
"       </td>",
"       <td>",
"        0.70%",
"       </td>",
"       <td>",
"        0.49%",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        70",
"       </td>",
"       <td>",
"        5.8%",
"       </td>",
"       <td>",
"        4.1%",
"       </td>",
"       <td>",
"        2.9%",
"       </td>",
"       <td>",
"        2.0%",
"       </td>",
"       <td>",
"        1.4%",
"       </td>",
"       <td>",
"        0.98%",
"       </td>",
"       <td>",
"        0.68%",
"       </td>",
"       <td>",
"        0.47%",
"       </td>",
"       <td>",
"        0.33%",
"       </td>",
"       <td>",
"        0.23%",
"       </td>",
"       <td>",
"        0.16%",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        80",
"       </td>",
"       <td>",
"        2.0%",
"       </td>",
"       <td>",
"        1.4%",
"       </td>",
"       <td>",
"        0.96%",
"       </td>",
"       <td>",
"        0.67%",
"       </td>",
"       <td>",
"        0.46%",
"       </td>",
"       <td>",
"        0.32%",
"       </td>",
"       <td>",
"        0.22%",
"       </td>",
"       <td>",
"        0.16%",
"       </td>",
"       <td>",
"        0.11%",
"       </td>",
"       <td>",
"        0.07%",
"       </td>",
"       <td>",
"        0.05%",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        90",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        0.45%",
"       </td>",
"       <td>",
"        0.31%",
"       </td>",
"       <td>",
"        0.22%",
"       </td>",
"       <td>",
"        0.15%",
"       </td>",
"       <td>",
"        0.11%",
"       </td>",
"       <td>",
"        0.07%",
"       </td>",
"       <td>",
"        0.05%",
"       </td>",
"       <td>",
"        0.04%",
"       </td>",
"       <td>",
"        0.02%",
"       </td>",
"       <td>",
"        0.02%",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        100",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        0.10%",
"       </td>",
"       <td>",
"        0.07%",
"       </td>",
"       <td>",
"        0.05%",
"       </td>",
"       <td>",
"        0.03%",
"       </td>",
"       <td>",
"        0.02%",
"       </td>",
"       <td>",
"        0.02%",
"       </td>",
"       <td>",
"        0.01%",
"       </td>",
"       <td>",
"        &lt;0.01%",
"       </td>",
"       <td>",
"        &lt;0.01%",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * These risk estimates reflect the prevalence pattern of RDS across the GA range observed in the current study data. The overall prevalence of RDS in a clinical setting depends on both the prevalence of RDS at each GA and on the distribution of GAs encountered.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Parvin, CA, Kaplan, LA, Chapman, JF, et al. Predicting respiratory distress syndrome using gestational age and fetal lung maturity by fluorescent polarization. Am J Obstet Gynecol 2005; 192:199. Copyright &copy; 2005 Elsevier.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_45_34525=[""].join("\n");
var outline_f33_45_34525=null;
var title_f33_45_34526="Analyte MoMs in the first trimester";
var content_f33_45_34526=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F61531&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F61531&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Analyte Multiples of the Median (MoMs): First trimester",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 309px; height: 688px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Each blue line refers to unaffected pregnancies and each red line refers to Down syndrome pregnancies.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Glenn E Palomaki, BS.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_45_34526=[""].join("\n");
var outline_f33_45_34526=null;
var title_f33_45_34527="Tongue retaining device";
var content_f33_45_34527=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F68697&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F68697&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Tongue retaining device (four views)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 241px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    When inserted into the suction cavity of this oral appliance, the tongue is held forward to maintain airway patency. (Tongue Retaining Device, Professional Positioners, Inc, Racine, WI)",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_45_34527=[""].join("\n");
var outline_f33_45_34527=null;
